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Mutations in genes that cause transcriptional dysregulation, such as genes that encode DNA 
and RNA-binding proteins (RNABPs), are a well-described cause of neurodevelopmental 
syndromes such as autism and epilepsy. Heterozygous de novo mutations involving the 
gene HNRNPU, which encodes the heterogeneous nuclear ribonuclear protein U, have been 
implicated in a neurodevelopmental syndrome most commonly characterized by epileptic 
encephalopathy. Although hnRNP U is a highly-abundant and ubiquitously-expressed DNA- and 
RNA-binding protein involved in a variety of important nuclear processes—most notably gene 
expression regulation—the role it plays in neurological disease is unclear and has yet to be studied. 
The work presented here examines a precision medicine approach for epilepsies thought to have a 
transcriptomic basis, starting with a thorough neurophysiological characterization of a 
heterozygous loss-of-function Hnrnpu mouse model (Hnrnpu+/113DEL), followed by a 
comprehensive and region-specific single-cell transcriptomic study, and finally the validation of 
implicated brain regions. Characterization of the Hnrnpu+/113DEL mouse line revealed an increased 
susceptibility to seizures in Hnrnpu+/113DEL mice, along with an increased perinatal mortality, 
global developmental delay and gait abnormalities. Gene expression profiling, including bulk 
RNA-sequencing of neocortex and single cell RNA-sequencing of both neocortex and 
hippocampus, revealed widespread, yet modest, dysregulation of gene expression that was largely 
inversely correlated to gene-length, and involved important, neurodevelopmental disease genes. 
In particular, pyramidal neurons of the subiculum displayed greater transcriptional burden upon 
 
 
heterozygous loss of Hnrnpu, with the known epilepsy gene Mef2c as a clear outlier showing 
greater than 50% reduction in expression. Follow-up investigation into whether this region- and 
cell-type specific gene dysregulation correlated to differences in neuronal function using c-Fos 
immunostaining, revealed an overall decrease in neuronal activity within the ventral subiculum in 
Hnrnpu+/113DEL mice. In summary, our data validates the presence of neurodevelopmental defects 
upon heterozygous loss of Hnrnpu and supports the notion of transcriptional dysregulation as a 
likely contributing factor to hnRNP U-related disease, possibly through the dysfunction of 
subiculum-derived excitatory neurons. Future studies evaluating the relationship between reduced 
activity within the ventral subiculum and hnRNP U disease phenotypes are an important next step, 
and may serve as the basis for targeted therapeutic discovery.
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Chapter 1: Introduction 
 With the recent advances in genomic sequencing technologies, our ability to identify and 
interpret human genomic variation has substantially improved over the last decade. Not only have 
these sequencing methods opened the gateway to the improved identification of both mendelian 
and complex disease genes through the statistical analysis of disease-associated common and rare 
variation, but they have also fostered the characterization of human genetic variation and 
ultimately the functional classification of variants. For many disease types, clinical and research-
based whole exome sequencing (WES) has opened the door to the identification of pathogenic 
variants in a considerable portion of patients. For example, WES identified disease-causing 
mutations in nearly 9% of individuals with chronic kidney disease (Groopman et al. 2019), 39% 
of patients with childhood-onset neuromuscular phenotypes (Waldrop et al. 2019) and 25% of 
patients with epilepsy and intellectual disability (Snoeijen‐Schouwenaars et al. 2019). These 
studies offer the opportunity to gain direct information regarding each patient’s precise cause of 
disease, and thus a better starting point for developing therapeutic strategies.  
 The primary focus of this thesis work has been to examine an approach to precision 
medicine in epilepsy by leveraging the genetic knowledge of a rare form of epileptic 
encephalopathy caused by mutations in the gene HNRNPU, followed by the functional 
characterization and mechanistic interrogation of a mouse model of this disease. The overall goal 
of this work has been to lay the foundation for improved, precision-based therapies. The 
manuscript presented in Appendix I (Dugger, Platt, and Goldstein 2018) offers a comprehensive 
review of the role genetics has played throughout drug discovery in recent history, and how 
advances in genetics now offer greater promise for improving patient treatment in our current era 
of precision medicine. The epilepsy precision medicine approach highlighted in this review serves 




1.1 Epilepsy in Humans: Diagnosis, Mechanisms, Etiology and Management  
 Epilepsy is the fourth most common neurological disorder in the U.S. affecting an 
estimated 2.2 million Americans and carrying an individual lifetime risk of roughly 4% (England 
et al. 2012).  Epilepsy is a spectrum of clinically and molecularly diverse neurological disorders 
characterized by a predisposition to recurrent and spontaneous seizures of varying types and 
severities (Chang and Lowenstein 2003). Compared to other neurological disorders, sudden 
unexpected death in epilepsy (SUDEP) is the second leading cause of lost years of life in all age 
groups (Thurman, Hesdorffer, and French 2014); however, mortality from epilepsy can also result 
from status epilepticus, motor vehicle and drowning accidents, falls, burns and suicide (Devinsky 
et al. 2016). Associated comorbidities depend on the etiology and severity of epilepsy, and include 
injuries sustained from falls caused from seizures, psychiatric illness, the associated stigma within 
certain cultures/societies, and severe intellectual disability and autistic features associated with the 
epileptic encephalopathies (Devinsky et al. 2016). Given the substantial clinical and molecular 
heterogeneity of this disorder, it is unsurprising that despite the presence of more than 24 
antiepileptic drugs (AEDs) available on the market, nearly one-third of patients’ seizures cannot 
be adequately controlled, indicating the need for more improved, precise therapeutic alternatives 
(Sankaraneni and Lachhwani 2015; Sillanpää and Schmidt 2006; Brodie et al. 2012).   
Epileptic seizures are defined as “the manifestation of epileptic (excessive and/or 
hypersynchronous) usually self-limited activity of neurons in the brain” (Panayiotopoulos 2005).  
A diagnosis of epilepsy is clinically-based, and first relies on the classification of seizure type 
based on seizure onset, followed by determination of epilepsy type, including Generalized 
Epilepsy—where seizures begin in both hemispheres simultaneously, Focal Epilepsy—where 
seizures originate in one hemisphere—and Combined Generalized and Focal Epilepsy—where 
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patients experience a combination of both epilepsy types (Figure 1.1). Generalized epilepsy is 
characterized by generalized spike-wave discharges on electroencephalography (EEG), which can 
present as absence (sudden, brief slip in consciousness), myoclonic (muscle jerks/spasms), tonic 
(increased muscle tone), atonic (loss of muscle tone) and tonic-clonic (stiffening, shaking and 
jerking of entire body) events (Scheffer et al. 2017). A diagnosis of focal epilepsy is based 
primarily on clinical history and supportive EEG findings, and can manifest as focal motor 
(spasms/jerking of muscle or muscle group) vs. non-motor (impairment in senses), focal aware 
(where awareness remains intact) vs. impaired awareness and focal to bilateral tonic-clonic 
seizures (beginning on one side of the brain and spreading to the other) (Scheffer et al. 2017).  For 
a subset of patients, their type of epilepsy may be further categorized into an epilepsy syndrome 
based on age of onset, seizure triggers, prognosis, etc. (Scheffer et al. 2017).  
On a fundamental level, the cellular phenotype of epileptiform activity is characterized by 
excessive synchronous bursting of neurons due to an imbalance between the level of excitation 
and inhibition amongst the affected circuit(s) (Staley 2015). In a simple, typical-functioning 
circuit, excitatory neurons, such as pyramidal cells, secrete excitatory neurotransmitters (i.e. 
glutamate) that bind to receptors of synapsed neurons, resulting in the increased probability of an 
action potential within the postsynaptic neurons, thus promoting neuronal activity within the 
network (Valenzuela, Puglia, and Zucca 2011). Alternatively, inhibitory neurons, such as 
interneurons, secrete inhibitory neurotransmitters (i.e. gamma-aminobutyric acid, or GABA) that 
decrease the likelihood of an action potential upon postsynaptic receptor binding, thereby serving 
to dampen network activity. Essentially, excitatory neurons function as the “gas” and inhibitory 
neurons as the “brake” of neuronal network firing. On a simplistic level, epilepsy is considered to 
be a result of either excessive excitatory neuron firing or impaired inhibition of this excitatory 
activity. The neocortex and hippocampus are both susceptible to generating this aberrant activity, 
4 
 
with a variety of molecular, cellular and network-level factors playing a role in their 
epileptogenicity (Scharfman 2007; Staley 2015), most notably:  
• Resting membrane potential- Deviations in the ionic environment can result in an 
imbalance in membrane potential thus leading to increased depolarization, 
neurotransmitter release and action potentials of excitatory neurons, or increased 
hyperpolarization and silencing of inhibitory neurons.  
• Synaptic transmission- Abnormalities involving the functional pools of major 
excitatory and inhibitory neurotransmitters glutamate and GABA (i.e. aberrant 
secretion, vesicle recycling, etc.) can lead to an altered excitatory/inhibitory balance.  
• Synchronization- Mechanisms such as excessive interconnectivity of glutamatergic 
synapses or abnormal interneuron-facilitated synchronization of pyramidal cell 
populations can lead to hyper-synchronization of neuronal networks.  
• Timing- With the exception of the severe epilepsies where there are essentially no 
regular periods of brain activity, seizures account for less than 1% of total brain activity 
in chronic epilepsies (Moran et al. 2004; Staley 2015). Seizure timing may be 
influenced by such factors as global brain states (i.e. sleep, hormonal fluctuations), 
unusually high network-level activity, synaptic plasticity and positive feedback loops 
sparked from temporary imbalances in inhibition and excitation. These vulnerabilities 
can result in activity that crosses a specific “seizure threshold”, thereby initiating 
ictogenesis (the transition from normal to seizure state) (Figure 1.2) (Staley 2015).  
These molecular, cellular and network changes have a variety of etiologies, both acquired 
and genetic. Examples of acquired epilepsies include those caused from infection (Chin, Neville, 
and Scott 2005; Ooi et al. 2008; Kariuki et al. 2013), brain tumor (You et al. 2012; Southwell et 
al. 2012), brain trauma (Christensen et al. 2009; Annegers and Coan 2000) and congenital brain 
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malformations (Barkovich et al. 2012; Mirzaa et al. 2004); however, even acquired epilepsies are 
thought to contain underlying genetic contributions (Thomas and Berkovic 2014). The role of 
genetics in epilepsy has been highlighted by twin studies, which show overall greater concordance 
for monozygotic rather than dizygotic twins (Berkovic et al. 1998; Vadlamudi et al. 2004; Kjeldsen 
et al. 2003). Furthermore, for idiopathic epilepsies, the risk of familial recurrence with an affected 
first-degree relative is increased by 2- to 4-fold (Ottman et al. 1996b; Ottman et al. 1996a). With 
recent advanced in genomic technologies, our understanding of these underlying genetic causes of 
and contributions to epilepsy has drastically improved. The genetic architecture of epilepsy that 
has emerged in recent history can be summed up as a continuum ranging from gene modifiers and 
susceptibility alleles to large-effect, fully-penetrant mutations (Thomas and Berkovic 2014) 
(Figure 1.3).      
While numerous genes influencing disease susceptibility have been identified (Helbig et 
al. 2008; Reid, Berkovic, and Petrou 2009; Dibbens et al. 2004; Mulley et al. 2005), most of the 
understood genetic basis for epilepsy stems from inherited and de novo monogenic variants of 
large-effect with earlier and more severe clinical presentations. The majority of these genes code 
for or are associated with ion channels or synaptic transmission machinery, such as SCN1A, 
KCNT1, DNM1 and STXBP1 (Simkin and Kiskinis 2018) (Table 1.1). However, other genes with 
less clear relevance to seizures such as the chromatin modifier CHD2, the DNA/RNA-binding 
protein HNRNPU and the transcription factor MEF2C have also been identified. Both gain- and 
loss-of-function effects have been described amongst these known epilepsy genes.  
While mutations residing in some of these genes are associated with milder forms of 
epilepsy, the majority are associated with the more severe epileptic encephalopathies (EEs)—an 
early-onset form of epilepsy characterized by essentially no normal periods of brain activity. This 
culminates in paroxysmal interictal activity and frequent, intractable seizures of infantile or 
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childhood onset, along with other cognitive, motor and sensory impairments that can progress over 
time with poor prognosis and increased risk of SUDEP (Berg et al. 2010; Noh, Jane Tavyev Asher, 
and Graham 2012). Developmental impairments can also occur in parallel and independently of 
the epilepsy (Scheffer et al. 2017). Other central nervous system (CNS) and non-CNS 
comorbidities are common and depend on the underlying genetic etiology. EEs are typically 
categorized into a syndrome based on the clinical presentation and specific genetic cause. 
Hallmark examples include Dravet syndrome, of which 70-80% of patients carry a mutation in the 
sodium channel subunit SCN1A and present with severe myoclonic epilepsy in infancy, and 
Ohtahara syndrome, which is associated with mutations in STXBP1 and ARX and present with 
early tonic spasms and psychomotor impairment that often evolve over time (Noh, Jane Tavyev 
Asher, and Graham 2012).    
Antiepileptic drugs (AEDs) are the primary treatment modality of seizures and other 
comorbidities for both patients with EE and those with epilepsy in general, with greater than 20 
distinct compounds available on the market. These drugs act through a variety of mechanisms in 
order to influence the bursting of neurons, reduce the level of synchronization and prevent spread 
of abnormal firing to other brain regions (Rogawski and Löscher 2004). In general, antiepileptics 
converge on one or more key mechanisms of action: (1) blocking of voltage-gated sodium and 
calcium channels to limit neuron depolarization and neurotransmitter release, (2) potentiation of 
potassium channels to limit neuron depolarization, (3) promotion of inhibitory activity through 
GABA signaling, and (4) blocking of glutamate receptors, such as NMDA or AMPA receptors, to 
limit spread of excitability (Rogawski and Löscher 2004). AED therapy is often a “trial and error” 
approach where patients are typically started with a first-line monotherapy, and if seizures remain 
refractory, are then transitioned to a different first-line drug (Knezevic and Marzinke 2018). If 
monotherapy is unsuccessful, combination therapies using adjunctive AEDs are attempted. Factors 
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influencing the type(s) of AEDs chosen include type of seizures, etiology of seizures, drug side 
effects, cost and contraindications with other medications (Knezevic and Marzinke 2018).  
 Nevertheless, despite the advances in our understanding of epilepsy and the availability of 
numerous AEDs, approximately one-third of patients’ seizures remain intractable to drug therapy. 
And while non-medicinal treatments including ketogenic diet (D’Andrea Meira et al. 2019) and 
surgical resection of the seizure-prone or damaged brain regions (Vakharia et al. 2018) have also 
demonstrated efficacy for certain drug-resistant seizure types, it’s becoming increasingly clear that 
a shift towards targeting the precise epileptogenic mechanisms for each patient—i.e. precision 
medicine—is imperative for continued improvement in patient treatment and outcomes. Promising 
strategies include drug repositioning, diet-based therapies (i.e. ketogenic diet), natural compounds 
(i.e. cannabidiol), antibodies, gene therapies (i.e. antisense oligonucleotides) and cell-based 
therapies (Maljevic, Reid, and Petrou 2017). However, the ultimate success of these approaches 
relies heavily not only on relevant in vitro and in vivo assays for phenotypic screening, but also on 
valid models of the disease.  
 
1.2 Using mice to model genetic epilepsies 
 While there is no animal model that fully recapitulates the mechanisms, phenotypes and 
treatment responses of human epilepsy, rodent models—particularly mice—by far have been the 
most widely-used and valuable model for studying pathogenesis. Mice are docile and rapid 
breeders, and also have an extensive level of literature surrounding their normal neurological 
function (Grone and Baraban 2015). Furthermore, mice have been used successfully for decades 
as a standard preclinical tool, serving as part of the drug development screening process through 
evaluating the effects of candidate antiepileptic compounds on electrically and chemically-induced 
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seizures. This has led to the discovery of many AEDs currently on the market (reviewed in Löscher 
2017).  
Beyond these factors, generating mouse models containing the precise human pathogenic 
mutation or pure loss-of-function allele has also become increasingly simplified with the advent 
of genome editing technologies such as CRISPR/Cas9. Large‐scale sequencing studies of the rare 
and more severe epileptic encephalopathies have made major progress in uncovering new 
causative genes, which include, but are not limited to, genes involved in ion channel activity, 
synaptic transmission, cell signaling and growth (EuroEPINOMICS-RES Consortium, Epilepsy 
Phenome/Genome Project, and Epi4K Consortium 2014; Epi4K Consortium et al. 2013). 
Moreover, approaches to characterize the electrophysiological consequences of such disease-
causing mutations are well-described and widespread including EEG for detection of spontaneous 
seizures and both electro- and chemo-convulsive threshold studies to assess seizure susceptibility 
(discussed in Chapter 2). Many ex vivo and in vitro electrophysiological approaches also exist 
including whole brain slice and dissociated neuronal culture electrophysiology (patch-clamp) and 
multielectrode arrays. Additional in vivo methods to assess for common neurodevelopmental and 
behavioral comorbidities, such as developmental delays and intellectual disabilities observed in 
patients with EE, are also available (discussed in Chapter 2). Armed with these tools, we can now 
take the causative epilepsy mutations of individual patients, rapidly assess their functional effects 
using the plethora of model systems and assays available and screen for drugs that alleviate these 
effects. It should be noted, however, that many of the current assays available to evaluate the 
functional effects of EE-associated mutations rely on excitability/neuronal activity read-outs. 
Treatments developed based upon these assays will therefore likely only rescue epilepsy-related 
phenotypes, and may fail to treat comorbidities caused from deficits in other neuronal processes 
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such as differentiation, intracellular signaling, metabolism, etc. Unfortunately, however, 
identifying useful assays for drug screening of the latter group is more of a challenge.   
A number of genetic epilepsy mouse models have already been generated, phenotypically 
characterized and mechanistically interrogated. The majority of these mouse models are of 
channelopathies, such as those affecting voltage-gated ion or ligand-gated channels important in 
action potential generation. Examples include Na+ channel subunits SCN1A, SCN2A and SCN8A, 
K+ channel subunits KCNT1 and KCNQ2, and the Ca2+ channel subunit CACNA1A, along with 
GABA receptor subunits GABRA1 and GABRG2, and NMDA receptor subunits GRIN2B and 
GRIN2D. Other examples of well-characterized mouse models beyond the channelopathies include 
the Tuberous Sclerosis gene TSC1 involved in the mTOR pathway, and STXBP1 and DNM1, 
involved in synaptic transmission. 
Many of these genetic models partially or fully recapitulate human epilepsy and other 
neurological comorbidities, and hence offer good preclinical models for therapeutic discovery 
(Oyrer et al. 2018). For instance, the gain-of-function knock-in SCN8A mouse model not only 
demonstrates spontaneous seizures, but also ataxia and increased sudden death as observed in 
patients (Wagnon et al. 2015; Lopez-Santiago et al. 2017). Functional studies of pathogenic 
variants indicate a persistent Na+ current (Lopez-Santiago et al. 2017; Estacion et al. 2014)—a 
cellular phenotype targetable by specific the Na+ current blocker PRAX-330 (GS967), which has 
already been shown to extend survival of the heterozygous N1768D/+ knock-in mouse model 
(Anderson et al. 2014). The heterozygous loss-of-function SCN1A mouse model of Dravet 
syndrome is associated with spontaneous seizures and increased mortality in certain genetic 
backgrounds (Yu et al. 2006). Notably, consistent with observations in human patients, this mouse 
model also demonstrates exacerbation of seizures with Na+ channel blockers and improvement 
with current first-tier drugs, further highlighting the efficacy in modeling the human form of the 
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disease (D. Cao et al. 2012; Hawkins et al. 2017). Another example of a robust pre-clinical model 
is the TSC1 mouse model of Tuberous Sclerosis Complex (TSC)—one of the most common 
genetic forms of epilepsy. Mice containing loss of TSC1 in glia showed abnormal activation of the 
mTOR pathway, progressive epilepsy and decreased lifespan. Treatment with mTOR inhibitors 
suppressed TSC-related seizures in mice and have also reduced seizure frequency in human trials 
(M. Li et al. 2019; Canpolat et al. 2018; Zeng et al. 2008). 
Yet, as with any model system, there are inherent limitations. First, many models 
evaluating heterozygous disease-causing mutations fail to corroborate the seizure phenotypes 
observed in humans (i.e. poor face validity) or in some cases require homozygous mutations to 
observe related phenotypes in mice (Oyrer et al. 2018). For example, mice harboring heterozygous 
loss-of-function mutations in the EE gene GRIN1, which encodes the GluN1 subunit of the NMDA 
receptor, do not show any evidence of spontaneous seizures, but do recapitulate some of the other 
neurodevelopmental comorbidities observed in patients (Nakazawa et al. 2002; Cui et al. 2004; 
Hasan et al. 2013). Additionally, heterozygous loss-of-function mutations in the K+ channel 
subunits KCNQ2 and KCNQ3, which are associated with autosomal dominant benign familial 
neonatal convulsions in humans, are not associated with spontaneous seizures in mice (Singh et 
al. 2008; Otto et al. 2009). However, these mice do show increased seizure susceptibility, and may 
thus serve as a model of milder disease. Moreover, heterozygous mutations in the voltage-gated 
K+ channel subunit KCNA2, associated with early infantile epileptic encephalopathy in humans, 
fail to result in spontaneous seizures in mice, yet homozygous mutations result in severe, 
spontaneous seizures and early mortality (Brew et al. 2007).  
Failure to recapitulate the human condition is likely due to obvious species-specific 
differences in brain structure and function, but could also be the product of the inability to detect 
such seizure events in mice; perhaps seizures are unable to be captured during the correct 
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developmental window, such as in newborn pups, or currently-available tools are technically 
limited in detecting such events, such as if they occur in deeper brain regions (reviewed in Yang 
and Frankel 2004). Further complicating this is the fact that the correlation between human and 
mouse development and disease onset is not always clear. Secondly, genetic background plays a 
major role in seizure susceptibility of mouse models, which presents an element of experimental 
complexity when studying epilepsy models. This was highlighted by Frankel and colleagues, who 
demonstrated using electroconvulsive threshold studies (ECTs) that mice of common inbred 
background strains have an array of different seizure thresholds, highlighting the presence of 
various genetic modifiers of neuroexcitability (Frankel et al. 2001).  
 Yet, despite these shortcomings, the overwhelming mechanistic and therapeutic advances 
stemming from mouse models along with the plethora of experimental assays that exist, support 
the utility of mice as a valuable tool for the dissection of molecular and physiological factors 
underlying genetic epilepsies. The examples of genetic epilepsy mouse models discussed above 
further highlight the tribulations and promise of using mice as a preclinical tool for human genetic 
epilepsies, and underscore the value of a thorough characterization of the mutation effects on 
mouse neurological function.  
 
1.3 Epilepsy and neurodevelopmental phenotypes of human 1q44 microdeletions and 
HNRNPU gene mutations  
 With the advent of oligoarray-based comparative genomics hybridization (aCGH), a surge 
of copy number variants, such as chromosomal microdeletions and microduplications, have been 
identified in pediatric patients with various neurodevelopmental phenotypes. In particular, within 
the past decade, recurring de novo microdeletions involving the distal long arm of chromosome 1 
(1q44) have been described in patients with moderate-severe intellectual disability, corpus 
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callosum abnormalities, seizures, dysmorphic facial features and microcephaly (Caliebe et al. 
2010; Ballif et al. 2012; Zaki et al. 2012; Gupta et al. 2014; Thierry et al. 2012; Selmer et al. 2012; 
Nagamani et al. 2012; Aktas et al. 2010; Hartmann et al. 2015; Du et al. 2014). Approximately 
half of these patients had seizures prior to the age of 3, and also presented with delayed 
development, primarily manifesting as delayed motor and verbal skills with severe speech 
impairment. Axial hypotonia and stereotypical behaviors were also reported along with 
dysmorphic facial features consisting of prominent forehead, hypertelorism, flat nasal bridge and 
malformed, low-set ears. Other systemic abnormalities, including cardiac and renal defects were 
reported as well.  
These deletions encompass multiple genes, which initially presented a challenge with 
regards to narrowing down the genes associated with each phenotype. However, through the 
compilation of numerous patients with overlapping deletions at 1q44, both Thierry and colleagues 
along with Ballif and colleagues independently pinpointed a ~100kb critically-deleted region for 
the seizure phenotype involving the genes FAM36A, HNRNPU and C1ORF199, whereas the 
smallest region of overlap (SRO) for microcephaly and agenesis of the corpus callosum involved 
genes AKT3 and ZNF238, respectively (Thierry et al. 2012; Ballif et al. 2012) (Figure 1.4).  
This 1q44 microdeletion-associated seizure phenotype has since been attributed to the 
haploinsufficiency of HNRNPU (heterogeneous nuclear ribonuclear protein U), as multiple, de 
novo pathogenic mutations within this gene have recently been identified in patients with epileptic 
encephalopathy and intellectual disability (Depienne et al. 2017; Yates et al. 2017; Hamdan et al. 
2014; Bramswig et al. 2017; Leduc et al. 2017; Need et al. 2012; Zhu et al. 2015; Epi4K 
Consortium et al. 2013; de Kovel et al. 2016; Carvill et al. 2013). These pathogenic mutations are 
germline (with the exception of a few mosaic cases) loss-of-function (LoF) variants, along with a 
few splice site and missense variants, all of which are widely-distributed throughout the gene body 
13 
 
(Figure 1.5, Table 1.2). These findings are consistent with a high pLI score of 1 (i.e. the probability 
of being loss-of-function intolerant), which strongly predicts HNRNPU to be a haploinsufficient 
gene based on the lack of loss-of-function mutations identified within the general population (Lek 
et al. 2016).  Overall, these data suggest HNRNPU haploinsufficiency to be the primary mechanism 
of disease.  
 Summary studies of patients carrying these mutations (Figure 1.6) found that nearly 90% 
had seizures with onset typically occurring around one year of age, ranging from only a few months 
to 5 years of age (Yates et al. 2017; Bramswig et al. 2017). The seizure types reported are 
heterogeneous and included generalized tonic-clonic, atypical absence, myoclonic, tonic, atonic 
and nocturnal tonic. Most patients (~62%) initially presented with febrile seizures (seizures 
triggered by fevers), some of which reportedly evolved into afebrile unprovoked, severe epilepsy 
syndromes including West syndrome and Lennox-Gastaut syndrome. While some patients were 
well-controlled on antiepileptics, others remained refractory to treatment. All (100%) patients were 
reported to have moderate to severe developmental delay/intellectual disability primarily affecting 
motor and speech abilities, noted prior to the onset of seizures. Beyond speech impairment, other 
autistic features noted include hand-flapping (35%) and other repetitive behaviors. Increased 
aggression with violent outbursts, Tourette syndrome and hyper-social personality were also 
described. Abnormal findings on brain MRI, including neuronal migration defects, enlarged lateral 
ventricles, corpus callosum defects, delayed myelination, mal-rotated hippocampus, absent 
olfactory bulbs, mild holoprosencephaly, Chiari I malformation, Dandy Walker malformation and 
temporal sclerosis, were found in roughly 60% of patients. Characteristic dysmorphic facies, 





1.4 The cellular and molecular functions of hnRNP U  
 The gene HNRNPU, also known as scaffold-attachment factor A (SAF-A), encodes a 120 
kDa RNA and DNA-binding, nuclear phosphoprotein, and is a member of the broader family of 
heterogeneous nuclear ribonuclear proteins (hnRNPs). The hnRNPs are a group of 20 
predominantly nuclear and highly abundant proteins (rivaling that of histones) that co-
transcriptionally bind to pre-mRNAs produced from RNA polymerase II, and are not constituents 
of other ribonucleoprotein (RNP) complexes, such as small nuclear RNPs (snRNPs) (G. Dreyfuss 
et al. 1993). HnRNP complexes are large, highly dynamic and diverse with no evidence for specific 
organization or structure across their associated pre-mRNAs. Instead, a unique constellation of 
hnRNPs are thought to assemble on each mRNA depending on mRNA sequence, hnRNP post-
translational modifications and abundance (Dreyfuss, Kim, and Kataoka 2002).  The resulting 
hnRNP stoichiometry effects the overall structure and interactions of their respective pre-mRNAs, 
thereby influencing their transcription, splicing, transport, stability, localization and translation.  
HnRNP U is the largest of all the hnRNPs (120kDa), and is generally thought to be 
confined to the nucleoplasm (Kamma, Portman, and Dreyfuss 1995). As with other hnRNPs, 
hnRNP U is highly abundant and ubiquitously expressed (Kamma, Portman, and Dreyfuss 1995; 
Uhlén et al. 2015, Human Protein Atlas available from www.proteinatlas.org). It contains four 
conserved domains: a N-terminal 35-residue DNA-binding SAP domain, C-terminal low-
complexity RNA-binding RGG box, a central SPRY domain and AAA+ domain with putative 
NTP-binding site (Figure 1.7).  The SAP domain is important for binding to AT-rich nuclear 
scaffold/matrix attachment regions (S/MARs) of the genome (Göhring et al. 1997; Romig et al. 
1992), whereas the RGG box functions in binding primarily to GU-rich distal-intronic regions of 
pre-mRNA and chromatin-associated RNAs (caRNAs) (Kiledjian and Dreyfuss 1992). The AAA+ 
domain mediates hnRNP U oligomerization with chromatin-associated RNAs following ATP 
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binding and hydrolysis (Nozawa et al. 2017). And while the function of hnRNP U’s SPRY domain 
is unclear, this domain in general has been shown to mediate protein-protein interactions and is 
often found in proteins that are important in signaling pathways (Woo et al. 2006; D’Cruz et al. 
2013).  
HnRNP U is an essential gene as homozygous hypomorphic mutations result in early 
embryonic lethality in mice by E11.5 (Roshon and Ruley 2005), and homozygous pathogenic 
variants have yet to be reported in humans (Landrum et al. 2018). Given hnRNP U’s ability to 
interact with DNA, RNA, ATP and other proteins including itself, it’s unsurprising that it plays 
such a crucial role in various nuclear processes, including genome organization, transcription, pre-
mRNA processing, X-chromosome activation, mitosis, telomere maintenance, DNA repair and 
apoptosis—each of which are reviewed below.  
Genome organization-  
Through its DNA and RNA binding capabilities, hnRNP U plays a major role in regulating 
3D-chromatin architecture at various levels.  HnRNP U binds AT-rich elements throughout 
S/MAR regions of the genome, and is capable of generating large aggregates/oligomers that in 
turn form looped DNA (Romig et al. 1992). Depletion of hnRNP U reportedly resulted in increased 
overall chromatin condensation and lamina-associated domains (LADs, which consist mostly of 
transcriptionally-silent chromatin), along with chromatin compartment switching of 7.5% of the 
genome, a reduction in the strength of topologically-associated boundaries (TADs) at 
active/inactive compartment borders and an overall decrease in chromatin loop intensities (Fan et 
al. 2018). HnRNP U was also reported to interact with other genome architecture regulators 
including CTCF and RAD21. The authors propose that hnRNP U may serve to stabilize chromatin 
to the nuclear matrix, and thus hnRNP U depletion leads to decreased chromatin constraint. A 
highly complementary study found that hnRNP U oligomerizes and associates with caRNAs 
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through its RGG-box to regulate interphase chromatin structure, predominantly within gene-rich 
chromosomal regions, in response to transcription (Nozawa et al. 2017). This oligomerization was 
dependent on ATP-binding and hydrolysis through hnRNP U’s AAA+ domain, and resulted in the 
decompaction of chromatin. Alternatively, the monomerization or loss of hnRNP U promoted 
irregular chromosome folding and DNA damage, yet surprisingly showed no major effect on 
global gene expression.   
Transcription-  
HnRNP U plays a pleiotropic role in gene expression, influencing various phases of 
transcription including pre-initiation, initiation and elongation by interacting with both cis- and 
trans-acting factors. HnRNP U preferentially associates with active chromatin domains (Fan et al. 
2018). In relation to genes, nearly 60% of hnRNP U binding occurs at promoters, and the strength 
of binding near transcription start sites (TSS) positively correlates with gene expression (Fan et al. 
2018). For example, hnRNP U was shown to complex with the non-phosphorylated C-terminal 
domain (non-phosphoCTD) of RNA Polymerase II (Pol II) at the proximal promoter of the 
pluripotent gene Oct4 in embryonic stem cells, which correlated with an increase in Oct4 
transcription. Furthermore, hnRNP U was shown to bind the promoter regions of the transcription 
factor Klf2, the regulatory gene OPN and the major circadian gene Bmal1, subsequently 
influencing their expression (Gao et al. 2005; Ahmad and Lingrel 2005; Onishi et al. 2008). 
Interestingly, hnRNP U bound the Brna1 promoter in a circadian manner, and was thus found to 
regulate Brna1 circadian expression (Onishi et al. 2008). OPN expression, however, was 
reportedly regulated through competitive antagonistic roles of hnRNP A/B and hnRNP U, where 
hnRNP A/B binding repressed promoter activity and hnRNP U binding to the same site fostered 
activity (Gao et al. 2005).  
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HnRNP U also interacts with other trans-acting factors to influence transcription, including 
transcription factors (TFs), chromatin modifiers, topoisomerase II and long non-coding RNA’s 
(lncRNAs). These interactions can either positively or negatively impact transcription. For 
example, hnRNP U can inhibit transcriptional activation mediated by the TF WT1 through the 
association of WT1 with hnRNP U’s middle domain (containing SPRY and ATP-binding site) 
(Spraggon et al. 2007). HnRNP U has also been described to interact with the ligand-dependent 
glucocorticoid receptor (GR) and Brain-4 (Brn-4) TFs (Eggert et al. 1997; Malik et al. 1997). 
Endogenous hnRNP U also reportedly interacts with BRG1, the ATP-dependent motor subunit of 
the human SWI-SNF chromatin remodeling complex (Vizlin-Hodzic et al. 2011). Simultaneous 
depletion of both hnRNP U and BRG1 abolished global Pol II transcription. In addition, hnRNP 
U associates with the transcriptional coactivator and histone acetyltransferase p300 at S/MAR sites 
prior to transcription activation (Martens et al. 2002). This correlates with local nucleosome 
acetylation, and thus the authors hypothesize that this interaction may prime target genes for 
transcription. Furthermore, topoisomerase II-B (topoIIB, plays a major role in regulating 
transcription in postmitotic neurons) genomic binding targets strongly overlapped with those of 
hnRNP U at AT-rich S/MAR regions adjacent to long genes expressed in neurons. In 
differentiating cerebellar neurons, topoIIB and hnRNP U reportedly associate in an RNA-
dependent manner through hnRNP U’s C-terminal RNA-binding domain (Miyaji et al. 2015). This 
association relieves the RNA-mediated inhibition of topoIIB, promoting topoIIB’s processivity in 
relaxing supercoiled DNA (Kawano et al. 2010).   
Evidence also suggests that hnRNP U is a component of the Pol II holoenzyme in vivo. 
HnRNP U binds nuclear actin through its own C-terminal domain and associates with the 
phosphorylated C-terminal domain (phospho-CTD) of Pol II—the abolishment of which led to 
inhibition of transcription (Kukalev et al. 2005). The authors proposed that this interaction serves 
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as a platform for recruitment of chromatin remodelers and histone acetyltransferases to promote 
elongation of Pol II. A follow-up study indeed found that the histone acetyltransferase PCAF is a 
component of this actin-hnRNP U complex, and that they associate together on the 
hyperphosphorylated form of Pol II CTD considered to be important for the elongation phase of 
transcription (Obrdlik et al. 2008). Both PCAF activity and BrUTP incorporation was reduced 
following the disruption of this actin-hnRNP U interaction. Furthermore, PCAF, actin and hnRNP 
U were all present at both the promoters and coding regions of the tested genes, and were 
associated with ribonuclear protein complexes (RNPs). These data together support a major role 
for PCAF-actin-hnRNP U in the elongation phase of transcription. H19, a lncRNA that regulates 
development, was found to disrupt this actin-hnRNP U interaction, ultimately preventing the Ser5 
phosphorylation of Pol II CTD and thus inhibiting transcription (Bi et al. 2013; Yanling Wang et 
al. 2007). Interestingly, a conflicting study identified hnRNP U as an inhibitor of TFIIH-mediated 
phosphorylation of the Pol II CTD and thus repressor of transcription elongation (Kim and 
Nikodem 1999). This effect relied on the association of hnRNP U’s middle domain with Pol II. 
While hnRNP U was found in the Pol II holoenzyme as part of the preinitiation complex, hnRNP 
U was subsequently reported to dissociate from the complex upon elongation.       
Pre-mRNA processing-  
HnRNP U functions as a global regulator of alternative splicing. Depletion of hnRNP U in 
human cells resulted in an array of splicing defects including intron retention, cassette exon events, 
alternative 5’ or 3’ exons and alternative start and ending exons (Huelga et al. 2012). However, 
the majority of observed events were cassette exons (46%), 71% of which resulted in exon skipping 
upon lack of hnRNP U, indicating that hnRNP U most often functions as an activator of exon 
inclusion. HnRNP U was also found primarily bound to GU-rich distal intronic regions of pre-
mRNA, but also bound to proximal intronic, 5’ UTR, 3’ UTR and exons, yet at lower frequencies. 
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These data were further supported by an independent study evaluating the homozygous conditional 
deletion of hnRNP U in cardiomyocytes, which also identified an extensive level of intron 
retention events and cassette exon events (Ye et al. 2015). Of the cassette-exon events observed, 
the majority (77%) were exon skipping events, consistent with the prior study’s results that hnRNP 
U most often promotes exon inclusion. A study investigating the mechanisms underlying this 
hnRNP U-mediated splicing failed to uncover a direct role for hnRNP U in splicing (Xiao et al. 
2012). Specifically, hnRNP U binding events only correlated with splicing changes in 8-10% of 
cases, suggesting that splicing effects may not be related to direct hnRNP U binding. Instead, the 
authors found that hnRNP U binds to all classes of non-coding RNAs, including small nuclear 
RNAs (snRNAs), and subsequently regulates U2 snRNP maturation and Cajal body formation. 
Specifically, loss of hnRNP U led to increased formation of the mature 17S U2 snRNP, an increase 
in the number of Cajal bodies and aberrant splicing.  
X-chromosome activation-  
HnRNP U is essential for the accumulation of Xist across the inactive X chromosome 
(Hasegawa et al. 2010). Proper Xist localization is reliant on both hnRNP U’s DNA binding SAP 
domain for interaction with matrix attachment elements, and RGG RNA binding domain for direct 
interaction with Xist RNA. Embryonic stem cells lacking hnRNP U fail to form the inactive X, 
resulting in biallelic gene expression from both X chromosomes.  
Mitosis-  
During mitosis, hnRNP U is localized to the spindles, spindle midzone and cytoplasmic 
bridge (Ma et al. 2011). This interaction with the mitotic spindle is dependent on hnRNP U’s 
association with Aurora-A kinase and the microtubule-binding/nucleator TPX2 (Targeting Protein 
for Xklp2). Depletion of hnRNP U led to a delay in mitosis and aberrant chromosomal alignment 
and spindle assembly. During mitosis, hnRNP U is also reportedly phosphorylated at Ser59 by 
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Polo-Like Kinase 1 (PLK1) and dephosphorylated by Protein Phosphotase 2A (PP2A), which are 
both required for proper exiting from mitosis (Douglas et al. 2015). Abolishment of this serine 
residue results in misaligned and lagging chromosomes and delayed mitosis. 
Telomere maintenance-  
HnRNP U copurified with the human telomerase reverse transcriptase (hTERT) and human 
telomerase RNA (hTR) (Landrum et al. 2018). Overexpression of hnRNP U led to progressive 
telomere shortening. Fu and Collins propose that hnRNP U could function to retain telomerase 
ribonuclear particles in the nucleus.  
DNA-repair-  
HnRNP U is phosphorylated at Ser59 by DNA-dependent protein kinase (DNA-PK) 
following double stranded breaks (Britton et al. 2009; Berglund and Clarke 2009). The degree of 
phosphorylation was inversely correlated to non-homologous end-joining repair capability 
(Britton et al. 2009). While hnRNP U is transiently recruited to damaged sites in a poly(ADP-
ribose)-dependent manner, it subsequently dissociates from these regions upon activity of kinases 
ATM, ATR and DNA-PK (Britton et al. 2014). Britton and colleagues propose that this represents 
an anti-R-loop mechanism at damaged transcription sites through the exclusion of mRNA 
biogenesis factors, such as hnRNP U. HnRNP U also reportedly interacts with NEIL1, a DNA 
glycosylase that initiates oxidized base excision repair, which enhances cell survival following 
oxidative stress through increasing NEIL1-mediated repair (Hegde et al. 2012).       
Apoptosis-   
 HnRNP U competes with hnRNP L for binding to exon 3 of caspase-9 transcripts, which 
promotes the production of the pro-apoptotic caspase-9a isoform (Vu et al. 2013). Furthermore, 
during early apoptosis, hnRNP U itself is cleaved within the DNA-binding domain in a caspase-
dependent manner, resulting in detachment from matrix attachment elements (yet RNA-binding 
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capability remains) (Göhring et al. 1997). Gohring and colleagues speculate that this dissociation 
could contribute to DNA fragmentation and nuclear breakdown.   
 
1.5 Hypothesis, research strategy and specific aims 
 Despite this wealth of research on hnRNP U’s role in various nuclear processes, the link 
between hnRNP U and disease remains obscure. Hnrnpu is an essential gene, with homozygous 
hypomorphic mutations resulting in embryonic lethality by E11.5 in mice (Roshon and Ruley 
2005). Interestingly, cell lines isolated from homozygous mutant pre-implantation blastocysts 
revealed only a 2- to 5- fold decrease in hnRNP U transcript levels, suggesting that near-normal 
levels of hnRNP U are required for development. A conditional knockout of Hnrnpu in 
cardiomyocytes also resulted in a lethal postnatal dilated cardiomyopathy associated with a 
multitude of abnormal splicing events, further supporting a critical role for hnRNP U in 
developmental processes  (Ye et al. 2015).  
Yet, how and why this abundant, ubiquitously-expressed gene causes a severe, early-onset 
neurodevelopment disease upon loss of one copy has yet to be investigated. In fact, the role of 
hnRNP U in the brain in general is unclear. HnRNP U, however, has been linked to the 
pathogenesis of amyotrophic lateral sclerosis (ALS) through interactions with various ALS-
associated proteins including the RNA-DNA binding protein TDP-43 and the RNA-binding 
protein FUS (Ebstein 2017; Suzuki et al. 2015). Upon overexpression, hnRNP U hampered TDP-
43-mediated toxicity in a neuronal cell line, whereas knockdown of hnRNP U caused neurotoxicity 
(Suzuki et al. 2015). Furthermore, conditional knockout of hnRNP U in motor neurons resulted in 
a reduced lifespan, with abnormal appearing nuclear morphology of motor neurons and loss of 
innervation to the tongue, diaphragm and tibialis anterior muscles (Ebstein, 2017). These findings 
underscore an essential role of hnRNP U in neuron survival. HnRNP U also plays an important 
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role in circadian regulation through binding to promoters of important circadian effectors, 
including Avp, Vip and Bmal1, in a circadian manner to augment gene expression (Lai et al. 2018; 
Onishi et al. 2008). Hnrnpu itself is expressed in a circadian pattern in the suprachiasmatic nucleus 
(SCN)—the region of the brain that controls circadian rhythm—with peak expression during the 
night, which is the typical active period for mice (Tamaru et al. 2003).  Heterozygous loss of 
Hnrnpu in mice resulted in hyperactivity during the day and inactivity during the night, along with 
altered metabolic rhythms (Lai et al. 2018). This locomotor phenotype was partially rescued by 
microinjection of Vip and Avp peptides. Lastly, the c. elegans homolog of hnRNP U, hrpu-2, was 
reported to regulate the expression of slo-2 expression, the homolog of the KCNT1 and KCNT2 
voltage-gated sodium channels (Liu et al. 2018). The authors report that loss of function mutations 
in hrpu-2 results in impaired SLO-2-mediated synaptic transmission. Overall, these studies argue 
that the dysregulation of important neuronal hnRNP U targets can produce abnormal neurological 
phenotypes.  
Further insight into HNRNPU-mediated epilepsy and neurological disease may be drawn 
from other RNA or DNA binding proteins, including fellow members of the hnRNP family, which 
have been implicated in various neurodevelopmental and neurodegenerative disorders. For 
example, pathogenic mutations in hnRNP A1, hnRNP A2B1 and hnRNP P2 (a.k.a. FUS), have 
been reported in cases of ALS and frontotemporal dementia (FTD) (Purice and Taylor 2018). 
Additionally, mutations in other RNA binding proteins SMN1, FMRP, RBFOX1 and PUM1 are 
causative of spinal muscular atrophy (SMA), Fragile X syndrome, autism spectrum disorder 
(ASD) and spinocerebellar ataxia, respectively (Nussbacher et al. 2019; Gennarino et al. 2018). 
Furthermore, mutations in DNA-binding proteins, such as the chromatin remodeler CHD8 and the 
methyl-CpG-binding protein MECP2, are causative of ASD and Rett syndrome, respectively 
23 
 
(Gompers et al. 2017; Bernier et al. 2014; Amir et al. 1999). These are only a few of the many 
examples of neurological disease-associated RNA and DNA binding proteins. 
And while the mechanisms underlying diseases caused from these RNA or DNA binding 
proteins are diverse, one common, unifying theme that has emerged over decades of research is 
altered RNA homeostasis. This could be at the level of gene transcription or downstream 
processing, transport or translation of target transcripts. For example, haploinsufficiency of the 
ASD gene Chd8 in mice causes transcriptional changes involving its target, promoter-bound genes 
(Gompers et al. 2017). These dysregulated targets were downregulated in expression, suggesting 
that Chd8 is important for specifically activating the expression of its targets. Furthermore, these 
targets were enriched for genes implicated in ASD along with genes important for chromatin 
control, cell cycle and RNA processing. The authors subsequently validated the presence of 
abnormal neuronal proliferation and perturbations in splicing throughout development in Chd8 
mutants. Another example is Rbfox1, an RNA binding protein associated with ASD, intellectual 
disability and epilepsy. Loss of Rbfox1 in mice resulted in aberrant splicing of target transcripts 
that are important for neuronal excitability and synaptic function (Gehman et al. 2011). A final, 
hallmark example is the RNA binding protein Fmrp associated with Fragile X syndrome, which 
plays a critical role in the transport and local translation of its specific targets, ultimately 
influencing synaptic transmission and plasticity (Santoro, Bray, and Warren 2012). Loss of Fmrp 
results in excessive protein synthesis at the post-synapse and synaptic dysfunction.  
Given the functional complexity and diversity of neurons, it is unsurprising that neurons 
are particularly reliant on the tight regulation of RNA and gene dosage, and both RNA and DNA 
binding proteins help to achieve this level of regulation. Likewise, slight changes in the levels of 
RNA binding proteins, for example, may be further exacerbated given their frequent effects on 
multiple levels of gene expression of their target transcripts (Nussbacher et al. 2019). Based on 
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this paradigm and given hnRNP U’s extensive role in gene expression regulation, I hypothesized 
that heterozygous loss of Hnrnpu results in transcriptional dysregulation of targets important for 
proper neuronal development and function. Furthermore, this dysregulation culminates in a 
“perfect storm” of cellular perturbations over time that ultimately impairs neuronal homeostasis, 
leading to disease expression. Through a comprehensive dive into the transcriptome of the 
neocortex and hippocampus, a major goal of this work was to pinpoint possible disease-relevant 
cell-types and genes that could be further interrogated with regards to their role in abnormal 
phenotypes and their potential for therapeutic tractability. The overall research strategy to achieve 
these goals is summarized in the following chapters of this dissertation and are highlighted in 
Figure 1.8:  
 
Chapter 1. Generation and Characterization of a Constitutive Hnrnpu+/- Mouse Model.  Mice 
containing a heterozygous loss-of-function mutation in Hnrnpu were generated, and associated 
electrophysiological, developmental and behavioral phenotypes were characterized.  
 
Chapter 2. Ascertainment of Potential Disease-Relevant Target Genes and Cell Types. 
Comprehensive gene expression profiling was performed using both bulk RNA-sequencing of 
neocortex, and single-cell RNA-sequencing of neocortex and hippocampus—two of the major 
brain regions implicated in epilepsy. Subsequent downstream analyses involving differential gene 
expression were performed at the bulk and single-cell level in effort to identify possible disease-




Chapter 3. Functional Evaluation of Transcriptionally-Vulnerable Brain Regions. 
Prospective disease-relevant brain regions were functionally interrogated using available in vitro 
electrophysiology and in vivo screening strategies.  
 
Overall, using this approach, I, in collaboration with others, was able to identify clear 
neurological phenotypes in the Hnrnpu mutant mice, such as seizure susceptibility and 
developmental delay, that overlap with patient symptoms. Furthermore, we observed global 
transcriptional dysregulation that occurs in a cell type-specific manner, and that preferentially 
affects long, neuronally-expressed genes important in various neuronal pathways. We found that 
the subiculum of the hippocampus, in particular, has excess transcriptomic burden, including 
known neurodevelopmental disease genes. We used both electrophysiological and molecular 
studies to evaluate for resulting regional-specific differences in activity involving the subiculum 
compared to other brain regions, and discovered an overall decrease in the number of active 
neurons in the subiculum. Additional studies aimed at elucidating the significance of this finding 
in relationship to hnRNP U-related seizures and other neurological comorbidities are warranted as 














Figure 1.1 Schematic of ILAE classification of the epilepsies. Epilepsy subtypes (gray box) are 
classified based on the seizure type (blue box), which is determined by the origin of seizure onset.  
In certain cases, epilepsy may be part of a broader syndrome (purple box) based on age of onset, 
seizure triggers and prognosis. With each level of classification, there may be existing 
comorbidities such as psychiatric disease, autism, traumatic brain injury, social stigma, etc. that 


























Figure 1.2 Overview of seizure timing. Transient shifts in excitatory and inhibitory balance 
(shown as the gray, blue and green) may cross a specific “seizure threshold” (dotted red line) 



























Figure 1.3 Genetic architecture of the epilepsies. Inherited or de novo highly-penetrant, single 
“large-effect” mutations often cause early-onset, severe epilepsies. On the opposite end of the 
spectrum, numerous genetic modifiers or susceptibility alleles of “small-effects” may influence or 
predispose individuals to epilepsy. Epilepsies with complex inheritance fall in the middle of the 
spectrum, containing variants of variable effect size that impact disease expression (adapted from 






































AARS CHRNA7 GABRA6 KCNA2 PNKP SLC25A22
ADRA2B CHRNB2 GABRB1 KCNB1 PNPO SLC2A1
ALDH7A1 CLCN2 GABRB2 KCNC1 PPP3CA SLC35A2
ALG13 CLCN4 GABRB3 KCND2 PRDM8 SLC6A1
AP3B2 CLN8 GABRD KCND3 PRICKLE1 SNIP1
ARHGEF9 CNTN2 GABRG2 KCNH5 PRICKLE2 SPTAN1
ARX CNTNAP2 GAL KCNMA1 PRRT2 SRPX2
ASAH1 CPA6 GNAO1 KCNQ2 RELN ST3GAL3
ATP1A2 CSTB GNB1 KCNQ3 SCARB2 ST3GAL5
CACNA1A DENND5A GOSR2 KCNT1 SCN1A STRADA
CACNA1H DEPDC GRIN1 KCNV2 SCN1B STX1B
CACNA2D2 DNM1 GRIN2A KCTD7 SCN2A STXBP1
CACNB4 DOCK7 GRIN2B LGI1 SCN3A SYN1
CAD EEF1A2 GRIN2D LMNB2 SCN8A SYNGAP1
CASR EFHC1 GUF1 MEF2C SCN9A SYNJ1
CDKL5 EPM2A HCN1 NHLRC1 SHANK3 SZT2
CERS1 FGF12 HCN2 PCDH19 SIK1 TBC1D24
CHD2 FOXG1 HNRNPU PHGDH SLC12A5 UBA5
CHRNA2 FRRS1L IER3IP1 PIGA SCL13A5 USP19
CHRNA4 GABRA1 IQSEC2 PIGP SCL1A2 WWOX




Figure 1.4 Summary of reported overlapping 1q44 microdeletions containing the smallest 
region of overlap for seizure phenotype. This region of overlap consists of genes HNRNPU, 
FAM36A and C1ORF199. Deletions manifesting in seizures are highlighted in red. (Illustrated 
deletions were compiled from Caliebe et al. 2010; Ballif et al. 2012; Zaki et al. 2012; Gupta et al. 
2014; Thierry et al. 2012; Selmer et al. 2012; Nagamani et al. 2012; Aktas et al. 2010; Hartmann 









Caliebre et al., 2010; Balif et al., 2012;  Zaki et al., 2012; Gupta et al., 2013; Thierry et al., 2013; Selmer et al., 2012; Nagamani et al., 
2012; Aktas et al., 2010, Hartman et al., 2015, Du et al., 2014  
Seizures
No seizures
1q44 microdeletion encompasses HNRNPU and is associated with 






Table 1.2 Summary of pathogenic HNRNPU variants reported in the literature to date. All 
pathogenic mutations reported in the literature to date (HNRNPU transcript variant 1, 
NM_031844.2) with the associated amino acid change and mutation type (PPT= predicted protein 











cDNA change (NM_031844.2) Amino Acid change Mutation Type Inheritance Reference
c.16delins p.Val6Ilefs*4 PPT Paternal mosaicism Depienne et al., 2017
c.23del p.Val8Glufs*4 PPT De novo Yates et al., 2017; 
c.418G>A p.Glu140Lys Missense De novo Yates et al., 2017
c.511C>T p.Gln171* PPT De novo Hamdan et al., 2014
c.523C>T p.Gln175* PPT De novo Bramswig et al., 2017
c.651_660del p.Gly218Alafs*118 PPT De novo Leduc et al., 2017
c.692-1G>A p.? Splice site De novo Depienne et al., 2017; 
c.817C>T p.Gln273* PPT De novo Bramswig et al., 2017
c.960G>A p.Trp320* PPT De novo Yates et al., 2017; 
c.970A>G p.Arg324Gly Missense De novo Bramswig et al., 2017
c.1089G>A p.Trp363* PPT De novo Leduc et al., 2017
c.1117+1G>A p.? Splice site De novo Yates et al., 2017; 
c.1132T/C p.Ser378Pro Missense De novo Bramswig et al., 2017
c.1424_1425insTC p.Ile476Profs*7 PPT De novo Yates et al., 2017; 
c.1615-1G>A c.1615-1G>A Splice site De novo Need et al., 2012; Zhu et al. 2015
c.1626_1627insA p.Lys543* PPT De novo Yates et al., 2017; 
c.1664del p.Leu555Argfs*51 PPT De novo Yates et al., 2017; 
c.1681C>T p.Gln561* PPT De novo, mosaic Depienne et al., 2017
c.1681del p.Gln561Serfs*45 PPT De novo Depienne et al., 2017
c.1714C>T p.Arg572* PPT De novo Leduc et al., 2017
c.1744-4_1749del p.? Splice site De novo Epi4K Consortium et al. 2013
c.1868dup p.Glu624Argfs*24 PPT De novo Depienne et al., 2017; de Kovel et al., 2016
c.2270_2271del p.Pro757Argfs*7 PPT De novo Leduc et al., 2017
c.2299_2302del p.Asn767Glufs*66 PPT De novo; mosaic Depienne et al., 2017
c.2425-3C>A p.? Splice site De novo Depienne et al., 2017
c.2471_2472delinsGA p.Tyr824* PPT
Unknown; mother 








Figure 1.5 Distribution of HNRNPU pathogenic variants.  The location of all predicted 
pathogenic variants, including protein truncating, splice site and missense, reported in the literature 































Figure 1.6 Clinical features associated with pathogenic HNRNPU mutations. (A) Common 
dysmorphic facial features (including hypertelorism, deep set eyes, bulbous nasal tip, depressed 
nasal bridge, long philtrum) and (B) phenotypes and their reported frequency among patients with 






















Figure 1.7 Conserved domains of hnRNP U. The N-terminal SAP domain binds DNA, the C-
terminal RGG-box binds pre-mRNA, the AAA domain is important for catalyzing hnRNP U 
oligomerization. The precise function of the SPRY domain remains unclear, yet is important for 
its interaction with nuclear actin and likely mediates other hnRNP U-protein interactions. HnRNP 





























Figure 1.8 Diagram illustrating the precision medicine framework underlying this thesis 
work. HNRNPU neurodevelopmental syndrome is modeled using a CRISPR/Cas9-generated 
heterozygous loss-of-function mouse model. Neuronal phenotypes, such as seizure, behavioral or 
neuroanatomical abnormalities, were first assessed and characterized. To identify potential 
disease-relevant dysregulated targets and vulnerable cell types of hnRNP U, a comprehensive 
transcriptomic profile of both the neocortex and hippocampus was obtained. Candidate targets 
were further interrogated for their relationship to known abnormal neuronal phenotypes and as 






Chapter 2: Generation and Characterization of a Constitutive 
Hnrnpu+/- Mouse Model   
2.1 Introduction 
As extensively reviewed in Chapter 1, de novo copy number variants (CNVs), intragenic 
deletions and single nucleotide variants (SNVs) encompassing the gene HNRNPU have been 
identified in association with an early infantile, EE in humans (OMIM# 602869: Epileptic 
encephalopathy, early infantile, 54). Regardless of whether the patient carries a microdeletion or 
a SNV involving HNRNPU, this disorder primarily manifests with moderate to severe intellectual 
disability (100%), severe speech impairment (100%), early-onset seizures (88%), short stature 
(52%), hypotonia (74%), other CNS abnormalities and atypical facial features (Bramswig et al. 
2017). These patients also frequently display autistic-like behaviors.  
Given the de novo, heterozygous microdeletions and loss-of-function mutations identified 
in patients and failure to identify these variants in the general population, along with the 
essentiality of Hnrnpu for mouse embryonic development, haploinsufficiency of HNRNPU has 
long been the leading explanation for cause of disease. As such, I aimed to model HNRNPU 
haploinsufficiency by evaluating mice containing a constitutive loss-of-function mutation in a 
single copy of the mouse Hnrnpu homologue.  
In effort to evaluate the resulting face validity (i.e. the degree of recapitulation of the 
phenotypic features observed in the human condition) of this mouse model, I in collaboration with 
others performed a wide array of characterization studies that assess for electrophysiologic, 
developmental, behavioral and neuroanatomic differences in the Hnrnpu mutant line. These 
studies are presented in detail within this chapter and include:  
• Growth & viability analysis 
• Gross neuroanatomy  
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• Developmental milestones 
• Adult behavior 
• Electroencephalography (EEG) 
• Electroconvulsive threshold (ECT) studies 
This gamut of studies was particularly chosen to not only reveal potential overlapping 
phenotypes between the mouse and human condition, but to also serve as future platforms on which 
to investigate the role(s) of candidate disease-relevant hnRNP U targets as well as any promising 
therapeutic strategies.  
Of the following studies, immunofluorescence of Hnrnpu localization was performed by 
myself. Hnrnpu CRISPR/Cas9 targeting was performed by Dr. Wayne Frankel’s group in 
collaboration with The Jackson Laboratory. Validation of mutant progeny, expansion and 
maintenance of the mutant line was performed by myself. Quantitative PCR and western blotting 
were performed by myself, along with all viability and growth assessments, developmental 
milestone and ultrasonic vocalization studies, including obtaining and analyzing data. I received 
assistance with quantifying pup ultrasonic vocalizations by Gino Montero and Gabriela Sampaio. 
All adult neurobehavior studies, including obtaining, analyzing and interpreting data, were 
performed by Dr. Mu Yang and Lizzie Rafikian of the Mouse Neurobehavioral Core. 
Electroencephalography studies, including surgical procedure, video recordings and review of 
recordings, were performed by Dr. Verity Letts and Sabrina Petri in Dr. Wayne Frankel’s group. 
Electroconvulsive threshold studies, including the procedure and data analysis, were performed by 
Dr. Wayne Frankel. Neuroanatomical studies, including brain dissection and slicing, along with 
imaging and analysis were performed by myself. Blinded review of images was completed by Dr. 





Generation of the Hnrnpu knockout mouse model 
HnRNP U is a highly-abundant, ubiquitously-expressed, nuclear protein. Expression is 
widespread throughout the mouse brain (Figure 2.1A). Among the neocortex and hippocampus—
two brain regions strongly implicated in epilepsy—total hnRNP U protein levels appeared higher 
in the hippocampus compared to the neocortex (Figure 2.1B). In the neocortex, hnRNP U co-
stained with the neuronal marker Map2, along with markers of various neuronal subtypes including 
inhibitory neurons (Gad67), deeper layer (Ctip2) and upper layer (Satb2) pyramidal neurons 
(Figure 2.1D-F). HnRNP U also co-stained with the astrocyte marker Gfap (Figure 2.1G). For all 
cells examined, hnRNP U expression appeared confined to the nucleus, as previously reported (G. 
Dreyfuss, Choi, and Adam 1984).  
In effort to model the loss-of-function mutations identified in patients, in collaboration with 
Wayne Frankel’s laboratory and Jackson Laboratory’s Genome Engineering Technology Core, 
exon 1 of mouse Hnrnpu was targeted using CRISPR/Cas9 to induce a constitutive out-of-frame 
insertion or deletion (indel) resulting in an N-terminal premature stop codon. Of the 15 potential 
founder progeny that survived to weaning, PCR and sequence analysis revealed that all contained 
indels of varying sizes. Six candidates that appeared most promising based on TIDE analysis were 
further evaluated using Topo-TA cloning to validate the resulting mutant allele(s). A single 
founder containing a 113-bp out-of-frame deletion (herein referred to as Hnrnpu113DEL) resulting 
in a premature stop codon in exon 2 was further expanded and maintained on a C57BL/6NJ 
background (Figure 2.2A).  
Quantitative RT-PCR and western blotting performed on isolated cerebral cortex of 
postnatal day 0 (P0) mice revealed only a modest and statistically insignificant reduction of around 
20-25% for both mRNA and protein levels in Hnrnpu+/113DEL pups (Figure 2.2B-C). These data 
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therefore suggest a potential compensatory feedback mechanism upregulating Hnrnpu expression 
in Hnrnpu+/113DEL mice (see Discussion). Furthermore, western blotting using an antibody that 
binds N-terminal to the deletion breakpoints failed to reveal an N-terminal-truncated version of 
hnRNP U (Figure 2.2D).  Hnrnpu+/113DEL intercrosses also revealed skewed Mendelian ratios, with 
failure to recover any homozygous progeny consistent with embryonic lethality, which has been 
previously reported with a different hnRNP U protein truncating conditional line and hypomorphic 
mutant line (Ye et al. 2015; Roshon and Ruley 2005) (Figure 2.2E).  
 
Growth & viability 
Hnrnpu+/113DEL mice also demonstrated increased perinatal mortality. While 
Hnrnpu+/113DEL by WT crosses revealed normal Mendelian ratios at P0, only about half the mutants 
were recovered on or beyond P10 (Fisher Exact Test (FET), p= 8x10-4) (Figure 2.3A-B). 
Intriguingly, there was a disproportionally higher loss of female mutants, with 0.27 odds of 
recovering a female mutant (FET p= 2x10-4) compared to 0.74 for males (FET p= 0.41) (Figure 
2.3A-C). While the cause of death was never formally determined, pups were frequently 
discovered trampled outside of the nest or cannibalized, most often within the first three days of 
age.  
Growth was also substantially impaired for Hnrnpu+/113DEL mice. At birth, mutant pups 
weighed on average 10% less than wildtype controls (MWU, permuted p=5.0E-03) (Figure 2.3D). 
This growth impairment was further exacerbated throughout the juvenile period, by which P12 
mutants weighed roughly 25% less than controls (permuted MWU p<0.01 for all time points) 
(Figure 2.3E). This degree of growth impairment also persisted throughout the juvenile period and 





To assess the presence of major neuroanatomical defects, such as seen in patients with 
1q44 microdeletions and HNRNPU gene mutations, histological evaluation was performed on 
whole brains of P0 pups using H&E staining.  Measurements of brain size, cortical thickness and 
hippocampal width did not reveal any notable mutant-specific differences (Figure 2.4A-B). 
However, review of images by a blinded reviewer (in collaboration with Wayne Frankel’s 
Laboratory) revealed that cells in CA1 (red arrow) and CA3b and CA3c regions (black arrow) of 
the mutant hippocampus were abnormally organized into two distinct layers indicating a 
lamination deficit (Figure 2.4C). Furthermore, mutants showed fewer axon fascicles in the striatum 
(Figure 2.4D). Unlike those in wildtype mice, these fascicles also appeared discontinuous and 
spotty (red arrowheads, Figure 2.4D), indicating a change in projection trajectory. Both of these 
findings suggest defective axonal guidance in mutants.   
 
Pup development 
In order to evaluate early postnatal behavioral development including reflex, sensorimotor 
and vestibular function and body strength, a series of developmental milestone studies were 
performed on pups ages P4 through P12, including righting reflex, negative geotaxis and vertical 
screen hold. The righting reflex (a.k.a. surface righting) test, which assesses the total time it takes 
a pup to orient from a supine to prone position, requires both sensory and motor inputs to adjust 
posture in response to the supine position (Vidal et al. 2004; Nguyen, Armstrong, and Yager 2017).  
Negative geotaxis, another independent measure of sensorimotor and vestibular function, is the 
total time it takes a pup to orient horizontally (90°) and fully upright (180°) after being placed face 
down on a 45° incline (Hill, Lim, and Stone 2008). The vertical screen test evaluates the latency 
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to fall upon placing the mouse upright on a 180° screen, and primarily assesses the grip strength 
of all four paws (Feather-Schussler and Ferguson 2016).  
When analyzing individual timepoints, Hnrnpu+/113DEL mutant mice showed a modest 
impairment in both righting reflex at P10 and the 90° negative geotaxis at P12, highlighting a trend 
towards delayed sensorimotor function (MWU permuted p=1.0E-03 and p=4.0E-03, respectively) 
(Figure 2.5A, C). There was no significant difference in 180° negative geotaxis for any time points 
(Figure 2.5D). Hnrnpu+/113DEL pups also showed a subtle increase in latency to fall, particularly at 
P6, as assessed through the vertical screen test (MWU permuted p=0.05) (Figure 2.5B). Of note, 
latency to fall was not significantly correlated with body weight (spearman r= -0.27, p= 0.13).  
To further assess for developmental delay in Hnrnpu+/113DEL pups, we evaluated separation-
induced ultrasonic vocalizations (USVs) in pups. USVs are functionally important signals that 
elicit maternal retrieval and care. Various abnormalities in pup vocalizations have been previously 
described in models of human communication disorders such as autism (Scattoni et al. 2008a; 
Wöhr et al. 2011; Michetti, Ricceri, and Scattoni 2012); however, whether this behavior serves as 
a correlate of human speech is highly controversial in the field. 
Analysis of pup USVs across all postnatal days tested revealed substantially reduced calls 
emitted by Hnrnpu+/113DEL pups, with a striking deficit observed at P5 and P7 (permuted MWU 
p=7.0E-03 and <1.0E-04, respectively) (Figure 2.6A, E). Further analysis of USV acoustic 
properties at P5 and P9 in collaboration with Dr. Mu Yang in the Mouse Neurobehavioral Core 
revealed a shorter duration (permuted MWU p=2.0E-03 and <1E-04, respectively) and overall 
higher frequency/pitch (permuted MWU p=7.0E-03 and 0.02, respectively) in mutants than 
controls (Figure 2.6B, C, E). Mutant vocalizations also trended towards having an increased peak 
amplitude (i.e. loudness), although this observation was only significant at P9 (permuted MWU 





In light of the moderate to severe intellectual disability, motor and neuromuscular 
impairments along with autistic-like behaviors observed in patients with HNRNPU mutations, 
adult mice were assayed for learning and memory, anxiety-like behaviors, locomotor activity and 
gait. In collaboration with Dr. Mu Yang in the Mouse Neurobehavioral Core, tests performed 
included elevated plus-maze, open field, Catwalk, Morris water maze, Y-maze, fear conditioning 
and acoustic startle response.  
The elevated plus-maze test did not reveal significant changes in anxiety-like behaviors. 
The percent time spent in the open arms (unpaired Welch’s t-test p=0.47) (Figure 2.7A) or in total 
arm entries (unpaired t-test p=0.12) (data not shown) were no different between genotypes. 
Evaluation of open field exploratory behavior revealed a significant main effect of genotype (two-
way Repeated Measures (RM) ANOVA p= 0.026) on total distance traveled, with Hnrnpu+/113DEL 
mice moving more during the first two 10 min time bins (t-test p<.05 for each), indicating a 
transient, novelty-induced hyperactivity in mutants (Figure 2.7B). No significant genotype effect 
was found for time spent in the center zone (two-way RM ANOVA p=0.09), further supporting 
normal anxiety-like behaviors (Figure 2.7C).  
Catwalk analysis of gait, motor function and coordination, revealed a number of intriguing 
findings, the most striking of which was a marked reduction in hind paw print size in 
Hnrnpu+/113DEL mice compared to controls (t-test p<1.0E-04), with only a modest change in front 
paw print size (t-test p=0.024) (Figure 2.7D). While visual examination did not reveal an actual 
change in paw size or clasping, a closer examination of catwalk print images revealed that mutant 
digits and/or foot pads make less contact with the ground (Figure 2.7E). The max contact max 
intensity (MCMI, or maximal intensity of the maximal contact area) was significantly reduced for 
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the hind paws (MWU p<1.0E-04) and trending towards reduced for the front paws (MWU p=0.08) 
(Figure 2.7F). These data indicate reduced weight bearing of the hind limbs. Moreover, base of 
support (BOS) of the hind paws (i.e. the width of stance) was significantly wider in mutants (MWU 
p=1.5E-03), yet was not different for the front paws (MWU p=0.08) (Figure 2.7G), likely reflecting 
a compensatory strategy in mutants with impaired hind limb support and stability. Furthermore, a 
least squares regression model showed no significant effect of weight and sex on hind paw features 
(MCMI p-values: sex= 0.64, weight= 0.13; paw print area p-values: sex= 0.17, weight= 0.77; BOS 
p-values: sex= 0.88, weight= 0.11), indicating that a bias in sex or reduced weight does not drive 
mutant-specific differences. Finally, the regularity index, or percentage of the run that was 
sequential (a measure of coordination), was not significantly different between the two genotypes, 
indicating normal coordinated walking (MWU p=0.13) (Figure 2.7H). Overall, these findings 
underline a potential, mild neuromuscular deficit in mutants.  
Spatial learning and memory were assessed using Morris water maze (MWM).  Mice of 
both genotypes reached criterion (finding the hidden platform in 15 seconds or less by day 5) 
during acquisition training. There were no significant genotype differences in latency to reach the 
hidden platform (two-way RM ANOVA p= 0.22) or in swim distance (two-way RM ANOVA 
p=0.1) (Figure 2.7I-J). Interestingly, swim speed was significantly slower in mutants across days, 
further suggesting the presence of neuromuscular deficits (two-way RM ANOVA p<1.0E-03) 
(Figure 2.7K). In the probe trial (hidden platform removed), WT mice spent significantly more 
time in the trained quadrant than in quadrants right to and opposite of the trained quadrant (one-
way RM ANOVA on ranks, p<0.01 for both), and Hnrnpu+/113DEL spent more time in the trained 
quadrant than in the opposite quadrant (one-way RM ANOVA on ranks, p=2.0E-03) (Figure 2.7L). 
Together, these data indicate that spatial learning and memory in mutants are largely comparable 
to WT, despite slower swim speed.  
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Y maze data also support normal spatial memory in mutants. In the novel arm preference 
test, both WT and Hnrnpu+/113DEL spent more time in the novel arm than in the familiar arm (one-
way RM ANOVA, HET p=3.0E-03, WT p=5.0E-03) (Figure 2.7M). Furthermore, no genotype-
specific differences in percent alteration were observed in the spontaneous alteration test, (Welch’s 
t-test p=0.86) consistent with normal spatial working memory (Figure 2.7N). Fear conditioning 
data were less straightforward to interpret. A global reduction of freezing in mutants was observed 
post-shock, and during contextual conditioning, pre-cue and cued conditioning (MWU p= 7.0E-
04, <1.0E-04, 0.022, 1.8E-03, respectively) (Figure 2.7O). Increasing or decreasing the movement 
threshold captured by the software yielded qualitatively similar results (data not shown). This 
reduced overall freezing precludes conclusive evaluation of conditioning memory in mutants. 
Acoustic startle response did not differ between genotypes across five different decibel levels (t-
test p=0.96), ruling out deafness as a confounding variable for the reduced freezing in mutants 
upon cued conditioning (Figure 2.7P). 
 
In vivo electrophysiology 
Along with other animals containing a central nervous system, mice are capable of 
demonstrating abnormal spontaneous neuronal hyperexcitability.  In mice, this abnormal activity 
may culminate in observable seizure events on an electroencephalogram (EEG), which may 
overlap in both behavior and EEG presentation with certain types of human seizures (e.g. mouse 
epilepsy mutants often have spike-and-wave discharges which model human absence epilepsy). 
Alternatively, this abnormal activity in mice may not manifest as spontaneous seizures and instead 
only result in a greater susceptibility to induced seizure events (such as assessed through ECT 
studies), which can nevertheless be indicative of a higher baseline state of neuronal excitability. In 
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effort to evaluate in vivo excitability phenotypes in the Hnrnpu+/113DEL mice, both EEG and ECT 
studies were performed on adult mice in collaboration with Dr. Wayne Frankel’s Laboratory.  
Contrary to human EEG studies which use scalp electrodes, EEGs in mice are invasive, 
requiring implantation of subdural intracranial electrodes. These electrodes can detect a range of 
abnormal spontaneous activity including convulsive seizures, silent absence-like seizures and 
interictal discharges. Furthermore, using simultaneous video surveillance, abnormal brain activity 
can be correlated to mouse behavior in real time. Despite over 300 total hours of video EEG 
recordings of seven Hnrnpu+/113DEL adults, there was no evidence of any spontaneous generalized 
seizure activity (Figure 2.8A-B). Moreover, no spontaneous seizure-like behaviors have been 
observed after nearly four years of routinely handling the mice.  
ECT studies assess evoked seizures, and are performed by applying precise levels of an 
electrical stimulus to the brain through transcorneal electrodes, then scoring the response of the 
animal based on specific behavioral endpoints including no response (0), stun (1), myoclonic jerks 
(2), generalized tonic-clonic seizures (3, also known in the ECT literature as minimal forebrain 
clonic seizures) to tonic forelimb extension (4) to maximal tonic hindlimb extension (5).  The 
resulting seizure threshold is determined by averaging the level of stimulus required to illicit a 
specific behavioral endpoint. For Hnrnpu+/113DEL mice, in collaboration with Wayne Frankel, we 
found that both male and female mutants demonstrated a significantly lower threshold for the more 










Figure 2.1 hnRNP U is expressed ubiquitously throughout the brain. (A) Hnrnpu RNA In Situ 
hybridization of 56-day-old male mouse. Image credit: Allen Institute (Lein et al. 2007), 
https://mouse.brain-map.org/gene/show/31290  (B) hnRNP U total protein levels in neocortex 
versus hippocampus. Beta-actin shown as loading control. (C-G) hnRNP U (red) co-staining with 
nuclear marker Dapi and cell markers (green) Map2 (neuronal), Gad67 (inhibitory), Ctip2 (deeper 
layer pyramidal neurons), Satb2 (upper layer pyramidal neurons) and Gfap (astrocytes). Scale bar= 
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Figure 2.2 Generation of a heterozygous knockout Hnrnpu mouse model. (A) Using 
CRISPR/Cas9, a 113-bp deletion was generated in exon 1 of mouse Hnrnpu leading to premature 
stop codon. A representative genotyping agarose gel is shown to the right. (B) Relative expression 
of Hnrnpu transcript levels based on qRT-PCR. N=6 P0 cortices per genotype. (C) Mouse hnRNP 
U protein expression quantified through densitometry and normalized to mouse B-actin. N=4 P0 
cortices per genotype. The corresponding western blot using a C-terminal antibody is shown to the 
right. (D) Western blot using an N-terminal hnRNP U antibody shows lack of C-terminal truncated 
form of hnRNP U. N=4 P0 cortices per genotype. (E) Observed versus expected Mendelian ratios 
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Figure 2.3 Viability and growth of Hnrnpu+/113DEL mice. (A) Odds of recovering HETs beyond 
P10 compared to P0. FET p-values: females= 2.0E-04, males=0.41, total=8.0E-04 (B-C) The 
breakdown of HET and WT mice recovered at P0 compared to post-P10, and for males and females 
separately (D) Weights obtained at P0, N=13 HET and 16 WT, unpaired t-test p= 3.9E-03 (E) 
Weights obtained in neonatal/infantile period, N=16 for each genotype, permuted MWU p-values: 
P4 & P6= <1.0E-04, P8= 2.0E-04, P10= 1.0E-04 and P12= 1.5E-03. Representative image of WT 
and HET P4 pup (F) Weights obtained in juvenile and adulthood, N=9 for each genotype. 
Permutated MWU p-values: wk4= 2.0E-04, wk5 & 6= <1.0E-04, wk7= 4.0E-04, wk8= 3.0E-04, 
wk9= 1.1E-03, wk10= <1.0E-04. Representative image of 8 wk adult WT and HET. PND= 
























































































Figure 2.4 Altered axonal trajectories and lamination defects in Hnrnpu+/113DEL mice.  (A) 
Representative whole brain coronal H&E stain of P0 WT and HET pup. N=3 per genotype. Black 
boxes highlight general brain regions of interest shown for both genotypes in C and D. Scale bar= 
1000µm (B) Standard brain measurements including brain width, height, cortical thickness and 
hippocampal width, N=3 of each genotype. All measurements were normalized to body weight of 
the respective animal. Multiple t-tests were performed with Bonferroni correction: p-adj >0.99 for 
all four tests (C) Representative WT and HET hippocampus, red arrow= double layer of cells in 
CA1 region, black arrow= double layer of cells in CA3 region. Scale bar= 250µm. (D) 
Representative image of WT and HET internal capsule, red arrows= abnormal axonal trajectories, 




































Figure 2.5 Hnrnpu+/113DEL mice exhibit modest delay of developmental milestones. (A) 
Surface righting, permuted MWU p-values: P4= 0.3, P6= 0.42, P8= 0.07, P10= 7.0E-04, 
P12=0.15 (B) Vertical screen, permuted MWU p-values: P4= 0.31, P6= 0.05, P8= 0.07, P10= 
0.07, P12= 0.96 (C) Negative geotaxis 90°, permuted MWU p-values: P4= 0.96, P6= 0.91, 
P8=0.14, P10=0.16, P12= 4.2E-03 (D) Negative geotaxis 180°, permuted MWU p-values: P4= 
0.39, P6= 0.2, P8=0.16, P10=0.47, P12=0.08. Significant p-values highlighted. N= 16 animals 





























































Figure 2.6 Ultrasonic vocalization abnormalities of Hnrnpu+/113DEL mice. (A) Quantity of pup 
calls over a 3 min time interval, N= 17 WT, 16 HET, permuted MWU p-values: P3= 0.61, P5= 
6.8E-03, P7<1.0E-04, P9= 0.06, P11=0.49 (B) Pup call duration, permuted MWU p-values: P5= 
2.1E-03, P9<1.0E-04. (C) Peak frequency (i.e. pitch), permuted MWU p-values: P5= 6.9E-03, 
P9= 0.02 (D) Peak amplitude (i.e. loudness), permuted MWU p-values: P5= 0.43, P9= 3.3E-03. 
For all qualitative analyses, N= 10 for each genotype at P5, N=11 for each genotype at P9 (E) 































































Figure 2.7 Adult behavior studies of Hnrnpu+/113DEL mice.  (A) % time spent in the open arm for elevated 
plus-maze. Welch’s t-test p=0.47, N=22 HET, 14 WT. (B) Open field ambulatory distance divided into six 
10 min bins. Two-way RM ANOVA p=0.026, N= 18 HETs, 16 WTs. (C) Time spent in the center of the 
open field, divided into 10 min bins. Two-way RM ANOVA p=0.09, N=18 HETs, 16 WTs. (D) Catwalk 
front paws and hind paws print area. Unpaired t-test front paw p=0.024, hind paw p<1.0E-04, N= 19 HETs, 
17 WTs. (E) Representative images of front and hind paw prints of WT and HET. (F) Catwalk max contact 
max intensity (MCMI) of front and hind paws. MWU front paw p=0.08, hind paw p<1.0E-04, N= 19 HETs, 
17 WTs. (G) Catwalk base of support for front and hind limbs. MWU front limb p=0.08, hind limb p=1.5E-
03, N= 19 HETs, 17 WTs. (H) Catwalk percent regularity index. MWU p=0.13, N=19 HETs, 17 WTs. (I) 
MWM latency to platform (acquisition period) measured over 5 consecutive days. Two-way RM ANOVA 
p=0.22, N= 18 HETs, 15 WTs. (J) MWM swim distance measured over 5 days. Two-way RM ANOVA 
p=0.1. N=18 HETs, 15 WTs. (K) MWM swim speed measured over 5 days. Two-way RM ANOVA 
p<1.0E-03, N=18 HETs, 15 WTs. (L) MWM probe trial measured as time spent in each quadrant. One-way 
RM ANOVA on ranks WT p-values: T vs L<1.0E-03, T vs R=0.2, T vs opp<1.0E-03; HET p-values: T vs 
R=2.0E-03, T vs L=0.64, T vs opp=0.42, N= 18 HETs, 15 WTs. (M) % duration spent in novel vs familiar 
arm of Y-maze. One-way RM ANOVA WT p=5.0E-03, HET p=3.0E-03, N= 18 HETs, 16 WTs. (N) % 
spontaneous alteration in Y-maze. Welch’s t-test p=0.86, N=18 HETs, 16 WTs. (O) % freezing upon fear 
conditioning. MWU post-train p=7.0E-04, context <1.0E-04, pre-cue= 0.022, cued= 1.8E-03, N= 18 HETs, 
16 WTs, (P) Response following acoustic startle. T-test p=0.96, N=13 HETs, 11 WTs.  
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Figure 2.8. Hnrnpu+/113DEL mice exhibit seizure susceptibility. (A) Summary table of EEG data. 
(B) Representative EEG tracings of 3 HET mice highlighting lack of spontaneous seizure activity. 
M1, M2 and M3= mouse 1, 2 and 3. FR= front right, FL= front left, BL= back left, indicating 
electrode placement. All EEGs were performed with video to correlate with tracings. Scale= 
3000uV. (C) Maximal seizure ECT endpoint, MWU p<1.0E-04. iRMS= root mean square current. 







































Through gene editing technology, an exon 1 frameshift mutation was introduced into 
mouse Hnrnpu leading to a premature stop codon in exon 2 and likely nonsense-mediated decay 
of mutant transcripts. While Hnrnpu+/113DEL mice do not appear to recapitulate certain aspects of 
the human condition, such as spontaneous seizures, they do demonstrate evidence of other 
neurological and systemic deficits including poor growth, perinatal lethality, abnormal brain 
morphology, developmental delay, abnormal gait, mild hyperactivity and greater seizure 
susceptibility. These findings, reviewed in greater detail below, overall support the use of this 
mutant line to investigate mechanisms underlying certain aspects of the patient condition.  
 
A modest reduction of hnRNP U is capable of inducing abnormal development 
Intriguingly, loss of a single copy of mouse Hnrnpu does not lead to 50% loss of protein 
product, as one would expect based on the protein truncating nature of the frameshift allele 
introduced. Instead, both mRNA and protein levels indicate only a 20-25% reduction, which 
surprisingly is enough loss of hnRNP U to elicit abnormal phenotypes. These observations are 
consistent with preliminary findings previously reported on a constitutive heterozygous C-
terminal-truncated Hnrnpu mutant derived from a published conditional line (Ebstein 2017, Ye et 
al. 2015). Heterozygous mutants demonstrated an insignificant decrease of roughly 20% compared 
to controls. Furthermore, wildtype and heterozygous crosses demonstrated skewed Mendelian 
ratios with greater loss of heterozygotes, and a consistent growth impairment from birth throughout 
the lifespan of the animal (Ebstein 2017). These findings are also consistent with the observation 
that a homozygous hypomorphic Hnrnpu mutation that results in embryonic lethality by E11.5, 
demonstrates only a 2- to 5-fold decrease in Hnrnpu transcript levels in ES cells derived from 
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mutant preimplantation blastocysts (Roshon and Ruley 2005). Overall, these data support the 
conclusion that near wildtype levels of hnRNP U are required for normal development.  
While the mechanism underlying this partial loss of Hnrnpu expression upon the genetic 
abolishment of one gene copy is unclear, possible explanations include the compensatory 
upregulation of Hnrnpu gene expression or enhanced stability of Hnrnpu transcripts. HnRNP’s, 
including hnRNP U, have been shown to associate not only with the transcripts of other hnRNPs, 
but also directly bind to their own transcripts (Huelga et al. 2012). For hnRNP U specifically, it 
has been shown to bind strongly to its own 3’UTR and therefore may play a role in autoregulating 
its expression. Furthermore, the hnNRPs A1, A2/B1, F, H1 and M also directly bind Hnrnpu, 
primarily within the 3’UTR, and may thus contribute to Hnrnpu gene regulation.  
Upregulation of Hnrnpu gene expression could also result from such mechanisms as 
transcriptional adaptation, where nonsense mediated decay (NMD) of mRNA resulting from a 
premature stop codon leads to the upregulation in expression of genes that share sequence 
similarity, including the mutated gene itself (El-Brolosy et al. 2019). This mechanism relies on the 
mRNA surveillance machinery to both prevent translation of the mutant alleles and trigger 
compensatory upregulation of related genes. El-Brolosy and colleagues propose that this 
upregulation may occur via the translocation of decay factors to the nucleus where they bind to 
specific loci (perhaps guided by the NMD-derived mRNA fragments) and recruit epigenetic 
modifiers that ultimately increase transcription. Or alternatively, the NMD-derived mRNA 
fragments could downregulate antisense transcripts that normally function to negatively regulate 
expression of target genes.  
To differentiate between transcriptional adaptation or increased transcript stability (such as 
through autoregulation from 3’UTR binding), we could compare HNRNPU expression levels in 
patients, or cells derived from patients, containing microdeletions encompassing the entirety of 
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HNRNPU versus patients containing mutations that result in premature stop codons. Or mice with 
the Hnrnpu+/113DEL mutation could be compared to another line carrying a heterozygous deletion 
of the Hnrnpu promoter.  If resulting expression levels in the presence of an entire gene deletion 
or the mouse promoter deletion are also only 20-25% reduced, this would support a transcript 
stability hypothesis. Alternatively, if expression levels were reduced by 50%, this would support 
the notion of transcriptional adaptation. Differentiating between these possibilities could provide 
avenues for molecular therapy, such as targeting the transcriptional adaptation mechanism to 
further upregulate Hnrnpu expression.  
 
Perinatal lethality of female mutants  
The observation that female Hnrnpu+/113DEL mutants have a higher incidence of mortality 
in the perinatal period suggests that female mice have a particular vulnerability to mutations in 
Hnrnpu. However, in humans, clear differences in phenotypic severity based on sex have yet to be 
described, possibly owing to the small cohorts examined thus far. Sex-specific trends may emerge 
in larger cohorts of patients carrying HNRNPU mutations with rigorous and consistent 
phenotyping efforts.  
It is interesting to speculate that hnRNP U’s essential role in X chromosome inactivation 
(XCI) could be a factor in the observed perinatal lethality of female mutant mice. HnRNP U is 
essential for the coating of Xist across the inactive X (Xi) chromosome, and the depletion of 
hnRNP U in ES cells results in failure to properly establish the Xi, ultimately leading to greater 
biallelic gene expression (Hasegawa et al. 2010). Hence, perhaps reduced levels of hnRNP U result 
in a slight impairment of XCI and overall greater expression of normally-silenced genes from the 
Xi, thereby leading to increased lethality. This phenomenon of impaired XCI has been reported 
previously in mice containing a strong hypomorphic mutation in Xist (Senner et al. 2011). Females 
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that inherit this mutation from paternal carriers demonstrated developmental arrest by E9.0, 
frequent open neural tube defects and greater expression of X-linked genes, consistent with 
incomplete XCI. While this serves as a more extreme example, perhaps minor reductions of 
hnRNP U are capable of inducing subtle perturbations in the degree of X chromosome silencing. 
Evaluating Xist localization through RNA fluorescence in situ hybridization (FISH) and 
accumulation of H3K27me3 histone marks (associated with Xi) using immunofluorescence in 
Hnrnpu+/113DEL mutant females may further elucidate whether impaired XCI is a contributor to 
perinatal lethality in females. Furthermore, assessing transcriptomic changes in a cohort of female 
mutant and wildtype mice may also shed light on whether there is upregulated expression of X-
linked genes in female mutants.   
 
Persistent growth impairment in Hnrnpu+/113DEL  mutants 
Hnrnpu+/113DEL mice demonstrated a growth impairment at birth that persists throughout 
the lifespan of the animal. At P0, mutants are on average 10% smaller; however, this is further 
exacerbated over time, with mutants weighing on average 25% less than controls by the late 
perinatal period. In humans, nearly half of patients carrying HNRNPU mutations have short 
stature.   
Abnormalities in growth are heterogeneous in etiology, and include defects in the skeletal, 
endocrine, gastrointestinal and immune systems. While the nature of this growth impairment in 
mutant mice is unclear, hnRNP U has been previously reported to regulate important aspects of 
adipogenesis and feeding behavior. For example, hnRNP U been shown to interact with the 
lncRNA ADAL, which is required for proper adipocyte differentiation, triglyceride synthesis and 
expression of adipogenic genes (X. Zhang et al. 2018). Furthermore, another Hnrnpu mouse model 
containing a constitutive heterozygous loss-of-function mutation found that mutants are less active 
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and consume less food during the night and also had an altered metabolic rhythm (Lai et al. 2018). 
These authors report that hnRNP U regulates gene expression of the suprachiasmatic nucleus 
(SCN)-enriched neuropeptides Avp and Vip through direct promoter binding, which are both 
transcribed in a circadian manner and are required for normal circadian-regulated locomotor 
activity and metabolic rhythms.  
Further research is required to define the specific mechanism(s) underlying the Hnrnpu-
related growth deficits. However, these findings fit with other observations supporting overall 
developmental delay in Hnrnpu+/113DEL pups.  
 
Reduced hnRNP U causes abnormal brain development 
Patients carrying HNRNPU mutations present with a range of abnormal MRI findings, 
including neuronal migration defects, enlarged lateral ventricles, corpus callosum defects, delayed 
myelination, mal-rotated hippocampus, absent olfactory bulbs, mild holoprosencephaly, Chiari I 
malformation, Dandy Walker malformation and temporal sclerosis. Morphological analysis of the 
Hnrnpu+/113DEL mouse brain demonstrated abnormal axon fascicles in the striatum, suggestive of 
aberrant axonal trajectories and possible underlying axon guidance defect. For example, the black 
arrow in Figure 2.4D points to a loss of thalamic projections, which are typically required for 
axonal pathfinding of cortical neurons (Deck et al. 2013). Furthermore, the process of axonal 
growth and extension is highly complex, requiring a combination of intrinsic and extrinsic growth 
instructions that ultimately guide the axon along its highly stereotyped path (Raper and Mason 
2010). While the exact cellular and molecular mechanisms governing this elaborate process are 
still under investigation, such guidance factors as the semaphorins and plexins family members 
have been shown to play important roles in generating attractive and repulsive cues that guide 
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axons. Adhesive factors, such as extracellular matrix molecules and cadherins, along with trophic 
factors, such as neurotrophins, are also imperative for proper outgrowth (Raper and Mason 2010).  
Hnrnpu+/113DEL mutants also form two cell layers in the CA1 and CA3 regions of the 
hippocampus, suggestive of aberrant hippocampal lamination. These findings are similar to what 
has been reported in mice with clear neuronal migration defects, such as caused from mutations in 
the genes Lis1 and Dcx which both encode important cytoskeletal proteins and are associated with 
human lissencephaly. In Lis1 mutant mice, heterotopic pyramidal neurons were present in both the 
CA1 and CA3 regions, forming abnormal, fragmented layers of cells (Fleck et al. 2000). 
Hippocampal slice electrophysiology revealed that the CA1 subfield of Lis1 mutants was hyper-
excitable, which the authors proposed could contribute to the spontaneous seizures observed in 
mutant mice. In mouse models of neuronal migration disorders, the CA3 region appears to be a 
particularly vulnerable and consistently-impacted brain region, often presenting with multiple cell 
layers within CA3 (Belvindrah, Nosten-Bertrand, and Francis 2014; Feng et al. 2017; Nosten-
Bertrand et al. 2008). These dysplastic cells have also been associated with abnormal, hyper-
excitable electrophysiological properties, such as observed in Dcx mutants (Nosten-Bertrand et al. 
2008).  
Overall, the neuropathological changes reported here were relatively modest compared to 
the range of abnormal brain MRI findings identified in HNRNPU patients.  This H&E study, 
however, was a basic morphological evaluation performed at a single time point, and thus does not 
rule out all brain defects. In fact, these findings hint at the presence of more widespread brain 
abnormalities in which H&E staining is technically limited in detecting. More extensive studies, 
including those performed at different developmental time points and with more sophisticated 
methods, are necessary to further characterize the neuroanatomical abnormalities of Hnrnpu 
mutant mice. For example, studies using the lipophilic fluorescent dye DiI to track axonal 
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projections will be useful for verifying the relationship between Hnrnpu mutants and axonal 
guidance. Additionally, studies assessing the electrophysiological properties of the heterotopic 
CA1 and CA3 neurons, such as through hippocampal slice electrophysiology, is an important next 
step to determining the functional consequences of this phenotype and the potential relevance to 
seizure susceptibility and behavioral deficits of mutant mice. Furthermore, findings in the 
hippocampus warrant an in-depth investigation into the neocortex for cortical lamination defects 
or other evidence of inappropriate differentiation, connectivity or structure, such as through 
immunofluorescence staining of upper and lower cortical layer markers at different developmental 
time points. Importantly, findings from these studies can inform the potential efficacy of targeted 
treatments as neurological phenotypes emerging from developmental defects involving neuronal 
migration and axon guidance are unlikely to be amenable to postnatal treatment (once the 
developmental deficits have occurred).   
 
Neonatal developmental studies reveal modest developmental delay in Hnrnpu+/113DEL mutants 
 Studies assessing the development of reflexes, sensorimotor and vestibular function and 
body strength, including surface righting, negative geotaxis and vertical screen, revealed that 
Hnrnpu mutants are marginally delayed in both righting reflex and negative geotaxis—two 
independent measures of sensorimotor and vestibular function. Mutants show a trend towards 
delayed surface righting by P6, around the time when the surface righting response typically 
appears (Feather-Schussler and Ferguson 2016). This reflex requires both trunk strength and 
control, along with sensorimotor coordination and vestibular function. In rodents, the average age 
for the negative geotaxis response to appear is P7. Hnrnpu mutants trended towards delayed 90° 
and 180° turn, yet this was only significant at P12 in the 90° test. Negative geotaxis primarily 
assesses motor and vestibular function. Other rodent models of neurodevelopmental disorders have 
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also revealed delays in these developmental parameters, including a mouse model of Down 
syndrome and the EL/Suz mouse model of multifactorial epilepsy (Kazim et al. 2017; McFadyen-
Leussis and Heinrichs 2005). Overall, these findings, in conjunction with impaired growth, 
increased perinatal lethality and deficits in pup ultrasonic vocalizations, argue in favor of global 
developmental delay of Hnrnpu mutants.    
 
Quantitative and qualitative defects of pup isolation calls in Hnrnpu+/113DEL mutants 
When isolated from the nest within the first two weeks of age, mouse pups produce 
ultrasonic vocalizations (USVs) to elicit maternal retrieval and care. This behavior is imperative 
for the survival and proper development of the pups. In this study, the evaluation of WT USVs 
revealed the classic inverted-U shape pattern from P3 to P9, characteristic of normal pups (Ferhat 
et al. 2016). WT calls increased in frequency until P7, at which time they peaked and began to 
decline thereafter.  Conversely, Hnrnpu+/113DEL pups emitted strikingly fewer calls, with an overall 
abnormal trajectory characterized by a slow increase in call frequency until P9 at which time call 
frequency nearly doubled then began to decline thereafter. Furthermore, mutant isolation calls 
were qualitatively abnormal, showing a shorter duration and higher pitch compared to controls. 
Hnrnpu+/113DEL calls were the same amplitude (loudness) at P5 and even have a greater amplitude 
at P9 compared to controls, suggesting that these pups are not necessarily weaker despite their 
smaller size and reduction in call number. 
Overall, these findings, combined with impaired growth and delayed sensorimotor 
function, are consistent with global developmental delay of Hnrnpu+/113DEL pups. Similar 
phenotypes have been observed in other developmental and epileptic encephalopathy mouse 
models studied in the IGM.  One such example is Gnb1-epileptic encephalopathy. Similar to 
Hnrnpu mutants, these mice show a persistent growth impairment, delayed sensorimotor function, 
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and a significant reduction in pup USVs (Colombo et al. 2019). Patients with this disorder exhibit 
global developmental delay, speech and motor defects, intellectual disability and spontaneous 
seizures (Hemati et al. 2018; Petrovski et al. 2016).  
Pup USVs have been extensively studied in the context of human communication 
disorders, such as verbal dyspraxia and autism (Fujita et al. 2008; Shu et al. 2005; Wöhr et al. 
2011; Scattoni et al. 2008b; Ey et al. 2013, 2). And although patients with HNRNPU mutations 
have been described as having autism and autistic-like features including severe speech 
impairment, whether pup USVs represent a true correlate of human communication disorders is 
highly controversial in the field of animal behavior. Notably, the region of the brain implicated in 
mouse ultrasonic vocalizations (hypothalamus) is different than the regions that govern the major 
aspects of human speech (including the periaqueductal gray and cerebral cortex) (Zimmer et al. 
2019). As such, the relationship between deficits in pup USVs and human communication 
disorders remains inconclusive.  
Nevertheless, evidence does support that certain alterations in USV emissions can modify 
maternal caregiving behavior. Pups that vocalize infrequently, for example, are less effective at 
eliciting maternal care (Bell 1979). Additionally, dams reportedly prefer calls that are longer in 
duration and within the range of 45-65 kHz compared to 55-75kHz (Smith 1976; Ehret 1992). 
Consequently, the short, high-pitched Hnrnpu+/113DEL pup calls are likely to be less efficient in 
prompting a maternal response. This could in turn influence the overall health of the mutant pups 
should they become neglected and malnourished, and could at least partially explain the increase 
in perinatal lethality and exacerbation of growth deficit throughout the perinatal period observed 
in Hnrnpu mutants. However, a direct causal link between these outcomes and poor maternal care 




Hnrnpu+/113DEL adults exhibit mild hyperactivity and abnormal gait 
Patients carrying HNRNPU mutations all demonstrate varying degrees of intellectual 
disability that typically range from moderate to severe. These individuals also display a wide-array 
of atypical behaviors including autistic-like traits (obsessive compulsiveness, hand-flapping and 
other stereotypic movements), motor and gait abnormalities, Tourette syndrome and 
anger/aggression issues (Yates et al. 2017; Bramswig et al. 2017). To further assess the face 
validity of the Hnrnpu+/113DEL model, a comprehensive assessment of adult mouse behaviors was 
performed, focusing on evaluating gait, learning and memory and exploratory behaviors.  
As assessed through elevated plus-maze and open field testing, Hnrnpu+/113DEL mice 
displayed no evidence of anxiety-like behaviors. However, open field testing showed transient 
novelty-induced hyperactivity, with mutants moving more within the first 20 minutes of testing, 
after which they habituated to their environment without any substantial difference in activity 
compared to controls. This behavior has been described previously in the AMPA receptor GluA1 
subunit (Gria1-/-) mouse model of neuropsychiatric disorders (Procaccini et al. 2011). These mice 
show nearly double the level of locomotor activity in response to a novel environment with 
eventual habituation occurring around 30-40 minutes later. This phenotype was associated with 
increased activity of neurons within the hippocampus, and was attenuated by treatment with the 
AMPA-receptor antagonist NBQX and phtyocannabinoid cannabidiol (CBD) (Procaccini et al. 
2011; Aitta-aho et al. 2019). Of note, hyperactive phenotypes have not been reported in patients 
carrying HNRNPU mutations.  
 Hnrnpu mutants also exhibited a peculiar gait profile, evinced by parameters including 
those that evaluate the maximal intensity or pressure exerted by the front and hind paws on the 
ground, the area of the floor contacted by the paws and overall stance/posture. Specifically, 
Hnrnpu+/113DEL mice had a smaller hind paw print area size and reduced intensity of the contact 
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area of the hind paw, indicating that mutants walk without the foot pads firmly touching the 
ground. The relatively smaller hind paws compared to front paw size observed in mutants is rather 
unusual as hind paw print size is typically equal to, or larger than, front paws in wildtype mice. 
Further physiological and neurological assessments are warranted to shed light on these unusual 
hind paw features.  Mutants also had a wider base of support (the width of stance when both feet 
are in contact with the ground)—an observation also specific to the hindlimbs. This finding may 
be a consequence of the reduced hind paw contact (support), reflecting an unsteady gait in mutants. 
Interestingly, a broad-based gait has been previously reported in patients carrying HNRNPU 
mutations, and may therefore represent phenotypic overlap between the mouse and human 
condition (Yates et al. 2017; Bramswig et al. 2017). Additional studies such as the rotarod test and 
nerve conduction velocity studies are warranted to further assess motor coordination and possible 
neuromuscular deficits. 
 Despite the presence of subtle lamination defects in the P0 hippocampus, both learning and 
memory—two major hippocampal functions—appear to be largely intact in Hnrnpu mutants as 
assessed through MWM, Y-maze and fear conditioning. MWM, which is largely thought to 
correlate to NMDA receptor function and hippocampal synaptic plasticity (Vorhees and Williams 
2006), failed to reveal any difference in spatial learning or reference memory (i.e. long-term 
memory). This was also the case for Y-maze, which through novel versus familiar arm and 
spontaneous alteration tests provide information on both spatial reference and working memory, 
respectively (Kraeuter, Guest, and Sarnyai 2019). Cued and contextual fear conditioning from a 
shock to the foot measures associative learning, with cued learning mostly stemming from amydala 
involvement and contextual learning containing a large hippocampal component (Curzon, Rustay, 
and Browman 2009). Results from current fear conditioning studies remain difficult to interpret as 
Hnrnpu+/113DEL mice exhibit a general decrease in freezing, not only upon exposure to the context 
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or cue, but also during the training and pre- cue phases of the study. The nature of this reduced 
response is unclear. Acoustic startle testing showed no difference between mutants and controls, 
ruling out hearing impairment as a potential confounder for lack of a cued response. However, 
limited contact of the mutant hind paws with the ground, as shown in catwalk studies, may 
theoretically lead to less disturbance from the foot shock and in turn less of a response to the 
particular cue or context. An alternate form of stimulus, such as an air puff, may instead be 
considered in follow-up studies.    
 
Greater seizure susceptibility of Hnrnpu+/113DEL adults 
The simultaneous monitoring of spontaneous neurological activity and mouse behavior 
using video EEG failed to uncover any seizure activity in Hnrnpu mutants. As previously discussed 
in the introduction, the lack of detection of spontaneous seizures in mouse models of epilepsy is 
not uncommon, and may clearly represent interspecies differences or technical limitations of the 
test. It goes without saying that the mouse and human brain are both structurally and functionally 
different. The human brain is not only clearly larger in size, but contains an extensive folding of 
gray matter that increases the surface area of the cerebral cortex, whereas the mouse cerebral cortex 
is smooth. Furthermore, the cell type diversity in humans is broader. Human astrocytes are 2.6-
fold larger, extend 10 times more projections and are more diverse in terms of subtypes compared 
to mice (Oberheim et al. 2009). They are also more responsive to glutamate, and could therefore 
have a larger impact on the electrical dynamics of the human brain (Zhang et al. 2016).  Human 
pyramidal neurons also have more extensive dendritic arborization, which has been shown to 
impact the level of cortical computational ability (Mohan et al. 2015; Beaulieu-Laroche et al. 
2018). These are just a few of the many examples highlighting such interspecies differences. Given 
the greater degree of complexity observed in human brains, it is reasonable to assume that certain 
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epileptogenic mechanisms may not be present, or are at least subtler, in the mouse brain. Another 
explanation for the lack of spontaneous seizures on EEG pertains to the developmental period 
under evaluation. In this study, mouse seizure phenotypes associated with these genetic human 
pediatric epilepsies were largely assumed to persist into adulthood, which may not be the case. 
Performing EEGs during the more disease-relevant infancy and juvenile periods is certainly more 
ideal. However, this is also more technically challenging and less feasible due to size limitations 
of younger animals. It is also possible that the subdural electrodes implanted onto the cerebral 
cortex are unable to detect focal seizure activity that fail to generalize to the more superficial 
regions of the brain.  
Electrically induced seizures, such as through ECT, offer another robust and powerful 
platform to detect baseline hyperexcitable states within the mouse brain. Both Hnrnpu+/113DEL 
females and males demonstrated a nearly 20% lower threshold to induction of maximal tonic 
clonic seizures compared to control littermates, consistent with an increased seizure predisposition. 
This finding is not unique to the Hnrnpu model: low seizure thresholds with lack of spontaneous 
seizures have been reported in other genetic models of developmental and epileptic 
encephalopathies. For example, mice containing a heterozygous variant S644G/+ in Grin2a 
(orthologous to a human pathogenic variant), which encodes an NMDA receptor subunit, does not 
show evidence of spontaneous seizures, but does exhibit greater susceptibility to both minimal and 
maximal seizure endpoints (Amador et al. 2019). Interestingly, mice homozygous for this mutation 
develop lethal spontaneous seizures during the third week of life. Furthermore, haploinsufficiency 
of Arfgef1 in mice is associated with a lower threshold to induction of minimal clonic forebrain 
seizures, but no evidence of spontaneous seizures (Teoh et al. 2019).  
ECT testing not only provides the opportunity to further characterize the seizure 
phenotypes of genetic epilepsy models, but also provides a benefit with regards to screening 
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potential therapies. The efficacy of a drug in rescuing the seizure threshold phenotype can be 
assessed by first generating a response curve over a range of stimuli in order to determine the level 
of stimulus associated with a 97% response rate for the specific behavioral endpoint for both sexes 
and genotypes. This stimulus level is then applied to all drug- and control-treated animals to assess 
whether the drug impacts the response (i.e. behavioral endpoint). This testing can be performed 
relatively quickly on large cohorts of mice, and thus is more amenable to larger-scale drug screens 




Hnrnpu+/113DEL mice were generated through The Jackson Laboratory’s Genome 
Engineering Technology Core using a CRISPR-Cas9 strategy targeting exon 1 of mouse Hnrnpu. 
Of 15 founder mice that survived, 6 appeared most promising based on TIDE analysis and were 
further evaluated using TOPO-TA cloning to validate the corresponding mutant alleles. A founder 
containing an out-of-frame 113 bp deletion was further expanded and maintained on a C57BL/6NJ 
background. All experiments were performed on the inbred background except for ECT studies, 
which were performed on the F1 hybrid background C57BL/6NJ (005304 JAX stock) x FVB/NJ 
(001800 JAX stock). Wildtype littermates were used as controls. All mice were maintained in 
ventilated cages with controlled humidity at ~60%, 12h:12h light:dark cycles (lights on at 7:00AM, 
off 7:00PM) and controlled temperature of 22–23°C. Mice had access to regular chow and water, 
ad libitum. Breeding cages were fed a high fat breeder chow. Mice were maintained and all 
procedures were performed within the Columbia University Institute of Comparative Medicine, 
which is fully accredited by the Association for Assessment and Accreditation of Laboratory 
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DNA was extracted from tail or ear clippings using the Kapa Mouse Genotyping Standard 
kit (KAPA Biosystems) and stored at -20°C. PCR was performed with 2x MyTaq HS Mix 
(Bioline), using the following Hnrnpu primers: FWD= 5’-GTCCGTTCTGCAGCAGCACT-3’, 
REV= 5’-TTACCTCCCGCCTGCTGTTG-3’. This amplifies a 745 bp product from the WT allele 
and a 632 bp product from the mutant allele.    
 
Primary neuronal culture 
P0 pups were tail sampled, weighed and genotyped for the Hnrnpu 113 bp deletion. Mutant 
and wildtype pups were decapitated and cortex and hippocampus were separately dissected in cold 
Hibernate A (Thermo Fisher). Tissue was diced into smaller pieces and dissociated in a solution 
containing pre-warmed Hibernate A, papain and DNase for 20 min at 37°C. Dissociated tissue was 
then centrifuged at 300 g for 5 min at RT, resuspended in pre-warmed Hibernate A, and triturated 
to further dissociate.  Undissociated tissue was allowed to settle to the bottom of the tube, and the 
single cell suspension was transferred to a new tube and centrifuged at 300 g for 5 min at RT. The 
cell pellet was resuspended in complete medium containing Neurobasal A (Thermo Fisher), B27 
Plus (Thermo Fisher), 1% FBS, Hepes, Glutamax and Penn/Strep. Cell viability and counts were 
obtained using a trypan blue exclusion assay, then further resuspended to the desired cell 
concentration using complete medium supplemented with laminin (5 ug/ml). Both cortical and 
hippocampal cells were plated on PDL-coated 12mm coverslips in a 24-well dish at a density of 
200,000 cells. Complete medium was changed the following morning to Neurobasal A, B27 Plus, 
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Hepes, Glutamax and Penn/Strep, and 50% medium changes were subsequently performed every 
other day.   
 
Immunocytochemistry 
On DIV9, mouse primary cortical and hippocampal cells were washed 2x with 1X PBS, 
fixed for 15 min in 4% paraformaldehyde at room temperature, and again washed 2x with 1X PBS. 
Cells were incubated in a staining solution comprised of 5% donkey serum, 1% BSA, 0.3% 
TritonX-100 in 1X PBS for 15 min at room temperature, then subsequently incubated in the 
primary antibody diluted in the staining solution for 2 hours at room temperature. Cells were 
washed 4x with 1X PBS, 0.2% TritonX-100, incubated with the fluorophore conjugated secondary 
antibody in staining solution for 30 min at room temperature then washed 4x with 1X PBS, 0.2% 
TritonX-100. Coverslips were mounted using ProLong-Antifade with DAPI on Superfrost Plus 
Microscope slides and allowed to dry in the dark prior to imaging. Imaging was performed using 
the Zeiss Axio Observer.Z1 Fluorescence Motorized Microscope and associated Zen2 Pro imaging 
software. Downstream image processing was performed using Adobe Photoshop. Primary 
antibodies used include: Mouse monoclonal anti-Map2 at 1:500 (Sigma M4403), mouse 
monoclonal anti-GFAP at 1:500 (Abcam ab10062) and rabbit polyclonal anti-HNRNPU at 1:500 
(Abcam 20666). Secondary antibodies include: 488 and 568 Alexa Fluorophore conjugated 
donkey anti-mouse and donkey anti-rabbit (Invitrogen), respectively, at 1:1000 dilution.  
 
Protein extraction 
Dissected tissue was snap frozen in liquid nitrogen and stored at -80°C until time of 
extraction. Tissue was thawed on ice and homogenized using a motorized pestle in RIPA buffer 
containing both protease and phosphatase inhibitor cocktails (Roche). Lysis was completed for 15 
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min on ice. Samples were subsequently centrifuged at full speed for 20 min at 4°C. The resulting 
supernatant was collected and protein was quantified using the BCA method (Pierce) with BSA as 
a standard.  
 
Western blotting 
All western blots were performed using the Novex NuPAGE system (Invitrogen). Protein 
lysates were diluted in LDS sample buffer and reducing agent, and heated at 70C for 10 min. Using 
the Xcell SureLock Mini Cell gel box, a total of 5ug of reduced protein lysates were loaded onto 
a 4-12% gradient Bis-Tris gel in 1X SDS Running buffer (Invitrogen) supplemented with the 
NuPAGE antioxidant, and ran at 180V for 1-1.5 hrs. Using the Xcell II Blot Module, proteins were 
subsequently transferred to a 0.2um methanol-activated PVDF membrane at 30V for 1.25 hrs at 
4C in Transfer buffer containing 20% methanol. Membranes were blocked for 1 hr at room 
temperature in 5% milk, then incubated overnight in the hnRNP U primary antibody at 1:1000 
(Rabbit polyclonal against C-terminus: Abcam ab20666; Rabbit monoclonal against N-terminus: 
Abcam ab180952) diluted in 5% BSA. Blots were washed 3x for 10min in PBST, incubated at 
room temperature for 1 hr in a secondary HRP-conjugated anti-rabbit (at 1:10,000) diluted in 5% 
BSA, then further washed 3x for 10 min in PBST. Proteins were incubated for 5 min in a standard 
ECL substrate (Pierce) and developed with either a Kodak X-OMAT 2000A Processor or iBright 
FL1000 Imaging system (Invitrogen). For a loading control, blots were subsequently incubated in 
an HRP-conjugated b-Actin secondary at 1:1000 (Santa Cruz #sc-47778) diluted in 5% BSA for 
1 hr at room temp, then washed and developed as previously described.  
Densitometry analysis was performed using the iBright FL1000 imager. Specifically, the 
Local Background Corrected Density, LBCD, (background-corrected volume/area) of each 
hnRNP U-probed sample was first normalized to the corresponding LBCD of b-Actin to generate 
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an hnRNP U/b-Actin ratio. WT and HET ratios were further divided by the average WT hnRNP 
U/b-Actin ratio and plotted individually.  
 
qRT-PCR 
Tissue was collected and immediately stored in RNALater Stabilization Solution (Qiagen) 
at 4°C. After 24 hours, the RNALater was subsequently removed, and samples were stored long 
term at -80°C. For RNA extraction, tissue was first mechanically homogenized using a motorized 
pestle in RLT buffer (Qiagen) supplemented with b-mercaptoethanol, then further homogenized 
using a QIAshredder spin column (Qiagen). RNA was extracted using the RNeasy Mini kit 
(Qiagen) per protocol instructions, and the resulting RNA concentration and purity were assessed 
using a NanoDrop. A total of 2.5 ug of RNA was used for the reverse transcription reaction, which 
was performed using the SuperScript IV First-Strand Synthesis System (ThermoFisher) with 
random hexamer priming. Resulting cDNA was used as input into pre-validated TaqMan Gene 
Expression Assays (ThermoFisher) and run with the TaqMan Fast Universal PCR MasterMix 2x 
(Applied Biosystems). The following TaqMan probes were purchased from ThermoFisher: 
mMef2c Mm01340839_m1 (spans exons 3-4), mHnrnpu Mm00469329_m1 (spans exons 1-2) and 
mCyc1 Mm00470540_m1 (spans exons 1-2). A total of six biological replicates were evaluated. 
TaqMan assays were run on a QuantStudio 5 Real-Time PCR System (Applied Biosystems) using 
the comparative Ct method.  
Analysis was performed using QuantStudio Design and Analysis Software v1.2 and 
Microsoft Excel. To analyze for gene expression differences, raw Ct values were first averaged 
across technical triplicates for each sample. A technical replicate was filtered out if its Ct value 
was one standard deviation above or below that of the mean of the triplicates. Samples required at 
least technical duplicates to be considered in the analysis. Delta Ct was calculated with the 
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corresponding Ct value for the Cyc1 loading control using the following formula (experimental Ct 
mean)/(Cyc1 Ct mean). Resulting delta Ct values were transformed into relative expression values 
using the formula 2^(-deltaCt). Each sample was subsequently normalized to the overall average 
WT relative expression value and these normalized values were independently plotted.  
  
Morphological study 
 P0 brains were extracted and fixed in Bouin’s solution overnight at room temperature. 
Fixed brains were embedded in paraffin with service provided by Columbia University’s 
Molecular Pathology Core Facility. Coronal sections in 5 µm thickness were obtained using a 
microtome (Leica RM2125RT) and subjected to hematoxylin-eosin staining. Briefly, the slices 
were deparaffinized in xylene and rehydrated with ethanol and water. Slices were then stained in 
hematoxylin, counterstained with eosin and subsequently dehydrated with ethanol and xylene. 
Stained slices were mounted with coverslips using Permount. Images were obtained using a Nikon 
Eclipse E800 Microscope packaged with NIS-Elements DV.4.51.00 imaging software and merged 
using Adobe Photoshop. Morphology analysis was performed blinded. Brain measurements were 
collected using ImageJ. The measurements were normalized to pup body weight. T-test was 
performed on each set of measurements to evaluate for significant genotype differences.  
 
Pup developmental milestones 
On postnatal day 2, pups were tattooed on the bottom of their paws for identification using 
a 25-30 G needle and Ketchum tattoo ink, following the AIMS tattoo chart. The following 
developmental milestone studies were completed on P4, P6, P8, P10 and P12 within a three min 
time window for each test subject.  
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Righting reflex: the latency to flip over from supine to prone position on all fours. Pups were gently 
placed on their backs on a hard surface and released. A stopwatch was used to measure the total 
time for each pup to right itself. The cutoff latency was 30s.  
Negative geotaxis: the latency to face upwards from a downward-facing start position on an 
inclined mesh screen. Pups were placed at a downward facing position on a 45° inclined screen 
and released. A stopwatch was used to record the time it takes for each pup to turn 90° then 180°. 
The cutoff latency was 30s. If the pup failed the trial by falling while turning, they were scored the 
maximum cutoff latency time of 30s.  
Vertical screen: the latency to fall from a vertically-positioned wire mesh screen. Pups were 
positioned to grasp the screen. Using a stopwatch, the time until fall was recorded. The minimum 
and maximum latency allowed was 1s and 30s, respectively.   
For each developmental test, every pup underwent two successive trials that were 
subsequently averaged and used in the downstream analyses. Throughout the testing period, the 
experimenter was blinded to genotype. The mean and standard error of the mean (SEM) for both 
genotypes were plotted across all tested timepoints. A two-way ANOVA (alpha = 0.05) was 
performed to assess genotype-specific differences across all tested days.  
 
Pup ultrasonic vocalizations 
USVs were assessed on P3, P5, P7 and P9. Each pup was gently removed from the nest 
and placed in a small, plastic container containing a 0.5 cm layer of fresh bedding. The cage lid 
was immediately returned to avoid irritating the dam and remaining pups in the nest. The container 
holding the pup was placed immediately into a sound-attenuating environmental chamber (Med 
Associates, St. Albans, VT, USA). After a 3-min recording, each pup was marked and returned to 
the nest. Ultrasonic vocalizations were recorded with an Ultrasound Microphone (Avisoft 
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UltraSoundGate condenser microphone capsule CM16, Avisoft Bioacoustics, Berlin, Germany) 
sensitive to frequencies of 10-180 kHz and using the Avisoft Recorder (Version 4.2) software. 
Sampling rate was 250 kHz, format 16 bit. Ultrasonic vocalizations were analyzed using Avisoft 
SASLab Pro software (Avisoft Bioacoustics). Spectrograms were generated for each 1-min audio 
file, with an FFT-length of 512 points and a time window overlap of 75% (100% Frame, Hamming 
window). The spectrogram was generated at a frequency resolution of 488 Hz and a time resolution 
of 1 ms. A lower cut-off frequency of 15 kHz was used to reduce background noise outside the 
relevant frequency band to 0 dB. Calls were inspected visually and manually labelled. Summary 
statistics were generated by Avisoft SASLab Pro and analyzed using Prism.  Only animals that 
emitted calls were included in the quantification analysis. All calls emitted over the 3 min 
recordings were quantified. For the qualitative analysis, one 1-min file (out of three 1-min files) 
that included the most USVs were analyzed for each mouse.  Mean and SEM were plotted, and 
two-way ANOVA was performed across tested days to assess genotype differences. 
 
Adult Behavioral tests 
 
Elevated Plus Maze test: The elevated plus maze test was conducted as described previously (M. 
Yang et al. 2012). This classic test for anxiety-like behavior is based on rodents’ innate fear for 
height and open space. The elevated plus-maze consists of two open arms (30cm x 5cm) and two 
closed arms (30 x 5 x 15 cm) extending from a central area (5 x 5 cm). Photo beams embedded at 
arm entrances register movements. Room illumination was approximately 5 lux. The test begins 
by placing the subject mouse in the center, facing a closed arm. The mouse is allowed to freely 
explore the maze for 5 min. Time spent in the open arms and closed arms, the junction, and number 
of entries into the open arms and closed arms, are automatically scored by the MED-PC V 64bit 
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Software (Med Associates). At the end of the test, the mouse is gently removed from the maze and 
returned to its home cage. The maze is cleaned with 70% ethanol and wiped dry between subjects.  
 
Open Field exploratory activity: The open field test is the most commonly used general test for 
locomotor activity. Each mouse is gently placed in the center of a clear Plexiglass arena (27.31 x 
27.31 x 20.32 cm, Med Associates ENV-510) lit with dim light (~5 lux), and is allowed to ambulate 
freely for 60 min. Infrared (IR) beams embedded along the X, Y, Z axes of the arena automatically 
track distance moved, horizontal movement, vertical movement, stereotypies, and time spent in 
center zone. At the end of the test, the mouse is returned to the home cage and the arena is cleaned 
with 70% ethanol followed by water, and wiped dry.   
 
Catwalk: Free-pace walking was evaluated using the Catwalk XT system (Noldus Information 
Technology) which consists of an illuminated walled glass walkway (130 cm x 10 cm) and a high-
speed camera underneath. Light is reflected and illuminates the stimulus (footprint) when 
downward pressure is applied. Walking patterns are captured with a high-speed camera mounted 
underneath the walkway. The experiment was done with dim room illumination (30lux). The 
mouse is allowed to traverse the walkway as many times as needed to obtain at least 3 compliant 
runs (runs with a speed variation under 80% in 20 seconds or less). Pilot experiments using a 60% 
speed variation limit (most common in the literature) proved to be too stringent for most 
heterozygous mice. Parameters automatically collected by the software include, but are not limited 
to, paw statistics, intensity measures, stride length, width, base of support, distance between 
ipsilateral prints, cadence, % limb support, regularity index, speed, and speed variation. A highly 
trained experimenter visually inspected all automatically scored runs, and manually classified any 
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prints that were too ambiguous for the software to identify accurately. The walkway is cleaned 
with paper towel moistened with 70% ethanol and wiped dry between trials.  
 
Acoustic startle response: Acoustic startle response was tested using the SR-Laboratory System 
(San Diego Instruments, San Diego, CA) as described previously (M. Yang et al. 2012). Test 
sessions began by placing the mouse in the Plexiglass holding cylinder for a 5-min acclimation 
period. For the next 8 min, mice were presented with each of six trial types across six discrete 
blocks of trials, for a total of 36 trials. The inter-trial interval was 10–20 s. One trial type measured 
the response to no stimulus (baseline movement). The other five trial types measured startle 
responses to 40 ms sound bursts of 80, 90, 100, 110 or 120 dB. The six trial types were presented 
in pseudorandom order such that each trial type was presented once within a block of six trials. 
Startle amplitude was measured every 1 ms over a 65 ms period beginning at the onset of the startle 
stimulus. The maximum startle amplitude over this sampling period was taken as the dependent 
variable.  Background noise level of 70 dB was maintained over the duration of the test session.  
 
Fear Conditioning: This is a classic test for conditioned learning. Training and conditioning tests 
are conducted in two identical chambers (Med Associates, E. Fairfield, VT) that were calibrated 
to deliver identical foot shocks. Each chamber was 30 cm × 24 cm × 21 cm with a clear 
polycarbonate front wall, two stainless side walls, and a white opaque back wall. The bottom of 
the chamber consisted of a removable grid floor with a waste pan underneath. When placed in the 
chamber, the grid floor connected with a circuit board for delivery of scrambled electric shock. 
Each conditioning chamber is placed inside a sound-attenuating environmental chamber (Med 
Associates). A camera mounted on the front door of the environmental chamber recorded test 
sessions which were later scored automatically, using the VideoFreeze software (Med Associates, 
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E. Fairfield, VT). For the training session, each chamber is illuminated with a white house light.  
An olfactory cue is added by dabbing a drop of imitation almond flavoring solution (1:100 dilution 
in water) on the metal tray beneath the grid floor. The mouse is placed in the test chamber and 
allowed to explore freely for 2 min. A pure tone (5 kHz, 90 dB) which serves as the conditioned 
stimulus (CS) is played for 30 s. During the last 2 s of the tone, a foot shock (0.5 mA) is delivered 
as the unconditioned stimulus (US). Each mouse received three CS-US pairings, separated by 90 
s intervals. After the last CS-US pairing, the mouse is left in the chamber for another 120 s, during 
which freezing behavior is scored by the Video Freeze software.  The mouse is then returned to its 
home cage.  Contextual conditioning is tested 24 h later in the same chamber, with the same 
illumination and olfactory cue present but without foot shock. Each mouse is placed in the chamber 
for 5 min, in the absence of CS and US, during which freezing is scored.  The mouse is then 
returned to its home cage.  Cued conditioning is conducted 48 h after training. Contextual cues are 
altered by covering the grid floor with a smooth white plastic sheet, inserting a piece of black 
plastic sheet bent to form a vaulted ceiling, using near infrared light instead of white light, and 
dabbing vanilla instead of banana odor on the floor. The session consisted of a 3 min free 
exploration period followed by 3 min of the identical CS tone (5 kHz, 90 dB). Freezing is scored 
during both 3 min segments.  The mouse was then returned to its home cage.  The chamber is 
thoroughly cleaned of odors between sessions, using 70% ethanol and water. 
 
Y maze- The Y-maze is a standard test for assessing short term memory in mice, based on the 
mouse’s natural tendency to explore novel locations. Memory impairment is indicated by failing 
to spend more time exploring the novel arm than the familiar arms. The test is conducted in the Y 
maze (Maze Engineer) consisting of three arms of equal arm lengths (35 cm), arm lane width (5 
cm), wall height (10 cm). One arm is the start arm, with a “=” sticker velcroed on the wall, to the 
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end of the arm. The two stickers (bus and plane) are velcroed on the wall at the end of the other 
two arms. The placement of the stickers were counterbalanced across animals. The novel arm 
preference test consists of two trials. In Trial 1, each mouse is placed in the designated start arm 
and allowed access the start arm and the one other arm for 10 min. The third arm is blocked with 
an opaque door.  At the conclusion of trial 1, the mouse was placed in a temporary holding cage 
for 10 min. For Trial 2, the subject mouse was returned to the start location, and allowed to explore 
all arms for 5 min. A camera mounted above the maze and interfaced with the Ethovision software 
(Noldus Information Technology) automatically records distance traveled, arm entries, and time 
spent in each arm. The maze is cleaned with 50% ethanol and allowed to dry between trials and 
between animals.   
 
Morris water maze- Spatial learning and reversal learning were assessed in the Morris water maze 
using procedures and equipment as previously described (M. Yang et al. 2012). The apparatus was 
a circular pool (120 cm diameter) filled 45 cm deep with tap water rendered opaque with the 
addition of non-toxic white paint (Crayola, Easton, PA).  Distal room cues were door, chairs, 
computers, and proximal cues are two 20cm x 20cm stickers.  Trials were recorded and 
automatically scored by Ethovision 12 (Noldus Information Technology). Acquisition training 
consisted of 4 trials a day for 5 days. Each training trial began by lowering the mouse into the 
water close to the pool edge, in a quadrant that was either right of, left of, or opposite to, the target 
quadrant containing the platform. The start location for each trial was alternated in a semi-random 
order for each mouse. The hidden platform remained in the same quadrant for all trials during 
acquisition training for a given mouse, but varied across subject mice. Mice were allowed a 
maximum of 60 s to reach the platform. A mouse that failed to reach the platform in 60 s was 
guided to the platform by the experimenter. Mice were left on the platform for 15 s before being 
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removed. After each trial, the subject was placed in a cage lined with absorbent paper towels and 
allowed to rest under an infrared heating lamp for 60 s. Two hours after the completion of training 
on day 5, the platform was removed and mice were tested in a 60 s probe trial. Parameters recorded 
during training days were latency to reach the platform, total distance traveled, and swim speed. 
Time spent in each quadrant and number of crossings over the trained platform location and over 
analogous locations in the other quadrants were used to analyze probe trial performance. 
 
Electroencephalography (EEG) 
Video EEGs were performed on 6-8 week adult mice as previously described (Asinof et al. 2016). 
Mice were anesthetized with tribromoethanol (250 mg/kg delivered via intraperitoneal injection, 
Sigma Aldrich cat# T48402), and three small burr holes were drilled through the skull 2mm lateral 
to the midline (1mm rostral to the bregma on both sides and 2mm caudal to the bregma on the 
left). One hole was also drilled over the cerebellum as a reference. Four Teflon-coated silver wires 
soldered onto pins of a microconnector (Mouser electronics cat# 575-501101) were placed in 
between the dura and brain. A dental cap was applied on top. Each mouse was provided the post-
operative analgesic Carprofen (5mg/kg subcutaneous Rimadyl) and allowed a recovery period of 
at least 48 hours prior to recording. For EEG recordings, mice were connected to commutators 
(PlasticOne) with flexible cables to allow free movement within the cage. Signal was obtained on 
either a Grael II EEG amplifier (Compumedics) or Natus Quantum amplifier (Natus Neuro). Data 
was analyzed with either Profusion 5 (Compumedics) or NeuroWorks (Natus Neuro). Differential 
amplification recordings were recorded pairwise between all three electrodes and the reference, 
resulting in 6 total channels for each subject. Mouse behavior was captured throughout the 
recording period through video using a Sony IPELA EP550 camera with infrared light for dark 




Electroconvulsive threshold (ECT) studies 
All tests were performed on 6- to 8-week-old mice as previously described (cite). In summary, 
transcorneal electrodes were used to deliver a predefined stimulus with the Ugo Basile Model 7801 
electroconvulsive device. High frequency (HF) electroshock was performed with the following 
fixed settings: 1.6ms pulse width, 0.2s shock duration and 299Hz pulse frequency with variable 
settings of 4-12mA amplitude. The individual threshold for each mouse was determined by testing 
in 0.5mA intervals on sequential days until the threshold was reached. The behavioral endpoint 
evaluated was a maximal tonic hindlimb extension seizure, which often start with tonic extension 
of the forelimbs that evolves into full tonic hindlimb extension. The overall stimulus is calculated 
as the iRMS (integrated root mean square, or the integrated area under the curve) using the 












Chapter 3: Ascertain Potential Disease-Relevant Genes and Cell 
Types 
3.1 Introduction 
 From its ability to influence transcription initiation and elongation to its role in alternative 
splicing and mRNA stability, hnRNP U confers multiple levels of gene expression regulation (see 
Introduction). While hnRNP U is expressed ubiquitously, neurons in particular rely heavily on the 
proper spatial, temporal and quantity of gene expression to achieve both the structural and 
functional complexity necessary for normal brain function. It is therefore perhaps not surprising 
that mutations in regulators of gene expression, such as in genes that encode RNA- and DNA- 
binding proteins, can cause neurological disease, with the prevailing paradigm being that the 
improper expression of target genes important for neuronal homeostasis ultimately culminate in 
disease phenotypes.  
There are multiple genetic epilepsies, highlighted in Table 3.1, considered to have a 
transcriptomic basis of disease, including hnRNP U. These types of epilepsies are not amenable to 
the more traditional precision medicine approaches relied on for common genetic epilepsies 
involving ion channels or synaptic transmission machinery. The potential utility of a 
transcriptome-guided precision medicine approach for hnRNP U-related neurodevelopmental 
disease was therefore assessed, relying on brain-region and single cell-level gene expression data 
to inform potential vulnerable cell types and key dysregulated genes that could be targeted 
therapeutically. A transcriptome-based approach to precision medicine and drug discovery is not 
a novel idea, and has been applied in fields like oncology with some success. One approach has 
been the search for compounds with transcriptional signatures that complement (i.e. are inversely 
correlated to) the gene expression profile of the tumor (Shigemizu et al. 2012; Chen et al. 2011). 
Another approach relies on the tumor transcriptome to identify master regulators of tumor activity 
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and progression that can be molecularly targeted with current FDA-approved drugs (Alvarez et al. 
2018). The approach described here, however, begins with a comprehensive cell type and brain-
region specific characterization of gene expression in the Hnrnpu+/113DEL mouse model, followed 
by the functional evaluation of implicated brain regions and cell types, and finally, although not 
part of this thesis work, the identification of compounds that restore the specific transcriptomic 
signature and rescue associated phenotypes. Initially, a pilot bulk RNA-sequencing study of the 
neocortex was performed to first confirm the presence of significantly differentially expressed and 
spliced genes, followed by single-cell RNA-sequencing to assess for cell population-specific 
vulnerabilities within the hippocampus and neocortex—two of the more epilepsy-relevant brain 
regions. Findings from these studies were next functionally evaluated using both in vitro 
electrophysiology and in vivo molecular readouts (discussed in Chapter 4). Results from this work 
should set the stage for targeted therapeutic discovery for this otherwise complex and pleiotropic 
genetic epilepsy.     
Of the work summarized below, the bulk RNA-sequencing pipeline was established by 
Bioinformaticians Brett Copeland and Dr. Matthew Halvorsen in the IGM, and the bulk RNA-
sequencing analysis was completed by myself. The TimeLapse Sequencing experiment was 
performed in collaboration with Dr. Matthew Simon (Yale University) and Dr. Daniele Canzio 
(UCSF). Specifically, all mouse breading, neocortical dissections and sample preparation were 
performed by myself under the guidance of Dr. Canzio. The TimeLapse Chemistry and library 
preparation of all samples were performed by Jeremy Schofield, Josh Zimmer and myself. The 
gene-length:gene-expression analysis on other DNA/RNA binding was also performed by me. The 
single cell RNA-sequencing experiment was performed by myself and fellow Goldstein 
Laboratory member Ryan Dhindsa. Specifically, I arranged the mouse matings, performed the 
tissue dissection and dissociation, and submitted the samples for single-cell RNA-sequencing. 
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Ryan Dhindsa established the single-cell RNA-sequencing pipeline in the IGM, and performed the 
formal data analysis reported in this work. I performed the gene-length/gene-expression analysis 




Bulk transcriptional profiling of neocortex revealed dysregulated expression of neuronal genes   
Differential gene expression- 
 Neocortices were dissected from four Hnrnpu+/113DEL and five WT littermate P0 pups. RNA 
was extracted and subjected to total, stranded, paired-end RNA-sequencing. The RNA-sequencing 
analysis pipeline utilized to complete this analysis was established by Bioinformaticians Brett 
Copeland and Dr. Matthew Halvorsen in the Institute for Genome Medicine. All samples 
sequenced had a RIN score of 8.9 or greater. RNA-SeQC metrics revealed an average mapping 
rate of 85% and estimated library size (accounting for total reads and duplication rate) of 
approximately 51 ± 8 million reads (DeLuca et al. 2012). The average number of genes and 
transcripts detected (defined as containing at least 5 exon-mapping reads) was roughly 22,000 ± 
435 and 81,000 ± 900, respectively. The 113-bp deletion in exon 1 of Hnrnpu was detected as a 
novel splice junction following STAR alignment in all mutants, and was confirmed absent in all 
WTs (data not shown). Principal component analysis (PCA) of gene expression using rlog-
transformed counts revealed obvious clustering of samples based on gender and litter, but not 
based on genotype (Figure 3.1A-B). Further investigation using principle variance component 
analysis (PVCA) revealed that nearly 50% of variation in gene expression among all samples was 
due to litter-specific effects, compared to roughly 17% for condition (i.e. genotype), 14% for 
gender:litter interaction, 9% for gender alone, 2% for litter:lane and 2% for lane:condition 
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interactions (Figure 3.1C). A residual level of variation of 6.5% remained unaccounted for 
following these tested variables of gender, litter, condition and sequencing lane.   
Library size normalization and differential expression analysis were performed using 
DESeq2 (Love, Huber, and Anders 2014). A likelihood ratio model was used to test for genotype-
specific changes in gene expression, with gender, litter and sequencing lane included as covariates. 
Assuming a false discovery rate (FDR) of 10%, a total of 558 genes, or 6.1% of all tested genes, 
were found to be significantly dysregulated: 327 downregulated (58.6%) and 231 upregulated 
(41.4%) (Figure 3.2A). The degree of differential expression was modest, with an average log2 
fold-change (log2FC) of -0.4 (0.76-fold) for significantly downregulated and +0.337 (1.26-fold) 
for significantly upregulated.  The top dysregulated gene, Malat1, is a highly-abundant lncRNA 
found to be downregulated 0.67-fold in mutants (p-adj = 1.03E-13). As expected, Hnrnpu was also 
significantly downregulated with a fold change of 0.77 (p-adj = 3.49E-05), consistent with prior 
qRT-PCR and western blot data (reviewed in Chapter 2). Of the significantly dysregulated genes, 
94% were protein coding, 2% were non-coding RNAs, 2% were pseudogenes and 1% were 
processed transcripts (Figure 3.2B). There did not appear to be any enrichment of hnRNP U 
binding sites across the corresponding pre-mRNA of significantly differentially expressed genes 
(DEGs) based on available cardiac CLIP-sequencing data (Figure 3.2C). In fact, a slight depletion 
of binding sites was observed in upregulated genes specifically (OR 0.58, 95%CI 0.36-0.96, FET 
p= 0.027).   
Disease gene enrichment analysis revealed a significant overrepresentation of known 
epilepsy, autism, developmental delay (DD) and haploinsufficient genes (HI) for significantly 
downregulated DEGs (ORs of 4.3, 4.0, 4.7 and 5.3 for epilepsy, autism, DD and HI genes, 
respectively) (Figure 3.2D). This is in stark contrast to upregulated genes which did not show this 
trend (ORs 0, 0.2, 0.5 and 0.5m respectively).  Downregulated epilepsy genes included Pcdh19, 
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Grin2b, Kcnq3, Stxbp1, Dnm1, Syn1 and Cacna1a etc. Example autism genes include Celf4, 
Plxna4, Ank3, Ank2, Tbr1, Shank1, Auts2, Sema5a, Chd8, and DD genes include Grin2b, Chd4, 
Auts2, Nf1, Crebbp, Tcf4 and Stxbp1.  
Gene ontology analysis revealed a distinct trend in biological function terms represented 
by significantly down versus upregulated gene sets (Mi et al. 2019). Downregulated genes showed 
enrichment for pathways important in neuronal function, such as axon guidance and extension, 
GABA secretion, regulation of synaptic vesicle cycle and presynaptic active zone assembly, etc. 
(FDR p<0.05) (Figure 3.2E). Alternatively, upregulated genes were enriched for terms involving 
ribosome assembly and protein translation (Figure 3.2F). Downregulated genes enriched for axon 
extension and guidance included the semaphorins Sema5a and Sema6a, plexins Plxna4, Plxna1 
and Plxnb2, along with genes that encode cytoskeletal proteins Map1b and Apc2. GABA secretion 
and synaptic vesicle cycle genes included those that encode the calcium channel Cacna1a, the 
membrane trafficking protein Syn1, the small GTPase Dnm1 and the protocadherin Pcdh17, 
among others. Other significant pathways represented from downregulated genes included 
neurotransmitter secretion, retrograde axonal transport, regulation of neuronal synaptic plasticity, 
neuron migration, negative regulation of neuron apoptotic process and associative learning.  
Upregulated genes important for translation and ribosomal subunit assembly included the 
eukaryotic translation initiation factors Eif4h, Eif4a2, Eif3m, and ribosomal proteins Rps2, Rps14, 
Rps27, Rps19, among others.  Together with the above disease gene enrichment results, these data 
suggest that hnRNP U plays an important role in promoting the expression of genes essential for 
proper brain development and function, and likely suppressing genes that function in cytoplasmic 
translation.  
 
Differential exon usage- 
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Considering hnRNP U is known to play a role in alternative splicing, DEXSeq (Anders, 
Reyes, and Huber 2012) was employed on protein coding genes to test for differential usage of 
annotated exons. Using gender, litter, sequencing lane and gene as covariates in the linear model 
and assuming a 10% FDR, this analysis revealed a total of 486 significantly differentially-
expressed exons out of 131,024 (~0.4%) total tested exon events corresponding to 336 different 
genes. Only 23 of these 336 alternatively-spliced genes (~7%) overlapped with the significant 
DEGs, indicating that the majority of exon-level splicing changes occur in genes with overall 
normal expression. Similar to the DGE analysis, the average fold changes for exon usage of 
significant events were modest, showing a 1.18 ± 0.21-fold change for increased exon usage versus 
0.82 ± 0.14 for decreased exon usage. In contrast to the DEGs, corresponding pre-mRNAs showed 
enrichment for hnRNP U binding compared to pre-mRNAs with non-significant exon usage events 
(OR= 4.3, FET p= 4.0E-04), consistent with the role of hnRNP U in the alternative splicing of pre-
mRNAs (Figure 3.2C).  Of note, Hnrnpu itself was found to contain two significant alternatively-
spliced exons, showing increased exon usage in mutants for both events (data not shown).  
Disease enrichment analysis of genes with significant exon-level events revealed a strong 
representation of autism genes (OR= 4.3, FET p= 1.3E-08) (Figure 3.2D). Only 5 of 26 total (19%) 
autism genes overlapped with the differentially-expressed autism genes, again indicating that 
despite changes in exon inclusion, the overall expression of these genes was no different than WT 
mice. Example genes include Foxp2, Cacnb2, Stxbp5, Nrxn3, Terf2 and Slc38a10. A significant 
overrepresentation of DD and HI genes was also observed (OR= 3.3 and 2.3, FET p= 1.1E-05 and 
9.4E-03, respectively), and included genes such as Grin2b, Smad4 and Tcf20 for DD and Atrx, 
Kdm5c, Pax6 and Rps19 for HI genes. No enrichment for epilepsy genes was observed.  
Gene ontology analysis evaluating the biological process of genes with significant exon-
level events revealed enrichment of only a few terms including positive regulation of neuron 
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projection development, regulation of dendrite morphogenesis, positive regulation of neuron 
migration and regulation of organelle organization (Figure 3.2G).   
 
Correlation between hnRNP U binding, gene length and gene expression dysregulation- 
Differential gene expression analysis previously demonstrated that hnRNP U is important 
for sustaining expression of important neuronal genes. While investigating whether these neuronal 
genes were known binding targets of hnRNP U, a clear trend amongst the number of hnRNP U 
binding sites and degree of gene dysregulation was observed. Specifically, there was a significant 
inverse correlation between the number of hnRNP U binding sites along the pre-mRNA—as 
determined by CLIP-sequencing of cardiac tissue—and the log2FC of the encoding gene 
(spearman R= -0.25, p<1.0E-04) (Figure 3.3A-B). Essentially, the more hnRNP U binding sites 
along the pre-mRNA, the greater the degree of downregulation of gene expression, and vise-versa. 
A similar negative correlation was also observed for log2FC and gene length— the longer the 
gene, the greater degree of downregulation (Spearman R= -0.30, p<1.0E-04) (Figure 3.3C-D). In 
particular, DEGs show striking differences in average gene length compared to non-DEGs, with 
downregulated DEGs over twice as long as non-DEGs and over six times as long as upregulated 
DEGs (Figure 3.3E). Upon normalizing the number of hnRNP U binding sites by gene length, the 
inverse correlation is abolished (Figure 3.3F) indicating that length is largely driving this 
observation amongst hnRNP U targets. Considering brain-expressed genes on average are longer 
than other tissue types (Gabel et al. 2015; Zylka, Simon, and Philpot 2015), these findings fit with 
prior data showing enrichment for neurodevelopmental disease genes and other important brain 
genes among the downregulated DEGs, and suggest that hnRNP U is particularly important in 
maintaining expression of long, neuronally-expressed genes (see Discussion). 
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This observation was further supported by TimeLapse sequencing, a novel method of 
RNA-sequencing that utilizes metabolic labeling to flag new transcripts thus providing a temporal 
dimension to RNA-sequencing data (Schofield et al. 2018). Specifically, in collaboration with Dr. 
Matt Simon’s Laboratory (Yale University) and Dr. Daniele Canzio (UCSF), dissociated cortex 
from P0 mutant and WT pups was incubated with 4-Thiouridine (4-sU) for 3 hours and 
subsequently subjected to TimeLapse chemistry, resulting in a low level of U to C mutations that 
mark nascent RNA. Differential expression analysis revealed an overall greater degree of 
downregulation of genes longer than 50kb compared to those less than 50kb, consistent with 
findings from the bulk RNA-sequencing (Figure 3.4). In terms of total RNA, this difference in 
gene length was evident for all genes tested and for “changed genes” (genes with p<0.1, n=1076) 
(Figure 3.4A-B). Furthermore, this trend was also observed for inferred new RNA (i.e. nascent 
transcripts), both for all genes tested and for changed genes (Figure 3.4C-D). Of note, the average 
log2FC of the >50kb length genes was markedly lower for the changed genes compared to total 
genes in both the total RNA and inferred new RNA analyses. Moreover, dysregulated nascent 
transcripts showed the greatest degree of downregulation in the >50kb group. These data are 
consistent with the notion that hnRNP U plays an important role in maintaining normal levels of 
newly transcribed and particularly long transcripts. 
  
Length-dependent gene expression changes in brain-expressed DNA/RNA-binding proteins 
To further investigate these length-dependent effects on expression on a broader scale, the 
relationship between gene expression and gene length was evaluated for other brain-expressed 
DNA- and RNA-binding proteins (DRBPs).  Specifically, a list of human genes with both DNA 
and RNA binding functions, including hnRNP U, was generated using experimentally-validated 
GO annotations (Ashburner et al. 2000; The Gene Ontology Consortium 2019) and was further 
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refined to 30 genes showing widespread expression in the brain based on available GTEx data 
(Table 3.2) (Carithers et al. 2015). These dual DRBPs are predominantly transcription factors, 
helicases and splicing factors. For each DRBP, raw knockdown (shRNA, siRNA or CRISPRi) and 
control RNA-sequencing data from human cell lines were downloaded from ENCODE, and 
analyzed for changes in global gene expression (ENCODE Project Consortium 2012; C. A. Davis 
et al. 2018). For the majority of DRBPs assessed, positive and negative correlations of gene length 
and corresponding log2FC were observed (Figure 3.5). Specifically, of the 30 DRBP genes 
examined, 18 showed a significant negative correlation, whereas 6 had a positive correlation 
(Figure 3.5, red boxes highlight significant DRBPs, Bonferroni-corrected Spearman p<0.0017). 
The DRBP with the greatest negative correlation was SFPQ (spearman r=-0.27, p<1E-04), which 
is consistent with recent literature implicating SFPQ in facilitating transcription elongation of long 
neural genes (Takeuchi et al. 2018). Alternatively, the DRBP with the greatest positive correlation 
was TARDBP (spearman r=0.15, p<1E-04), which is consistent with its reported role as a 
transcriptional repressor (I.-F. Wang, Reddy, and Shen 2002; Lalmansingh, Urekar, and Reddi 
2011). In line with the bulk RNA-sequencing findings, hnRNP U also had a significant negative 
correlation (spearman r= -0.1, p<1E-04), supporting the claim that hnRNP U plays an important 
length-dependent role in gene expression. Interestingly, known OMIM genes and genes associated 
with CNS dysfunction in humans and/or animal models were amongst those with significant 
correlations, including SFPQ, PA2G4, UBTF, DDX3X, HNRNPK, HNRNPA1 and TARDBP, 
consistent with the hypothesis that length-dependent effects on transcription and global gene 
expression may act as a broader mechanism of neurological disease (see Discussion).    
 
Single-cell transcriptomics of neocortex and hippocampus reveal cell population-specific gene 
dysregulation in Hnrnpu+/113DEL mice 
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To assess the cell type-specific transcriptomic effects upon reduced expression of Hnrnpu, 
single-cell RNA-sequencing was performed in collaboration with fellow Graduate Student Ryan 
Dhindsa of the Goldstein Laboratory (who performed the data analysis), on neocortex and 
hippocampus obtained from Hnrnpu+/113DEL and WT littermate P0 pups. For both brain regions, 
two pups of each genotype were evaluated, including one of each sex. Neocortical and 
hippocampal tissue were dissected from different mice originating from separate litters. Tissue 
from each brain region was dissociated and the resulting single cell suspensions were processed 
using the 10X Genomics platform (Figure 3.6A).  A total of 18,171 single-cell expression profiles 
from the neocortex and 21,487 from the hippocampus were generated. For each cortical and 
hippocampal sample, an average of 4,543 and 5,372 cells was sequenced, respectively, with an 
average of 76,553 and 65,113 reads sequenced per cell. Furthermore, the fraction of reads in cells 
were 87.6% and 72%, with an average of 64.6% and 61.3% mapping confidently to the 
transcriptome for cortex and hippocampus, respectively. The median number of genes detected 
per cell and the total number of genes detected was 2,023 and 18,164 for neocortex, and 2,172 and 
19,139 for hippocampus. All samples reached a sequencing saturation of 75% or greater, and 
contained a comparable number of unique genes and total molecules detected in each cell, along 
with percent reads mapping to the mitochondrial genome (Figure 3.6B-C). Cells that did not meet 
pre-defined thresholds for these parameters (as indicated by the dotted line, Figure 3.6B-C) were 
considered poor-quality cells and were filtered out prior to downstream analyses.    
To group based on cell type, unsupervised clustering was performed on cells combined 
from both genotypes for each brain region separately. For both neocortex and hippocampus, 
clustering was performed using expression data derived from the first 30 principal components 
(PCs) which captured the majority of gene expression variance (Figure 3.7A). A total of 28 and 24 
clusters were subsequently generated for neocortex and hippocampus, respectively. Resulting 
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clusters were merged and annotated based on the expression of known cell-specific markers into 
13 distinct cell populations for each brain region (Figure 3.7B-C) (Table 3.3). These included 
overlapping cell populations such as astrocytes, Cajal-Retzius cells, radial glia, other proliferative 
cells, intermediate progenitors, oligodendrocyte precursor cells (OPCs) and inhibitory 
subpopulations including SST- and VIP-positive neurons (Figure 3.7B). For neocortex, pyramidal 
neurons were classified based on layers 2-4 and layers 5/6 markers, whereas in hippocampus, 
pyramidal neurons were grouped based on their respective hippocampal subfield, including dentate 
gyrus, CA1, CA2/3 (referred to herein as CA3), subiculum and entorhinal cortex (Figure 3.7B-C). 
Of note, to ensure that clustering was not driven by genotype, datasets were harmonized prior to 
clustering (Figure 3.7D). Furthermore, the number of cells contributed to each cluster from each 
sample were comparable (Figure 3.7E).   
Hnrnpu expression was observed across all clusters evaluated, consistent with ubiquitous 
expression, as previously reported. While expression appeared relatively constant across clusters, 
proliferative cell populations, comprised primarily of neural stem cells, appeared to express higher 
levels of Hnrnpu in both the neocortex and hippocampus (cortex=1.24 and hippocampus=1.38 log-
norm UMIs) (Figure 3.8).  
In order to determine cell population-specific transcriptomic differences between mutants 
and WTs, DGE analysis was performed on cell clusters derived from each brain region using a 
linear model approach, using both sex and gene detection rate included as covariates. Despite the 
small sample size of only two mutants (one male and one female) of each genotype, sequencing 
thousands of cells derived from each sample enables a high-powered gene expression study as 
each cell is considered a biological replicate. In effort to limit false-positives and focus the analysis 
on likely biologically-relevant changes, only genes with both an FDR-corrected q-value of less 
than 5% and at least a 10% change in expression level (log2FC > ±0.14) were considered to be 
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statistically significant. Furthermore, variation in gene expression among mice of the same 
genotype should be controlled for by including sex as a covariate in the linear model. Using these 
criteria,  454 genes were identified as statistically dysregulated among 9 cell populations in the 
neocortex (inhibitory progenitors, intermediate progenitors, layers 2-4 and layers 5/6 pyramidal 
neurons, LGE-derived interneurons, radial glia, SST- and VIP-positive interneurons), and 955 
were dysregulated among 9 populations in the hippocampus (CA1, CA2/3, dentate gyrus, 
entorhinal cortex, subiculum-derived pyramidal neurons, intermediate progenitors, radial glia, 
SST- and VIP-positive interneurons) (Figure 3.9A). For neocortex, 51% of genes were 
downregulated and 49% were upregulated, whereas for hippocampal dysregulated genes, roughly 
73% were downregulated and 27% were upregulated (Figure 3.9A). In terms of all significantly-
dysregulated genes, there was an average 0.83-fold decrease and 1.18-fold increase in expression 
for neocortex and 0.85-fold decrease and 1.18-fold increase for hippocampus. Hnrnpu expression 
was significantly downregulated in layers 2-4 and layers 5/6 pyramidal neurons and inhibitory 
progenitor populations of the neocortex, along with CA1, subiculum and radial glia populations of 
the hippocampus, with an average fold change of 0.86 amongst these cell populations.  These data 
are consistent with bulk RNA-sequencing results which showed a minor decrease in Hnrnpu 
expression in heterozygous mutants and corresponding modest, yet widespread, level of 
dysregulation across the transcriptome. Likewise, downregulated genes in both the neocortex and 
hippocampus converged onto important neuronal pathways involving axonogenesis, synaptic 
transmission, modification of postsynaptic structures, neuron differentiation and neuronal 
migration, etc. (Figure 3.9B).  
In effort to assess for cell population-specific vulnerabilities caused from heterozygous loss 
of Hnrnpu, a down-sampled dataset was generated including 300 cells from each cell type cluster, 
thus permitting a fair comparison of the total dysregulated genes across cell types. Differential 
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gene expression analysis performed on each down-sampled cluster revealed a greater number of 
dysregulated genes in the subiculum of the hippocampus compared to other hippocampal and 
neocortical cell populations (Figure 3.10A). Furthermore, analysis for disease gene enrichment of 
all significantly downregulated genes (not just those resulting from the down-sampled dataset) 
using current epilepsy, developmental delay (DD) and autism gene sets, revealed an over-
representation of genes from all three diseases in the subiculum (Figure 3.10B). Enrichment of DD 
and epilepsy genes was also observed in the downregulated genes of somatostatin (SST)-positive 
cells of the neocortex, along with a minor, yet significant, enrichment of DD genes within the 
inhibitory progenitors, radial glia and layer 5/6 neurons (Figure 3.10B). Of note, given low 
expression of epilepsy genes in this dataset, for this analysis the significance threshold was relaxed 
to an FDR < 0.1 and log2FC of 0.074 (5% difference in gene expression).  
To further evaluate cell type specific differences in gene expression, the correlation 
between length and log2FC across all tested genes was calculated for the neuronal populations in 
the neocortex and hippocampus. Similar to the bulk RNA-sequencing study, significant negative 
correlations were observed for multiple neuronal populations in both brain regions, consistent with 
the downregulation of long genes in certain neuronal subtypes of mutant P0 mice (Figure 3.10C). 
This negative correlation was most pronounced for pyramidal neurons of the subiculum (spearman 
r= -0.23, p<1E-04) and in layers 5/6 of the neocortex (spearman r= -0.24, p<1E-04) (Figure 3.10C). 
As expected, the significantly-downregulated genes in both cell types were comprised primarily 
of long (mean length >100kb), important neuronal genes including cell adhesion molecules 
(Pcdh9, Cdh2, Chl1, Opcml, Cadm2), axon guidance proteins (Epha4, Epha7, Robo2, Slitrk5), 
ATP-dependent ion transporters (Atp1b1, Atp2b4, Atp2b1), NMDA and AMPA-receptor subunits 
(Grin2b, Gria2) and transcription factors (Tshz2, Tcf4). Interestingly, this length-dependent effect 
on gene expression was not always observed in cell types with a significant decrease in Hnrnpu 
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expression. For example, there were no observed length-dependent effects on gene expression 
despite a highly-significant 0.77-fold decrease in Hnrnpu transcript levels in neocortical inhibitory 
progenitors. This suggests an epistatic mechanism involving hnRNP U and other unknown factors, 
such as other transcription regulators, that ultimately influence gene expression within these 
various cell types (i.e. context dependent effects, see Discussion). Altogether, these data indicate 
that while transcriptomic dysregulation in mutant mice is pervasive among the transcriptome yet 
modest in effect size, the effects on gene expression appear more substantial in pyramidal neurons 
of the subiculum, including genes known to cause phenotypes associated with mutations in hnRNP 
U.  
Investigation into the genes dysregulated within the subiculum revealed a striking outlier 
in the gene Mef2c. Not only was Mef2c the most significantly dysregulated gene in the subiculum 
(FDR p= 8.33E-37), Mef2c also had a more sizeable fold-change of 0.46 (>50% decrease in 
expression), unlike the other dysregulated genes with only minor fold-changes (Figure 3.9A). 
Mef2c is a transcription factor important for synaptic development. Heterozygous loss-of-function 
mutations in this gene cause a neurodevelopmental disorder with strong phenotypic overlap to that 
of patients with HNRNPU mutations including epilepsy, developmental delay and autistic features 
(see Discussion). Expression at P0 is primarily confined to both the subiculum and SST-positive 
interneurons of the hippocampus, yet is more widespread among the neocortex including the L2-
4 and L5/6 pyramidal neurons, along with SST- and VIP-positive interneurons (Figure 3.11A). In 
addition to the subiculum, Mef2c was found to be significantly downregulated in SST interneurons 
of the neocortex, yet to a lesser degree showing a 0.78-fold change (FDR p= 8.9E-09). Based on 
available hnRNP U CLIP-sequencing data from cardiac tissue, Mef2c transcript is a strong binding 
target of hnRNP U, residing at the 98.5%ile for number of hnRNP U binding sites (Figure 3.11B). 
Mef2c is also a long gene measuring 163kb in length, consistent with the preferential 
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downregulated expression of long genes observed in Hnrnpu mutants. Given the 50% loss of 
Mef2c expression in the subiculum, and its known role in epileptic encephalopathy, closer 
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Table 3.1 Genetic epilepsies with a likely transcriptomic basis. 
GENE FULL NAME INHERITANCE FUNCTION
CDKL5 Cyclin-Dependent Kinase-Like 5 X-linked
Phosphorylates important nuclear & cytoplasmic targets, including gene 
expression regulators Mecp2, Dnmt1 and Ngl1. Important for synapse 
development and function, and neuronal outgrowth. 
FOXG1 Forkhead Box G1 De novo heterozygous Transcription factor important in telencephalic development
MEF2C Myocyte Enhancer Factor 2C
De novo 
heterozygous
Transcription factor that regulates expression of genes important in synaptic 
development
CHD2 Chromodomain DNA Helicase Binding Protein 2
De novo 
heterozygous
Is recruited by cell-type specific transcription factors to important 
developmentally-regulated genes. Remodels chromatin to a permissive state. 
ARX Aristaless Related Homeobox X-linked
Regulates expression of genes important in cortical development including 
cell differentiation and migration, particularly involving interneurons
HNRNPU Heterogeneous Nuclear Ribonuclear Protein U
De novo 
heterozygous
Ubiquitous DNA and RNA-binding protein that plays a role in transcription 
initiation, elongation, mRNA splicing 
SIK1 Salt Inducible Kinase 1 De novo heterozygous
Regulates expression of genes important in neuronal development and 




Figure 3.1 Variation in gene expression is driven by litter, gender and genotype. (A-B) First 
two principal components of pseudo-log transformed gene expression data. Samples are labelled 
based on genotype and litter (A) along with genotype and sex (B). (C) Principal variance 
component analysis (PVCA) using litter, gender, condition (i.e. genotype), sequencing lane and 
the interactions among each. Litter drove the greatest changes in gene expression, followed by 
condition (i.e. genotype), gender and gender:litter interaction. The numbers above each bar 


























































































































Figure 3.2 Downregulation and aberrant exon-level splicing of important neuronal genes in 
Hnrnpu+/113DEL mutants.  (A) MA plot showing the average normalized count and corresponding 
log2FC of each tested gene. Significant DEGs are highlighted in red. (B) Breakdown of gene type 
found significantly dysregulated in mutants. (C) Odds ratio (with 95% CI) of hnRNP U binding 
across all significant DEGs, those found downregulated and upregulated, along with those with 
differential exon usage. Fishers exact test p-values are shown next to each plot. (D) Odds ratio 
(with 95% CI) for the presence of known epilepsy, developmental delay (DD), haploinsufficient 
(HI) and autism genes in the upregulated and downregulated genes, and genes with differential 
exon usage. Fisher’s p-values are shown next to each plot. (E-G) GO analysis (“biological 
function” terms) showing -log(q) (q= FDR p-value) of downregulated (E), upregulated (F) and 
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Figure 3.3 Length-dependent effects on gene expression observed in Hnrnpu+/113DEL mutants. 
(A) A running average plot showing log2FC-ranked genes (x-axis) with average log2FC calculated 
and binned for every 100 ranked genes plotted against mean number of hnRNP U binding sites. 
(B) Corresponding Spearman plot showing significant negative correlation between number of 
hnRNP U binding sites and log2FC (p<1E-04). (C) Running average plot of log2FC-ranked and 
binned genes against mean gene length (D) Corresponding Spearman plot showing significant 
negative correlation between gene length and log2FC (p<1E-04). (E) Average gene length of 
downregulated (blue), upregulated (red) and non-differentially-expressed genes (black). (F) 
Spearman plot showing reduced correlation upon normalizing the number of hnRNP U binding 
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Figure 3.4 Total and nascent transcripts derived from long-genes are preferentially 
downregulated. (A-D) TimeLapse-seq data showing mean log2FC of genes less or above 50kb in 
length for total RNA analysis of all genes tested (A), total RNA of changed genes with DESeq2 
p<0.1 (B), inferred new RNA (i.e. nascent transcripts) of all tested genes (C), and inferred new 
RNA of changed genes with DESeq2 p<0.1 (D). The difference in log2FC between genes less or 











Figure 3.5 Length-dependent effects on gene expression of other DRBPs. Two-tailed 
Spearman correlation coefficient (with 95%CI) of log2FC and gene length for each brain-
expressed DRBP assessed. Dotted red lines= DRBPs with significant correlations (Bonferroni-







Table 3.2 DRBPs analyzed for length-dependent effects on gene expression. 
DRBP Encode Accession
Study 
type Ctrl Accession(s) DNA GO term RNA GO term
BCLAF1 ENCSR410ZPU shRNA ENCSR245BNJ DNA binding RNA binding
CCAR1 ENCSR386YEV shRNA ENCSR667PLJ RNA polymerase II distal enhancer sequence-specific DNA binding RNA binding
DDX3X ENCSR000KYM shRNA ENCSR913CAE DNA binding RNA binding
FUBP3 ENCSR373KOF shRNA ENCSR913CAE RNA polymerase II proximal promoter sequence-specific DNA binding RNA binding
HMGB2 ENCSR263IOO CRISPRi ENCSR016WFQ DNA binding RNA binding
HNRNPA1 ENCSR048BWH shRNA ENCSR438MDN single-stranded DNA binding RNA binding
HNRNPA2B1 ENCSR794NUE shRNA ENCSR164MUK single-stranded telomeric DNA binding RNA binding
HNRNPC ENCSR634KBO shRNA ENCSR572FFX RNA polymerase II proximal promoter sequence-specific DNA binding RNA binding
HNRNPD ENCSR660MZN shRNA ENCSR279HMU telomeric DNA binding RNA binding
HNRNPK ENCSR529JNJ shRNA ENCSR129RWD RNA polymerase II proximal promoter sequence-specific DNA binding RNA binding
HNRNPL ENCSR563YIS shRNA ENCSR031RRO transcription regulatory region DNA binding RNA binding
HNRNPU ENCSR047IUS shRNA ENCSR438MDN DNA binding RNA binding
ILF2 ENCSR126ARZ shRNA ENCSR419JMU DNA binding RNA binding





RNA polymerase II proximal promoter 
sequence-specific DNA binding RNA binding
NPM1 ENCSR346DZQ shRNA ENCSR164MUK core promoter binding RNA binding
PA2G4 ENCSR309PPC shRNA ENCSR661HEL DNA binding RNA binding
PCBP1 ENCSR545AIK shRNA ENCSR129RWD single-stranded DNA binding RNA binding
RPS3 ENCSR642GBC CRISPRi ENCSR772DUM RNA polymerase II regulatory region sequence-specific DNA binding RNA binding
RTF1 ENCSR783YSQ shRNA ENCSR815CVQ single-stranded DNA binding RNA binding
SFPQ ENCSR535YPK shRNA ENCSR164MUK DNA binding RNA binding
SUB1 ENCSR047AJA shRNA ENCSR815CVQ single-stranded DNA binding RNA binding
SUPV3L1 ENCSR778SIU shRNA ENCSR661HEL DNA binding RNA binding
TARDBP ENCSR731XIE CRISPRi ENCSR095PIC double-stranded DNA binding RNA binding
TRIM28 ENCSR591QYK CRISPRi ENCSR095PIC DNA binding RNA binding
UBTF ENCSR608ORR CRISPRi ENCSR016WFQ RNA polymerase I CORE element sequence-specific DNA binding RNA binding
UPF1 ENCSR251ABP shRNA ENCSR174OYC telomeric DNA binding RNA binding
XRCC5 ENCSR715XZS shRNA ENCSR815CVQ double-stranded telomeric DNA binding RNA binding
XRCC6 ENCSR232CPD shRNA ENCSR815CVQ double-stranded telomeric DNA binding RNA binding




Figure 3.6 Single-cell RNA-sequencing approach and sample QC. (A) Experimental approach 
to this scRNA-seq study. Specifically, neocortex and hippocampus were derived from separate 
litters of P0 mice, including a male and female of each genotype. Tissue was subsequently 
dissociated into single cells, then subjected to sequencing using the 10X Chromium platform (see 
Methods). (B-C) Cell-level QC metrics of neocortical (B) and hippocampal (C) cells, including 
the number of unique genes (nFeature_RNA), number reads detected in each cell (nCount_RNA) 
and percent reads mapping to the mitochondrial genome (percent_mito). Black dotted line= cut-
offs for filtering out cells. HET_F= heterozygous female, HET_M= heterozygous male, WT_F= 























Figure 3.7. Identification of cell type-specific populations within the neocortex and hippocampus. (A) 
The level of variation (standard deviation) in gene expression across all cells attributed to the first 30 
principal components (PC). (B) Heatmap of canonical cell markers utilized for cell type annotation and 
their corresponding expression in each cell type of neocortex (left) and hippocampus (right). (C) UMAP 
plot displaying results of unsupervised clustering and cell type annotation (D) UMAP plot for each genotype 
separately (left= HET, right=WT) demonstrating that clustering is not driven by genotype. (E) Total number 
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Figure 3.8 Ubiquitous Hnrnpu gene expression across neocortical and hippocampal cell 
types. Violin plot of the log-normalized UMI counts (log10(UMI + 10000)) of Hnrnpu across all 
13 cell types in both cortex (top) and hippocampus (bottom). Horizontal black line= mean log-












Figure 3.9 Differential gene expression analysis across neocortical and hippocampal cell 
populations. (A) Volcano plots showing log2FC of tested genes and their corresponding -log10 
FDR q-value. Colored text boxes= significant genes among certain cell types. (B) Gene ontology 
(“biological function” terms) of downregulated genes among all cell types of the neocortex (left) 













Figure 3.10 Transcriptional dysregulation across cell types of the neocortex and 
hippocampus. (A) The total number of differentially-expressed genes (DEGs) resulting from 
DGE analysis performed using a down-sampled data set consisting of 300 cells from each cell type 
(B) Level of enrichment of known disease genes indicated by -log10(FDR) from BH-corrected 
Fishers exact test, performed across neocortical and hippocampal cell types. (C) Spearman 
correlations of gene length and log2FC across each cell type. Red dotted line= significant 










Figure 3.11 Mef2c is highly expressed in the subiculum of the hippocampus and is an RNA 
binding target of hnRNP U. (A) uMAP plots showing all annotated cell types (left) and 
corresponding expression pattern of Mef2c in the neocortex (top) and hippocampus (bottom). (B) 
Histogram of the number of hnRNP U binding sites across transcripts based on available cardiac 































































 The efforts to model hnRNP U-related neurodevelopmental syndrome have thus far 
revealed multiple in vivo phenotypes in mice, some of which overlap in presentation with human 
patients (i.e. impaired growth, seizure susceptibility). In attempt to elucidate mechanisms 
underlying these phenotypes and lay the groundwork for targeted therapies, I hypothesized that 
heterozygous loss of Hnrnpu leads to dysregulation of targets important for neuronal function and 
homeostasis. In collaboration with others, we performed the first, to our knowledge, 
comprehensive transcriptomic study—including bulk RNA-seq, TimeLapse-seq and scRNA-
seq—assessing gene expression consequences in the Hnrnpu mutant brain. Overall, these studies 
revealed global transcriptional dysregulation in a manner highly linked to gene length, and further 
identified pyramidal neurons of the subiculum as particularly vulnerable to the heterozygous 
Hnrnpu mutation.  
Such abnormal hnRNP U phenotypes could be caused from either a few “large-effect” 
dysregulated genes, a conglomerate of “small-effect” dysregulated genes that converge on 
important neuronal processes, or from a complex interplay of both large- and small-effect genes. 
For instance, depending on the gene expression regulator, the bulk of a disease phenotype may be 
accounted for by a single or a few dysregulated targets, such as observed with the RNA-binding 
protein Pumilio1 (Pum1) in association with spinocerebellar ataxia type 1 (SCA1).  Pum1 directly 
binds to and regulates the stability of Ataxin (Atxn1) mRNA. Expansion of the polyQ tract of 
Atxn1, which has been identified in patients with SCA1, has been proposed to increase the stability 
and overall abundance of Atxn1 protein throughout the cell, ultimately triggering toxicity and 
eventual degeneration of cerebellar neurons. Haploinsufficiency of Pum1 resulted in a near 50% 
increase in WT Atxn1 levels and SCA1-like neurodegenerative phenotypes in mice (Gennarino et 
al. 2018). Alternatively, disease phenotypes may be caused from the cumulative effects of 
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numerous dysregulated targets that converge on important neuronal pathways. The Rett syndrome 
gene Mecp2, for example, is a transcriptional repressor that reportedly targets methylated sites 
within long genes. Loss of Mecp2, such as in the case of Rett syndrome, results in the upregulation 
of long, target genes, whereas overexpression of Mecp2 causes the downregulation of such targets 
(Gabel et al. 2015). Furthermore, partial rescue of cellular abnormalities of a Rett syndrome model 
was observed following the pharmacologic reduction in long-gene expression, further highlighting 
the impact of numerous gene expression perturbations on disease-relevant phenotypes. 
For hnRNP U, these data revealed transcriptome-wide dysregulation that was largely 
correlated to gene length, yet was only modest in effect size. Given the partial 20-30% decrease in 
Hnrnpu gene expression observed in the heterozygous loss-of-function mutants (see Chapter 2 for 
further discussion), subtle fold changes in gene expression of downstream targets was not 
unexpected. However, it is unknown whether these transcriptomic effects recapitulate the human 
condition as studies evaluating the specific dysregulated targets and the magnitude of their fold 
change have yet to be studied in the brain of patients with pathogenic HNRNPU mutations. 
Nevertheless, modest changes in gene expression have been reported in postmortem brain samples 
obtained from patients with autism (Velmeshev et al. 2019). Dysregulated genes converged on 
pathways important for upper layer cortical and microglial function. These findings support the 
notion that subtle transcriptional changes converging on important neuronal processes can be 
associated with neurodevelopmental disease in humans. Fold changes of similar magnitude have 
also been reported in mouse models of other gene expression regulators, such as Chd8, in 
association with abnormal neurodevelopmental phenotypes (Gompers et al. 2017). Upon 
heterozygous loss of Chd8, the majority of the widespread gene expression changes were less than 
1.5-fold, yet involved genes important for neuronal processes implicated in neurodevelopmental 
disease including neurogenesis, neuroimmune pathways and synaptic function.  
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For Hnrnpu+/113DEL mice, certain cell types demonstrate a length-dependent change in gene 
expression. These downregulated genes were also enriched for known neurodevelopmental disease 
genes, and converged on pathways essential for neuronal function. Considering neurons express 
some of the longest genes in the genome (i.e. cell adhesion molecules, ion channel proteins, 
synaptic proteins, etc.), they are particularly vulnerable to dysfunctional transcription—
specifically in fulfilling the increased demands of transcription across lengthy gene bodies. This 
was highlighted in recent work that evaluated transcriptional elongation defects on neuronal 
differentiation and mouse neural development. Specifically, mutations resulting in a slow RNA 
Polymerase II (Pol II)  were found to impair neural differentiation from embryonic stem cells 
(ESCs), and led to reduced expression and aberrant alternative splicing of long neuronal genes 
involved in synapse signaling (Maslon et al. 2019). Additionally, loss of the DRBP SFPQ 
reportedly resulted in the downregulation of essential neuronal genes that were >100kb in length, 
ultimately leading to neuronal apoptosis (Takeuchi et al. 2018). SFPQ was found to sustain 
transcription of long genes through activation of Pol II CTD during elongation. Furthermore, 
knockdown of and inhibitors targeting topoisomerases—a group of genes that have been 
associated with autism spectrum disorders—resulted in the reduced expression of long genes in 
mouse and human neurons due to impaired transcriptional elongation (I. F. King et al. 2013).  
As discussed extensively in the Introduction, hnRNP U plays a major role in multiple levels 
of gene expression regulation, including transcription initiation, elongation and alternative 
splicing. Based on findings from bulk RNA-sequencing, the gene expression changes observed in 
Hnrnpu mutants are unlikely to be related to hnRNP U’s role in alternative splicing. First, there 
was lack of enrichment of hnRNP U RNA binding targets amongst the significant DEGs, whereas 
enrichment was observed for genes with significant exon-level events, as expected. Second, genes 
with alternative exon events showed limited overlap with those found to be differentially-
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expressed, suggesting that such cassette exon events are unlikely to be responsible for the observed 
DEGs. Of note, however, this analysis cannot rule out other alternative splicing events, such as 
intron retentions or cryptic exons, that could impact gene expression.  
Regardless, these findings, in concert with the current literature implicating transcription 
deficits in these “long-gene transcriptopathies”, suggest that hnRNP U’s regulatory role in 
transcription is likely at fault. Prior work has demonstrated the importance of hnRNP U in 
positively regulating the transcription of numerous genes such as Klf2, Opn and Brnal1 (Gao et al. 
2005; Ahmad and Lingrel 2005; Onishi et al. 2008). HnRNP U has also been shown to associate 
with the Pol II holoenzyme alongside PCAF and nuclear actin, thus facilitating transcription 
elongation (Kukalev et al. 2005; Obrdlik et al. 2008). Moreover, hnRNP U associates with 
topoisomerase IIB (topo-IIB) in an RNA-dependent manner, which facilitates topo-IIB’s 
processivity of unwinding supercoiled DNA during transcription (Miyaji et al. 2015; Kawano et 
al. 2010).  Overall, the vulnerability of long genes to transcriptional deficits and hnRNP U’s role 
in transcription, may explain, at least in part, how a highly-abundant, ubiquitously-expressed gene 
like Hnrnpu results in a severe neurodevelopmental disease upon heterozygous loss-of-function 
mutations. Of note, length-dependent effects on gene expression were not observed for all cell 
types investigated (see Figure 3.10C), even those with significant depletion of Hnrnpu (such as 
inhibitory progenitors in the neocortex). One potential explanation is that an epistatic mechanism 
involving hnRNP U and likely other transcriptional regulators (such as those that associate with 
hnRNP U and facilitate elongation) results in context-dependent changes in transcription. Follow-
up experiments assessing hnRNP U’s effects on transcription initiation and elongation of these 
long neuronal genes, and how this is influenced by other transcriptional regulators, are warranted. 
Additional informatic analyses, such as evaluating hnRNP U whole genome CHIP-sequencing and 
corresponding RNA-seq data, could be useful in determining whether hnRNP U’s DNA-binding 
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role correlates to associated gene expression changes. Also, employing experiments that can assess 
transcriptional changes over time under conditions of synchronized RNA Pol II, such as MTS 
chemistry studies, can help elucidate whether elongation defects exist in Hnrnpu mutants (Duffy 
et al. 2018).   
This mechanism of aberrant transcription of long, neuronal genes may also be broadened 
to other DRBPs as depletion of other brain-expressed DRBPs showed significant length-
expression correlations (see Figure 3.5). As expected, depletion of SFPQ showed a negative 
correlation, consistent with its reported role in maintaining transcription through activation of Pol 
II (Takeuchi et al. 2018); whereas depletion of TARDBP, a known transcriptional repressor, 
showed a significant positive correlation (I.-F. Wang, Reddy, and Shen 2002; Lalmansingh, 
Urekar, and Reddi 2011). Other genes, such as UBTF, DDX3X, HNRNPK and HNRNPA1, are 
known to play a role in transcription and have been implicated in abnormal neurological 
phenotypes (Sanij et al. 2015; Edvardson et al. 2017; Sharma and Jankowsky 2014; Snijders Blok 
et al. 2015; Michetti, Ricceri, and Scattoni 2012; Proepper et al. 2011; Folci et al. 2014; Lemieux 
et al. 2015; Bekenstein and Soreq 2013). Additional studies examining the relationship between 
gene length and transcriptomic dysregulation, and the role each gene plays in transcription of these 
long genes may prove fruitful for gaining insight into underlying disease processes. Furthermore, 
other significantly-correlated genes, such as HNRNPL, HNRNPD, BCLAF1, CCAR1, etc., may be 
considered for further evaluation of a possible role in neurological disease.  
We next asked whether certain cell populations amongst the two primary brain regions 
implicated in epilepsy showed greater vulnerability to loss of Hnrnpu. Using single-cell RNA-
sequencing technology, a population of pyramidal neurons derived from the subiculum were found 
to contain excess gene expression dysregulation. Specifically, when performing DGE analyses on 
all cell types using equal cell numbers (i.e. the down-sampled dataset), the subiculum had a greater 
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number of dysregulated genes compared to other cell types. Furthermore, the subiculum showed 
greater enrichment for known disease genes (autism, epilepsy and developmental delay) and a 
strong negative gene length: gene expression correlation compared to other hippocampal and 
neocortical cell populations. However, it must be noted that these hippocampal and neocortical 
studies were derived from separate animals, and thus it is possible the apparent severity of gene 
expression in the subiculum is caused from variable expressivity of the mutation. Nevertheless, it 
is reassuring that this effect in the subiculum was observed in replicate animals of different sexes. 
Moreover, the average reduction in Hnrnpu gene expression was similar between cells of the 
cortex (0.87 fold) and hippocampus (0.91 fold), therefore arguing against litter-specific effects.   
The subiculum, or the subicular complex, functions as the primary output of the 
hippocampus, largely receiving input from CA1 of the hippocampus proper and sending output to 
the entorhinal cortex (EC) (S. M. O’Mara et al. 2001), and is important for hippocampal-related 
functions, such as learning and memory (Aggleton and Christiansen 2015; Roy et al. 2017). 
Considering it serves as a major hub of information exiting the hippocampus, it is unsurprising 
that it plays a major role in the seizure generation of temporal lobe epilepsies, and has been 
considered the “choke point” for the dissemination of synchronous activity during secondary 
generalization of temporal lobe seizures (Yi Wang et al. 2017). Furthermore, seizures and interictal 
events (abnormal activity occuring between seizures) have been shown to originate in the 
subiculum of brain slices derived from patients with temporal lobe epilepsy (X.-X. Wang et al. 
2017; Cohen et al. 2002). Interestingly, while the origin of seizure onset was not reported for most 
patients with HNRNPU mutations, two patients reportedly had temporal lobe epilepsy, one of 
which consequently evolved in West syndrome, followed by treatment-resistance Lennox-Gastaut-
like epilepsy (Bramswig et al. 2017; Leduc et al. 2017).  
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 While the majority of genes found to be dysregulated in the subiculum were also of low-
effect, as observed with other cell types and the bulk RNA-sequencing data, one gene in particular, 
Mef2c, showed a striking level of dysregulation, with >50% loss of expression. The basis for this 
greater level of dysregulated expression remains unclear. However, based on findings from 
available hnRNP U CLIP-seq data from cardiac tissue (performed and made available by Dr. 
Junqiang Ye of the Maniatis Laboratory), the encoded Mef2c transcript is also a strong RNA 
binding target of hnRNP U, suggesting a potential role for hnRNP U in Mef2c transcript 
processing. Mef2c is a transcription factor important for the development of numerous tissues 
including vascular tissue, bone and brain (Skerjanc and Wilton 2000; Yi Wang et al. 2017; Arnold 
et al. 2007), and is also necessary for cell maturation, including skeletal muscle and neurons 
(Potthoff et al. 2007; Lyons et al. 1995). Mef2c expression in the brain is highly dynamic 
throughout development, reflecting roles in both progenitor development (H. Li et al. 2008; Z. Li 
et al. 2008) and neuronal maturation (Lyons et al. 1995). In the adult mouse brain, Mef2c 
expression is largely localized to the cerebral cortex, hippocampus, thalamus, amygdala and 
cerebellum (Lyons et al. 1995), where expression appears restricted to neurons (Harrington et al. 
2016). Complete loss of Mef2c is embryonic lethal, while conditional loss in the brain revealed a 
role for Mef2c in neuron maturation and migration (H. Li et al. 2008), along with synapse 
maintenance (Barbosa et al. 2008). Specifically, brain-wide conditional loss was associated with 
excessive synapse assembly, and was accompanied with deficits in hippocampal-dependent 
learning and memory (Barbosa et al. 2008). Alternatively, conditional deletion of Mef2c in mouse 
excitatory cortical neurons resulted in increased inhibitory and reduced excitatory 
neurotransmission, and overall suppression of network activity (Harrington et al. 2016). Excitatory 
neurons had a greater number of inhibitory synapses and reduced density of dendritic spines. These 
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mice also displayed abnormal neurodevelopmental phenotypes including cognitive impairments 
and autistic-like features.  
 Microdeletions encompassing human MEF2C at 5q14.3, along with mutations residing in 
MEF2C, have been reported in patients with a severe neurodevelopmental disorder—MEF2C-
haploinsufficiency syndrome (MHS)—with clinical overlap to that of patients with HNRNPU 
mutations (Paciorkowski et al. 2013; Rocha et al. 2016). These individuals have been reported to 
have severe intellectual disability, severe motor impairment (unable to walk), absent speech, 
hypotonia, epilepsy, autistic-like features, minor brain malformations and dysmorphic facial 
features (Paciorkowski et al. 2013; Rocha et al. 2016). The types of seizures reported include tonic-
clonic, complex partial, atonic and myoclonic (Rocha et al. 2016). Contrary to findings in the 
conditional excitatory neuron Mef2c knockout, a mouse model of MEF2C-haploinsufficiency 
revealed altered synaptic function, with overall reduced inhibitory and increased excitatory 
neurotransmission (Tu et al. 2017). Furthermore, long-term potentiation was suppressed, and the 
mice demonstrated poor spatial learning and memory along with abnormal stereotypic behaviors. 
These findings were ameliorated upon chronic treatment with the NMDA-receptor antagonist 
Nitrosynapsin (Takahashi et al. 2015; Tu et al. 2017). The authors propose that Nitrosynapsin, 
through blocking extrasynaptic NMDA receptors, acts to restore the excitatory: inhibitory 
imbalance by increasing excitatory signaling onto compromised inhibitory neurons, thereby 
bolstering inhibitory activity (Tu et al. 2017). Further studies evaluating the efficacy of 
Nitrosynapsin in treating Hnrnpu-related neurological phenotypes could prove fruitful.    
Overall, obtaining a single cell perspective of gene expression changes upon heterozygous 
loss of Hnrnpu has highlighted pyramidal cells of the subiculum as particularly susceptible to gene 
expression dysregulation. In addition to numerous low-effect gene expression changes, this cell 
population demonstrated greater than 50% loss of Mef2c expression, which is known to cause a 
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severe neurodevelopmental disease when haploinsufficient. While these findings represent a single 
developmental time point (postnatal day 0) which may not be consistent at earlier or later 
developmental stages, the fact that a single major dysregulated neurodevelopmental gene was 
accompanied by numerous, minor perturbations of other important neuronal genes, implies a more 
complex role for hnRNP U in gene expression regulation. This is supported by existing literature, 
which has unveiled regulatory roles for hnRNP U at multiple levels of gene expression. This 
complexity is likely further amplified by epistatic interactions with other transcriptional regulators, 
which is supported by the findings that despite significant Hnrnpu depletion in certain cell types, 
trends in gene expression changes, such as the gene length-dependent effects, are not always 
present. Nevertheless, additional studies assessing the role of the subiculum, and Mef2c in 
particular, in hnRNP U-related phenotypes is warranted. Single cell transcriptomics of a later 
developmental time point will also be useful in assessing the temporal nature of these cell type 
specific gene expression changes, and can determine whether the subiculum and Mef2c remain 




Neocortex was dissected from four Hnrnpu+/113DEL and five wildtype littermate P0 pups 
obtained from three separate litters. Tissue was preserved in RNAlater (ThermoFisher) RNA 
stabilization solution per manufacturers protocol and kept at -80C. At time of RNA extraction, 
tissue was mechanically homogenized in RLT buffer (Qiagen) and passed through a QIAshredder 
(Qiagen) spin column. RNA was subsequently extracted using the RNeasy mini kit (Qiagen) per 
manufacturers protocol. Sample concentration and integrity was evaluated using a bioanalyzer. 
RIN scores were all greater than 8. RNA-sequencing libraries were prepared in the Institute for 
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Genomic Medicine’s High Throughput Sequencing Core Facility using RiboZero rRNA depletion 
kit and Kapa Stranded RNA-sequencing kit, and paired-end sequencing was performed on an 
Illumina high throughput sequencer, aiming for a depth of roughly 60 million paired-end reads per 
sample.  
Merged FASTQs were aligned using STAR two-pass mode for improved novel splice 
junction detection (Dobin et al. 2013). Annotation sources included mouse build 38 primary 
assembly and Ensembl v.87. Transcript-level quantification was performed using eXpress 
(Roberts and Pachter 2013) and subsequent gene-level quantification was performed using a 
custom script that sums the relevant values from eXpress across all transcripts in a gene to produce 
gene-level values for downstream differential expression testing. RNA-SeQC (DeLuca et al. 2012) 
was used to evaluate sample QC metrics. All samples had >0.81 mapping rate, >0.96 intragenic 
rate (<0.04 intergenic rate), >0.70 unique rate of mapped and estimated library sizes >40 million.  
Library normalization and differential gene expression analysis was performed using the R 
package DESeq2. In summary, raw reads counts (Eff_counts) from gene-level quantification were 
used to generate a raw read count sample matrix. Library size and gene dispersion estimates were 
generated using DESeq2 and the resulting dataset was used in the following binomial likelihood 
ratio test: 
H0:  expr ~ gender + litter + sequencing lane + genotype 
H1:  expr ~ gender + litter + sequencing lane 
A 10% false-discovery rate (FDR) was assumed using the Benjamini Hochberg (BH) correction 
for multiple comparisons. 
Differential exon usage analysis was performed using DEXseq (Anders, Reyes, and Huber 
2012; Reyes et al. 2013). Briefly, a gtf containing exon boundaries based on mouse GRCm38.87 
was used to create collapsed exon counting bins (intervals corresponding to a single exon or part 
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of an exon). Paired-end, strand-preserved reads overlapping these boundaries were subsequently 
quantified, normalized and gene dispersions were estimated using DEXseq. The following 
likelihood ratio test was used to evaluate differential exon usage:  
H0: ~sample + exon + gender:exon + litter:exon + lane:exon + condition:exon 
H1: ~sample + exon + gender:exon + litter:exon + lane:exon 
An FDR of 10% was assumed using the BH adjustment.  
 HnRNP U binding enrichment analyses were performed using CLIP-sequencing (CLIP-
seq) data performed on wildtype mouse cardiac tissue by Junqiang Ye in the Laboratory of Dr. 
Tom Maniatis, that was made available through collaboration. Specifically, data containing 
chromosome location, binding coordinates, # of CLIP tags, strand, gene name, gene domain and 
gene type was provided. All intergenic regions were filtered out. HnRNP U clip tags that 
overlapped with greater than one transcript boundary were assigned separately to both transcripts. 
A single hnRNP U CLIP tag mapped to a distinct location was considered as sufficient evidence 
for an hnRNP U binding site. The total # of binding sites were tallied for each target transcript and 
used for downstream analyses. For binding enrichment analyses, all downregulated, upregulated 
and non-significant DEGs were annotated based on whether they contained at least one hnRNP U 
binding site and a Fishers exact test was performed to determine degree of enrichment (odds ratio 
and p-values reported). The same analysis was also performed for genes with significant exon 
usage events compared to those with non-significant events.    
For disease gene enrichment analyses, human homologs for all tested mouse genes were 
obtained using biomaRt (Durinck et al. 2009). Significant and nonsignificant mouse genes were 
annotated based on the respective human homolog disease gene status. Genes without human 
homologs were not used in the analysis. The epilepsy-associated gene list was based on a prior 
publication (Simkin and Kiskinis 2018). Autism genes were based on SFARI genes with gene 
121 
 
scores 1, 2, 3 and S (Abrahams et al. 2013). Confirmed monoallelic developmental delay genes 
(obtained in 2019) were obtained from the Deciphering Developmental Disorders study (The 
Deciphering Developmental Disorders Study et al. 2015) and haploinsufficient genes were 
comprised of ClinGen’s genes with “sufficient evidence for haploinsufficiency” (Rehm et al. 
2015). A Fishers exact test was performed on significant downregulated and upregulated DEGs 
compared to all non-significant DEGs. This was also performed for genes with demonstrated 
differential exon usage events compared to genes with non-significant events. The significance 
threshold was set at p<0.05.  
 Gene ontology analysis was performed using the Gene Ontology Resource (Ashburner et 
al. 2000; The Gene Ontology Consortium 2019). Downregulated and upregulated DEGs were 
separately evaluated against all expressed genes from the DESeq2 output for enrichment of 
biological process terms using Fishers exact test. Results were sorted hierarchically such that the 
most specific subclasses of terms for each related group of terms were reported. Significant 
subclasses (FDR <0.05) were subsequently arranged in order of their respective -log(FDR) and 
plotted. This was also performed for genes with differential exon usage events.  
 The relationships between hnRNP U binding, gene length and expression dysregulation 
were evaluated using the cardiac CLIP-seq data described above and results from the current RNA-
sequencing study. Gene lengths were annotated using Ensembl BiomaRt Browser (Ensembl Genes 
97, mouse genes GRCm38.p6) (Durinck et al. 2005). Spearman’s correlation was used to evaluate 
the relationship between # of hnRNP U binding sites, gene length and gene dysregulation. To 
better visualize these relationships, genes were also ranked by their log2FC, and the mean # of 
binding sites and mean gene length was calculated in bins of 100 genes and plotted. Furthermore, 




For TimeLapse Seq, neocortex of HET and WT P0 pups was dissected and dissociated as 
previously described (see Chapter 1 Methods: Primary Neuronal Culture). Cells were resuspended 
in lowBind epi tubes and spun down at 500g for 5 min at RT. Cells were subjected to 500uM 4-
Thiouridine (4-sU, Fisher Scientific) diluted in pre-warmed complete neurobasal media for 3 
hours, rotating at 37C. A -4sU control was also obtained in parallel. The cells were subsequently 
pelleted at 4C for 5 min at 500g, washed in 1mL cold 1xPBS, pelleted again at 4C for 5 min at 
500g, then flash-frozen in 1mL Qiazol (Qiagen) for future RNA extraction. RNA preparation, read 
alignment and mutation counting for TimeLapse-Seq was performed as previously described 
(Schofield et al. 2018). Fraction new was determined for each gene with a minimum of 125 reads 
per sample (n = 8843) by fitting the observed mutation distribution to a binomial model. Inferred 
new reads were determined by multiplying total read counts by the estimated fraction new. 
Log2FC and associated p-values were determined using DESeq2 on total read counts and on 
inferred new reads for all genes with a fraction new estimate. Significance values between <50 kb 
and >50 kb fold change was determined using a t-test.  
 
DRBP gene length and gene expression correlation analysis 
The terms “DNA binding” and “RNA binding” were used to generate a list of overlapping 
human genes using the GO database (Ashburner et al. 2000; The Gene Ontology Consortium 
2019). This list was filtered to include only genes with experimental evidence of RNA and DNA 
binding function (109 genes total), and was further refined to genes with widespread expression in 
the brain based on publicly-available GTEx data. Widespread expression was considered if all 
brain regions (amygdala, anterior cingulate cortex, caudate, cerebellar hemisphere, cerebellum, 
cortex, frontal cortex, hippocampus, hypothalamus, nucleus accumbens, putamen, spinal cord and 
substantia nigra) had a TPM greater than 10. The resulting list was comprised of 30 DRBPs total. 
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Raw gene expression data of gene knockdown studies from each DRBP was subsequently obtained 
from ENCODE. Specifically, available paired-end fastq’s were downloaded for each DRBP gene 
knockdown and corresponding control sample(s). Reads were aligned using STAR (two pass 
mode) (Dobin et al. 2013) and transcripts were quantified using RSEM (Li and Dewey 2011). 
Output from RSEM was used to perform differential gene expression analysis using DESeq2 
(Love, Huber, and Anders 2014). For each DRBP evaluated, a spearman’s r and p-value were 
calculated assessing the correlation between log2FC and corresponding length of all genes tested. 
Gene length was obtained from biomaRt human GRCh38.p12. Spearman’s r and 95% CI were 
plotted for all 30 DRBPs. Bonferroni correction was performed given multiple tests, with a 
significance threshold set at 0.0017. 
  
Single-cell RNA-sequencing  
Neocortical and hippocampal tissue was dissected from postnatal day 0 pups and subjected 
to a papain dissociation, as described in Chapter 1 Methods- Primary neuronal culture, with the 
following modification: following papain dissociation and tissue trituration, all neocortical and 
hippocampal samples were filtered through a 40um cell strainer to enrich for single cells in the 
resulting suspension. Cell viability was subsequently assessed, with a cutoff of 70% or greater to 
be used for sequencing. Single cell RNA-seq libraries were constructed using the 10X Chromium 
Single Cell 3′ Reagent Kits v2 according to manufacturer descriptions, and samples were 
sequenced on a NovaSeq 6000. Reads were aligned to the mm10 genome using the 10X 
CellRanger pipeline with default parameters to generate the feature-barcode matrix.   
Seurat v3 was used to perform downstream QC and analyses on the resulting feature-
barcode matrices. For both the hippocampal and cortical dataset, all genes that were not detected 
in at least 4 cells and cells with less than 200 genes detected were removed. For the cortical 
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samples, all cells with fewer than 1,200 genes or more than 4,000 genes expressed per cell were 
removed. We also excluded all cells with greater than 8% of reads mapping to mitochondrial genes. 
In the hippocampal dataset, all cells with fewer than 1,000 genes and more than 5,000 genes were 
removed. We further excluded all cells with greater than 15% of reads mapping to mitochondrial 
genes. After filtering, the following numbers of cells per sample remained: 
 
 Cortex Hippocampus 
Wildtype female 4,279 4,848 
Wildtype male 3,502 4,211 
Hnrnpu+/113DEL female 4,113 6,000 
Hnrnpu+/113DEL male 5,138 5,468 
 
 The filtered matrices were log-normalized and scaled to 10,000 transcripts per cell. We 
used the variance-stabilizing transformation implemented in the FindVariableFeatures function in 
order to identify the top 2,000 most variable genes per sample. To harmonize gene expression 
across datasets prior to clustering, we used Seurat’s data integration method. We first identified 
anchors between samples in each dataset using the FindIntegrationAnchors function, which uses 
canonical correlation analysis (CCA) to identify pairwise cell correspondences between samples. 
We then computed an integrated expression matrix using these anchors as input to the 
IntegrateData function.  
 Next, we used linear regression to regress out the number of UMIs per cell and percentage 
of mitochondrial reads using the ScaleData function on the integrated expression matrices. We 
then performed dimensionality reduction using PCA. We visualized the standard deviation for the 
top 50 principal components. For both datasets, we selected the top 30 dimensions to compute a 
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cellular distance matrix, which was used to generate a K-nearest neighbor graph. The KNN was 
used as input to the Louvain Clustering algorithm implemented in the FindClusters function. For 
the cortical cells, we chose a clustering resolution parameter of 1.2; for the hippocampal dataset, 
we chose a resolution parameter of 0.8. We visualized the cells using UMAP, via the RunUMAP 
function. Finally, we visualized the expression of canonical marker genes in order to annotate and 
merge clusters.  
We performed cell type-specific differential gene expression analysis using MAST, as 
implemented in Seurat’s FindMarkers function. We excluded all non-coding genes, genes 
encoding ribosomal proteins, and pseudogenes from the analysis to reduce the multiple testing 
burden. For each cell type, we fit a linear mixed model that included sex and gene detection rate 
as latent variables (ngeneson; i.e the scaled number of genes detected per cell):  
zlm(~genotype + gender + ngeneson) 
P-values were corrected using the Benjamini Hochberg FDR method. We considered genes 
with a log2FC value of at least 0.14 (10% difference) and FDR < 0.05 as differentially expressed. 
We performed gene ontology analysis using Panther, using all tested genes as a background set. 
P-values were generated using Fisher’s Exact Test and corrected via FDR. We also used Fisher’s 
Exact Test to test whether there was an enrichment of known developmental delay, epilepsy, and 
autism genes amongst the differentially expressed genes in each cell type. Considering we are 
underpowered to detect enrichment of certain disease genes as they are not highly expressed in 
this dataset, we relaxed the FDR and log2FC cutoffs for this analysis to 0.1 and 0.074 (5% 
difference), respectively. Likewise, these p-values were corrected via FDR.  
In a separate analysis, we down-sampled the number of cells tested per cluster in order to 
identify whether there was a differential burden of gene dysregulation per cell type. For this 
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analysis, we performed MAST-based DGE as described above, but included only 300 cells from 

























Chapter 4: Functional Evaluation of Transcriptionally-Vulnerable 
Brain Regions 
4.1 Introduction 
The characterization of Hnrnpu+/113DEL mutant mice thus far has revealed impaired growth, 
increased perinatal mortality, greater seizure susceptibility, along with delayed pup development 
and abnormal adult behaviors. Furthermore, transcriptomic studies highlighted gene expression 
dysregulation across many cell types (mostly neuronal), yet the subiculum of the hippocampus 
showed a greater level of dysregulation from the heterozygous loss of Hnrnpu. The next major 
question was whether these regional differences in gene expression correlate with activity-level 
changes. Specifically, does the hippocampus, and the subiculum in particular, show evidence of 
hyperactivity? To answer this question, two different approaches were utilized: multielectrode 
array (MEA) recordings of neocortical versus hippocampal primary cultures and immediate early 
gene analysis (c-Fos) of electrically-stimulated and non-stimulated mice.  
MEAs are an electrophysiological tool that non-invasively detect extracellular action 
potentials and local field potentials from a population of neurons, either in vitro or in vivo. The 
array is composed of multiple embedded electrodes that capture changes in flow from all ionic 
processes occurring in the vicinity of the electrodes. MEAs have been utilized in neuroscience to 
study various neurological processes including neuronal network communication, along with 
information processing and encoding (Obien et al. 2015). MEAs have also been used to evaluate 
for potential neurotoxic effects of therapeutic compounds (McConnell et al. 2012; Bradley and 
Strock 2019; Shafer 2019). However, more recently, MEAs have been used to monitor the 
spontaneous activity profiles of genetic models of neurological disease, such as in Tuberous 
Sclerosis, Fragile X syndrome, Williams syndrome and ALS (Bateup et al. 2013; Z. Cao et al. 
2012; Chailangkarn et al. 2016; Wainger et al. 2014). This has been further extended to genetic 
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models of epilepsy, such as recently reported with GNB1- and GRIN2A-related encephalopathies. 
Both of these models demonstrated aberrant bursting activity suggestive of hyperexcitability in 
mutant networks (Colombo et al. 2019; Amador et al. 2019). Importantly, Colombo and colleagues 
further showed that the antiepileptic drug Ethosuximide suppressed both the abnormal bursting 
activity in vitro along with spike wave discharges (SWD) in vivo, highlighting the utility of MEA 
as a pre-clinical tool for genetic epilepsy models (Colombo et al. 2019).  
Here, MEA was employed on neocortical and hippocampal primary cells derived from 
heterozygous Hnrnpu mutant and WT mice, and subsequently characterized the networks through 
the evaluation of over 25 different activity features. Mutant hippocampal networks were 
hypothesized to show hyperactive phenotypes compared to neocortical networks, given the 
excessive dysregulated expression of important genes, such as Mef2c, in the subiculum. 
Importantly, any mutant phenotypes could then be evaluated for the degree of rescue upon 
treatment of the MEA cultures with Nitrosynapsin—the drug that rescued mutant phenotypes in a 
mouse model of Mef2c-related neurodevelopmental syndrome (Tu et al. 2017)—or other 
promising therapeutic compounds.  
To further assess for region-specific activity differences, the expression of the immediate 
early gene (IEG) c-Fos was evaluated. IEGs are rapidly activated after external stimuli, and are 
most often transcription factors that regulate expression of a wide array of targets (Herrera and 
Robertson 1996). C-Fos in particular is a proto-oncogene and transcription factor that is induced 
rapidly after cellular depolarization, and has thus been relied on extensively as an early marker of 
neuron activity (Herrera and Robertson 1996). C-Fos mRNA and protein expression patterns have 
been used to map, at a cellular level, the brain regions and networks activated during chemically 
and electrically-induced seizures (Woldbye et al. 1996; Labiner et al. 1993; Szyndler et al. 2009), 
along with spontaneous seizures of rodent epilepsy models (Peng and Houser 2005), including 
129 
 
those resulting from underlying genetic abnormalities. For example, in the Hyperthermia-Induced 
Seizure Susceptible (Hiss) rat model containing a missense mutation in Scn1a (modeling human 
Scn1a-related febrile seizures), c-Fos expression was reportedly elevated in the limbic and 
paralimbic regions following hyperthermic seizures, suggesting a primary role for these brain 
regions in Scn1a-related febrile seizure generation (Ohno et al. 2011). In two different 
heterozygous Stxbp1 mouse models, c-Fos activation was found to be greater in the prefrontal 
cortex, motor cortex and somatosensory cortex of mutant mice compared to seven other brain 
regions, implicating these brain regions in the observed spontaneous seizures (Kovačević et al. 
2018). C-Fos expression patterns have also been used to evaluate for evidence of hyperactivity in 
rodent models of genetic epilepsies. In the Kcnq2 mouse model of benign familial neonatal 
epilepsy, despite the lack of spontaneous seizures, c-Fos expression was found to be elevated in 
the dorsal hippocampus of homozygous mutant neonatal mice, supporting the likely hyperactivity 
of this brain region (Tomonoh et al. 2014).  
Despite the lack of spontaneous seizures in Hnrnpu+/113DEL mutants, we asked whether c-
Fos expression, and hence neuronal activity, was specifically altered in the subiculum of mutant 
mice, and hypothesized that the level of transcriptional dysregulation observed in the subiculum 
may correlate with an increase in spontaneous neuronal activity of this brain region, or may 
increase activity in response to an induced seizure. C-Fos immunoreactivity of the dorsal and 
ventral subiculum was thus evaluated along with other hippocampal and neocortical brain regions 
following an evoked convulsive seizure as well as in non-stimulated mice.    
 Of the following experiments, the MEA studies were performed by myself. The c-Fos study 
was a collaborative effort: the ECT and handling of mice was completed by Dr. Yueqing Peng and 
Dr. Wayne Frankel, the mouse perfusions, brain dissections, fixation, slicing and c-Fos 
immunostaining were performed by Dr. Fenghua Zhen in Dr. Peng’s group, the high resolution 
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imaging was completed by Gabriela Sampaio in the Goldstein Laboratory, and the quantification 
and results interpretation were performed by myself.  
 
4.2 Results 
Multielectrode array studies  
Neocortex and hippocampus were dissected from P0 mice from both mutants and WTs, 
subjected to enzymatic dissociation and plated at a high density on a 48-well MEA plate (Figure 
4.1). Mutant and WT primary neuronal cultures were typically arranged such that they were 
equally represented on the MEA plate (half mutant, half WT) and evenly distributed to avoid any 
plate-specific effects. Cultures were recorded every other day followed by a 50% media change. 
Given the inherent variability observed in this assay, multiple experimental groups were attained 
for neocortex and hippocampus, containing at least three replicate plates (biological replicates) 
with multiple replicate wells of each genotype (technical replicates).  
Numerous activity features were extracted from the data (Table 4.1) and assessed over 
multiple days in vitro. These features include various measures of spike, burst and network events. 
Spike and burst-level features provide information on the general firing of the network, whereas 
network-level events offer information on the general organization of this firing and synchrony. A 
spike is considered a putative action potential, and bursts are a series of spikes that occur in rapid 
succession. Network-level events include network spikes and network bursts. 
In order to reliably detect differences in genotype among the activity features evaluated, 
analyses were restricted to days that fell within a stable, synchronous period of firing. Specifically, 
for each experimental batch, the mean firing rate (MFR, the frequency of neuronal firing) was 
combined from all WT replicate wells across all plates. A Mann Whitney U test was then used to 
identify significant differences in MFR between consecutive days in vitro. Only “stable” periods—
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devoid of any significant fluctuations in MFR—were included for the formal analysis. The days 
in vitro that remained in the network development phase of the culture were filtered out. 
Specifically, the feature spike train tiling coefficient (STTC) was used to determine the 
developmental versus mature, synchronous phase of the networks. STTC measures the pairwise 
correlations of firing between pairs of electrodes, and has been used previously to examine network 
synchronization (Colombi et al. 2016; Z. W. Davis, Chapman, and Cheng 2015). A Mann Whitney 
U test was used to evaluate for a significant difference in STTC between each consecutive day in 
vitro of an experimental batch. The network was considered mature once there ceased to be any 
significant deviations in STTC over the course of culture development.  Only days in vitro falling 
in both a stable, synchronous period were included in downstream analyses. These days in vitro 
could therefore vary between experimental batches, depending on overall culture development 
among the replicate plates. Of note, at least three consecutive days in vitro were required to be 
included in the analysis for each experimental batch.  
Here, three experimental groups for hippocampus and two groups for neocortex are 
reported. Hippocampal networks from the first two experiments demonstrated a rapid increase in 
MFR that peaked around day in vitro 13-15, then subsequently declined and plateaued around day 
in vitro 17-19 (Figure 4.2A, C). The third experimental group, which contained the media 
supplement B27-Plus (reportedly improves neuron survival, activity and neurite outgrowth), 
demonstrated a slightly different MFR trajectory, with a rapid rise in firing that initially peaked at 
day in vitro 11 then plateaued (Figure 4.2E). For the first two experiments, network synchrony, as 
measured by STTC, appeared to stabilize by day in vitro 19 (Figure 4.2B, D). For the first 
experimental group, DIVs 19-29 were used in downstream analyses, given both a stable MFR and 
network synchrony during this period (Figure 4.2A-B). However, a slight increase in pairwise 
electrode correlation was observed between DIVs 23 and 25 of the second experiment; therefore, 
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day in vitro 25 through 29 were used for analysis (Figure 4.2C-D). For the third experiment, STTC 
overall plateaued around day in vitro 13; however, significant increases in STTC were observed 
between day in vitro 15 and 17 as well as 19 and 21. Thus, day in vitro 21 through 25 were used 
for further analysis (Figure 4.2E-F). Batch effects on firing rate were observed amongst the three 
experimental groups. Plates from the second experimental group showed clustering separate from 
plates of the first and third experiments (Figure 4.2G). While the developmental trajectory of the 
second batch was similar to the first, the firing rate was subjectively decreased. The MFR from the 
second experimental group plateaued around 1 Hz compared to 3-4 Hz for the first and third 
experiments.  
For the neocortex, the first experimental group showed a gradual increase in MFR over the 
course of the culture (Figure 4.3A). This increase was statistically significant across consecutive 
days in vitro until day 23. STTC increased until day 17, at which time it plateaued (Figure 4.3B). 
days in vitro 23-29 were therefore used in the final analyses. The second experimental group, 
which was plated at double the cell density (100,000 cells/well versus 50,000 cells/well) and also 
cultured in B27-Plus, exhibited a gradual increase in MFR that stabilized around day in vitro 17, 
and then drastically declined at day 23 (Figure 4.3C). While the reason for this decline is unclear, 
it may be secondary to a decline in the health of the culture as the number of active electrodes also 
decreased on day 23 (data not shown). These networks showed a high-degree of synchrony at the 
earlier days in vitro, with a statistically significant rise in STTC until day 17 (Figure 4.3D). Days 
in vitro 17-21 were therefore used for all downstream analyses. Batch effects were less evident for 
these two experimental groups, which showed overlap among plates when clustered based on MFR 
(Figure 4.3E).   
For the activity features analyzed (Table 4.1), wells from plates within each experimental 
group were first normalized to WT values for each day in vitro. These values were then combined 
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across all plates within the experimental group, then tested for significance using a permuted Mann 
Whitney U test. The first hippocampal experimental group, comprised of six total MEA plates, 
revealed a striking increase in MFR in mutant networks—a phenotype suggestive of spontaneous 
hyperactivity in mutants (MWU permuted p<0.001) (Figure 4.4A). This finding was supported by 
four of the six replicate plates (Table 4.2), and was accompanied by differences in other features 
including a decreased inter-spike interval (ISI) and an increase in number of bursts per minute, 
total spikes in bursts and network bursts (Table 4.2)—changes that were most likely driven by the 
elevated firing rate. However, the second hippocampal group, comprised of three replicate MEA 
plates, demonstrated the opposite finding of a reduced MFR (MWU permuted p=2E-03) (Figure 
4.4B). This was largely driven by a single plate with a statically significant decrease in firing 
(Table 4.2). Considering this batch of plates fired at an overall lower frequency compared to plates 
from the first experimental batch (Figure 4.2C compared to 4.2A), we hypothesized that the 
increased MFR phenotype observed in mutant networks relies on a greater level of overall network 
activity in order to detect. An additional experiment using B27-Plus media supplement 
(ThermoFisher Scientific) was therefore performed given its reported positive effect on neurite 
outgrowth, neuron viability and network activity. A total of four replicate plates were obtained as 
part of this group. Using B27-Plus supplement, the firing rate of WT wells across the four plates 
was restored to roughly 3-4 Hz—similar to that of the first experimental group (Figure 4.2E). 
Nevertheless, the combined analysis of these four plates revealed no significant difference in MFR 
between mutant and WT networks (Figure 4.4C) (Table 4.2). This was based on two plates with 
an increase MFR, one with a reduced MFR and one that showed no difference.  
The only feature that replicated across the combined analyses of the hippocampal 
experimental groups was an increase in the mean duration of network spikes (Figure 4.4A-C) 
(Table 4.2). While the significance of this finding is unknown, network spikes are synchronous 
134 
 
events, and as such, longer network spikes may negatively affect the transfer and the ultimate 
encoding of information across the network. The normal number of spikes and inter-spike intervals 
within mutant network spikes suggests an overall similar distribution of spikes contributing to 
these network events. However, longer network spikes imply a temporal shift in the information 
propagated throughout the network. Considering certain circuits rely on complex and precise 
temporal codes to transmit information, a longer duration of network spikes in vivo could 
presumably have a deleterious effect (Gerstner et al. 1997). Yet, whether longer network spikes 
represent a hyperexcitability phenotype remains unclear.    
For neocortex, combined analyses from the first experimental group failed to reveal 
significant differences between WT and mutant networks, including mean firing rate (Figure 4.5D) 
(Table 4.3). However, the exception was peak electrodes involved in network spikes—a measure 
of network synchrony—which was found to be significantly decreased (Figure 4.5D) (Table 4.3). 
A replicate experiment performed using a higher density of cells along with B27-Plus supplement, 
revealed numerous significant features, including an elevated firing rate, which was supported by 
all three replicate plates (Figure 4.5E). Furthermore, the average total spikes in bursts and network 
bursts were both consistently increased, and mean ISI was decreased, likely influenced primarily 
by the elevated MFR. Similar to the first experimental group, the peak electrodes contributing to 
a network spike was significantly decreased (Figure 4.5E). Beyond this, the percentage of spikes 
contributing to network spikes—a measure of network synchrony—was decreased across all 
plates. Findings from this second experimental group suggest that mutant cortical networks fire at 
a greater frequency, yet this increase in firing is not accompanied by a higher degree of synchrony.  
Overall, the MEA data presented here show a high degree of variability. For both 
hippocampus and neocortex, the increased MFR phenotype failed to replicate among the 
experimental groups, and even among individual plates within each group (Tables 4.2 & 4.3). This 
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was also the case for majority of other features evaluated. Even features that replicated across each 
experimental group did not always show significance for each replicate plate within the group. 
These data highlight the inconsistency and complexity of this assay (see Discussion).  
 
Immediate Early Gene Expression Studies 
In collaboration with Dr. Wayne Frankel and Dr. Yueqing Peng’s groups (CUIMC), adult 
Hnrnpu+/113DEL and WT mice were subjected to a high frequency electroshock aimed to induce a 
minimal clonic forebrain convulsive seizure. All animals were perfused 1 hour after the evoked 
seizure, and coronal brain slices were subsequently stained for c-Fos. A cohort of non-stimulated 
mice were also perfused 1 hour after handling and processed for c-Fos expression in parallel with 
the stimulated group (sham mice). Two mice of each genotype and each condition were analyzed. 
Brain regions containing the dorsal and ventral subiculum were evaluated and compared to c-Fos 
expression of the dentate gyrus, CA1 and neocortex.  
By visual inspection, no overt differences in c-Fos expression were observed across mutant 
and WT brains, or among stimulated and non-stimulated mice (Figure 4.6). Quantification of c-
Fos positive cells did, however, reveal modest differences in expression. Interestingly, non-
stimulated Hnrnpu+/113DEL mutant mice exhibited a significant decrease in the density of c-Fos 
positive cells within the ventral subiculum compared to WT non-stimulated mice, with an average 
of 124 cells/mm2 for WT and 76 cells/mm2 for mutant mice (MWU p= 4E-04) (Figure 4.7A). This 
difference was observed for both mice of each genotype (Figure 4.7B). Upon seizure induction, c-
Fos expression in the ventral subiculum did not change for WT animals, yet was modestly higher 
in mutants—an effect that appeared largely driven by a single mutant (MWU p=0.02) (Figure 4.7A 
& B). The dorsal subiculum showed a different trend. There was no difference in expression among 
non-stimulated mice; however, a significant decrease in c-Fos positive cells was observed in WT, 
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but not mutant, stimulated animals (Figure 4.7C). This reduction in c-Fos expression was observed 
in both WT mice examined (Figure 4.7D). In the other regions of the brain that were evaluated, 
the dentate gyrus failed to show any difference in c-Fos expression between WT and mutants or 
stimulated versus non-stimulated mice (Figure 4.7E & F). Alternatively, a subtle increase in c-Fos 
positive cells was observed in heterozygous mutants upon stimulation in the CA1 of the 
hippocampus (Figure 4.7G). This difference was primarily driven by a single mutant (Figure 
4.7H). Finally, while there were no genotype-specific differences observed in the neocortex, both 
WT and mutant mice showed a significant increase in c-Fos expression upon induction of a clonic 
convulsive seizure—an effect observed across all mice examined (p= 4.8E-03 and 8E-04 for WT 
































nAE number of active electrodes
MFR/nAE mean firing rate for only active electrodes
mean ISI avergae inter-spike interval per well
mutual information a metric that compares patterns between two electrodes
entropy a measure of the amount of disorder at an MEA electrode
STTC evaluates pairwise correlation between a pair of electrodes
Burst Features
nbursts/min average number of bursts per minute
mean burst ISI average inter-spike intervals within bursts
mean burst duration average burst duration in seconds
mean freq in bursts average spike frequency in bursts (spikes/burst duration)
mean IBIS average inter-burst intervals
mean spikes in bursts average number of spikes in bursts
total spikes in bursts total number of spikes in bursts
% spikes in bursts percentage of spikes participating in bursts
Network Spike Features
duration of NS average duration of network spikes
mean spikes in NS average number of spikes in network spikes
mean peak average number of electrodes contributing to network spikes
mean INSI average inter-spike interval within network spikes
% spikes in NS percentage of spikes participating in network spikes
Network Burst Features
mean NB time/sec average network burst length
mean spikes in NB average number of spikes in network bursts
mean spikes in NB/nAE spikes per active electrodes, averaged for all network bursts
mean spikes in NB/nAE/dur spikes per active electrodes per second, averaged for all network bursts
% spikes in NB percent of spikes in network bursts
spike intensity by active electrodes spike frequency for only active electrodes in network bursts
total spikes in all NB total spikes in network bursts
total spikes in all NB/nNB average spikes for all network bursts combined




Figure 4.1 Multielectrode array as a noninvasive approach to monitoring neuronal network 
activity. (A) Primary neuronal cultures derived from brain regions of interest from postnatal day 
0 pups of both genotypes were plated at a high density on a 48-well MEA plate. Each well 
contained dissociated cells from a single genotype (with each genotype equally represented 
amongst all 48 wells) seeded on top of 16 embedded electrodes. (B) Each electrode (horizontal 
lines) detects neuronal spiking activity (i.e. action potentials, represented by vertical lines), present 
as either a single spike or a series of rapid, consecutive spikes (burst). Spikes or bursts that occur 
simultaneously across multiple electrodes are considered network-level events. These data were 
captured over a 15-minute interval, recorded every other day over the duration of the culture. (C) 
Raw data captured throughout the experiment was processed using the meaRtools package in effort 
to provide summary results and statistics on numerous single-electrode (i.e. mean firing rate, burst 
rate, burst duration) and pan-electrode (such as percent spikes in bursts, percent of spikes in 
network spikes, mutual information) firing parameters as summarized in Table 4.1.  
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Figure 4.2 Summary of wildtype hippocampal network activity. Mean firing rate (MFR) and 
STTC of WT networks for experimental group 1 (A) and (B), experimental group 2 (C) and (D) 
and experimental group 3 (E) and (F), respectively. Red boxes indicate the days in vitro used in 
downstream analyses based on a stable MFR and peak network synchrony as determined by STTC. 
Mann Whitney U p-values shown <0.0001= ****, <0.001= ***, <0.01= **, <0.05= *. (G) First 2 
PC’s of the 3 separate hippocampal experimental groups clustered based on average WT MFR 
from days in vitro 7-25. Red= experimental group 1, green= experimental group 2 and blue= 
experimental group 3.  













































































































Figure 4.3 Summary of wildtype neocortical network activity. Mean firing rate (MFR) and 
STTC of WT networks for experimental group 1 (A) and (B) and experimental group 2 (C) and 
(D), respectively. Red boxes indicate the days in vitro used in downstream analyses based on a 
stable MFR and peak network synchrony as determined by STTC. Mann Whitney U p-values 
shown; <0.0001= ****, <0.001= ***, <0.01= **, <0.05= *. (E) First 2 PC’s of the 2 separate 
neocortical experimental groups clustered based on average WT MFR from DIVs 7-23. Red= 
experimental group 1, blue= experimental group 2. 
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WT 12 11 18 12 12 22 87 24 24 24 72 24 24 12 12 72
Het 12 13 12 12 12 24 85 24 24 24 72 24 24 12 12 72
perm_pval <0.001 0.42 0.173 0.48 <0.001 0.012 0.1 0.478 0.105 0.036 0.501 <0.001 0.205 0.027 0.72 0.282
MW.pval 2.39E-09 0.0767 4.14E-03 0.256 0.325 3.07E-07 1.09E-03 0.703 0.0148 8.32E-04 0.314 0.0128 0.561 1.02E-03 0.734 0.0877
direction decrease same same same decrease decrease same same same increase same decrease same increase same same
perm_pval <0.001 0.016 <0.001 0.06 2.00E-03 0.906 < 0.001 0.599 0.11 2.00E-03 0.002 0.002 0.1 0.004 <0.001 0.061
MW.pval 4.04E-23 6.99E-04 7.48E-25 3.00E-05 5.02E-07 0.79 7.47E-37 0.454 0.0505 3.32E-07 1.71E-05 4.35E-08 0.0351 6.92E-05 6.93E-15 4.17E-03
direction increase increase increase same increase same increase same same decrease decrease increase same decrease increase same
perm_pval <0.001 0.011 <0.001 0.05 1.00E-03 0.854 < 0.001 0.626 0.031 1.00E-03 0.005 <0.001 0.072 0.005 <0.001 0.016
MW.pval 3.88E-23 5.86E-04 1.50E-24 3.11E-05 5.02E-07 0.709 7.71E-39 0.471 5.52E-03 2.36E-07 2.71E-05 3.02E-08 0.0147 7.68E-05 1.70E-15 8.40E-04
direction decrease decrease decrease same decrease same decreased same increase increase increase decrease same increase decrease decrease
perm_pval <0.001 0.107 <0.001 2.00E-03 <0.001 0.984 0.033 0.371 7.00E-03 2.00E-03 0.544 0.206 0.839 0.077 <0.001 0.578
MW.pval 1.36E-15 3.67E-03 1.42E-29 1.47E-09 4.38E-16 0.979 2.30E-05 0.161 1.44E-04 8.32E-08 0.353 0.064 0.784 0.0177 2.12E-09 0.432
direction decrease same increase increase increase same increase same decrease increase same same same same increase same
perm_pval <0.001 0.053 <0.001 0.001 0.175 0.315 0.381 0.123 0.098 <0.001 0.033 0.207 0.039 0.016 <0.001 0.206
MW.pval 4.00E-25 1.17E-03 2.37E-19 5.88E-11 0.0674 0.0601 0.0713 0.0226 0.0372 1.19E-14 1.49E-03 0.0985 0.0354 5.60E-04 1.23E-08 0.0836
direction increase same decrease decrease same same same same same decrease decrease same increase decrease increase same
perm_pval <0.001 0.021 <0.001 <0.001 <0.001 0.434 0.067 0.535 0.061 <0.001 0.234 0.69 0.15 <0.001 <0.001 0.322
MW.pval 6.87E-05 3.06E-04 7.82E-30 7.41E-18 8.73E-16 0.174 1.81E-04 0.311 4.25E-03 2.63E-10 4.47E-02 0.498 0.141 9.20E-08 1.81E-06 0.16
direction decrease decrease increase increase increase same same same same increase same same same increase decrease same
perm_pval <0.001 0.057 <0.001 0.781 <0.001 0.712 < 0.001 0.043 0.511 0.164 0.049 4.00E-03 0.516 8.00E-03 6.00E-03 0.015
MW.pval 1.51E-09 2.07E-03 1.01E-27 0.588 4.59E-12 0.516 1.63E-18 3.58E-03 0.415 0.029 5.58E-03 2.10E-05 0.432 6.92E-05 7.90E-04 1.33E-03
direction increase same increase same increase same increase decrease same same decrease increase same decrease increase increase
perm_pval <0.001 0.367 <0.001 1.00E-03 <0.001 0.917 0.055 0.931 8.00E-03 0.029 0.003 <0.001 4.00E-03 0.015 0.029 < 0.001
MW.pval 3.09E-20 0.168 1.13E-29 3.00E-09 2.70E-13 0.859 3.31E-04 0.89 1.48E-04 2.75E-04 1.93E-06 1.67E-16 1.17E-03 7.64E-04 3.60E-03 6.81E-06
direction increase same decrease decrease decrease same same same decrease decrease decrease decrease increase decrease increase decrease
perm_pval <0.001 3.00E-03 <0.001 0.036 0.012 0.368 0.078 0.29 <0.001 0.055 0.004 <0.001 0.101 <0.001 <0.001 7.00E-03
MW.pval 3.93E-11 1.87E-05 3.81E-27 3.84E-05 6.14E-05 0.142 8.04E-04 0.134 3.32E-08 6.32E-03 4.77E-05 7.91E-11 0.0496 1.14E-06 1.21E-09 4.36E-04
direction increase decrease decrease increase decrease same same same decrease same decrease decrease same decrease increase decrease
perm_pval <0.001 0.778 <0.001 0.071 <0.001 0.227 0.028 0.458 2.00E-03 0.116 0.887 <0.001 0.355 <0.001 8.00E-03 < 0.001
MW.pval 2.17E-18 0.735 1.56E-27 2.54E-04 5.09E-09 0.0569 1.49E-05 0.21 8.37E-05 8.82E-03 0.808 1.32E-19 0.269 7.29E-11 2.20E-04 2.23E-08
direction decrease same increase same increase same increase same decrease same same increase same increase decrease increase
perm_pval <0.001 0.045 <0.001 0.731 <0.001 0.803 < 0.001 0.055 0.23 0.069 0.034 1.00E-03 0.864 5.00E-03 3.00E-03 0.023
MW.pval 4.57E-12 9.20E-04 7.65E-27 0.491 6.52E-12 0.649 2.86E-21 3.84E-03 0.122 4.47E-03 2.79E-03 2.27E-05 0.834 5.03E-05 3.13E-04 7.90E-03
direction decrease decrease decrease same decrease same decrease same same same increase decrease same increase decrease decrease
perm_pval <0.001 <0.001 <0.001 <0.001 0.259 0.321 0.828 5.00E-03 1.00E-03 0.025 0.494 0.057 <0.001 0.559 <0.001 0.822
MW.pval 5.81E-12 8.67E-17 7.67E-23 6.11E-19 0.0355 0.129 0.602 7.64E-06 3.85E-07 1.69E-04 0.248 7.21E-03 3.68E-10 0.373 1.09E-11 0.714
direction decrease decrease increase increase same same same increase decrease increase same same decrease same increase same
perm_pval 0.324 0.382 <0.001 8.00E-03 <0.001 0.418 < 0.001 0.717 0.013 0.399 0.209 0.001 0.121 0.373 <0.001 0.032
MW.pval 0.0652 0.199 1.63E-29 1.52E-08 6.33E-13 0.14 6.19E-14 0.583 2.78E-03 0.187 0.0705 4.31E-07 0.0358 0.191 2.98E-14 1.81E-03
direction same same increase increase increase same increase same decrease same same increase same same increase increase
perm_pval <0.001 <0.001 <0.001 1.00E-03 <0.001 0.22 0.711 0.546 <0.001 <0.001 0.714 <0.001 0.163 <0.001 0.097 0.502
MW.pval 1.19E-21 1.36E-07 9.55E-30 8.29E-14 4.39E-18 0.0213 0.458 0.355 1.45E-16 5.73E-11 5.58E-01 1.49E-13 0.0751 2.82E-08 0.0101 0.307
direction decrease decrease increase increase increase same same same decrease increase same decrease same increase same same
perm_pval <0.001 0.191 <0.001 <0.001 <0.001 0.937 0.01 0.151 <0.001 1.00E-03 < 0.001 <0.001 <0.001 0.1 <0.001 0.026
MW.pval 1.60E-16 0.0229 3.72E-29 6.45E-17 1.39E-14 0.915 3.35E-07 0.0496 1.62E-14 8.14E-08 1.69E-20 1.48E-09 2.25E-10 0.0206 1.98E-12 4.40E-04
direction decrease same increase increase increase same increase same increase increase increase increase decrease same increase increase
perm_pval <0.001 0.661 <0.001 8.00E-03 <0.001 0.113 8.00E-03 0.794 0.011 0.01 0.939 <0.001 <0.001 <0.001 0.013 < 0.001
MW.pval 4.17E-25 0.482 1.85E-24 2.52E-08 1.92E-16 3.79E-03 3.91E-08 0.721 2.11E-05 1.61E-05 0.886 1.55E-10 2.22E-05 2.78E-09 1.28E-03 1.49E-08
direction decrease same increase increase increase same increase same decrease increase same increase decrease increase increase increase
perm_pval <0.001 0.574 <0.001 0.019 <0.001 0.214 8.00E-03 0.47 0.068 2.00E-03 0.631 <0.001 <0.001 <0.001 0.952 0.015
MW.pval 1.71E-24 0.372 2.60E-27 1.43E-06 1.13E-16 0.0252 2.04E-07 0.266 3.51E-03 6.5E-07 0.419 4.90E-06 1.25E-05 1.24E-10 0.942 0.000433
direction decrease same increase increase increase same increase same same increase same increase decrease increase same increase
perm_pval <0.001 0.213 5.00E-03 0.206 0.342 0.618 0.028 0.053 0.079 0.01 0.004 0.01 <0.001 <0.001 0.412 0.084
MW.pval 9.56E-19 0.0654 2.78E-07 7.30E-03 0.109 0.308 4.84E-06 8.92E-03 9.35E-03 1.13E-04 1.83E-05 4.72E-04 1.97E-06 2.78E-09 0.219 0.0202
direction decrease same decrease same same same decrease same same increase increase increase decrease increase same same
perm_pval <0.001 0.446 <0.001 4.00E-03 0.292 0.503 0.886 0.039 <0.001 6.00E-03 0.269 2.00E-03 <0.001 0.793 <0.001 0.611
MW.pval 2.49E-17 0.287 2.44E-18 1.75E-09 0.0531 0.201 0.757 1.27E-03 3.72E-08 2.70E-05 0.0698 4.70E-06 2.32E-17 0.716 6.63E-16 0.437
direction decrease same increase decrease same same same decrease decrease increase same decrease increase same decrease same
perm_pval <0.001 0.05 0.527 3.00E-03 <0.001 0.832 < 0.001 0.368 1.00E-03 0.68 0.018 <0.001 0.025 0.843 0.042 0.08
MW.pval 1.07E-24 0.0237 0.313 6.23E-08 4.29E-10 0.7 2.74E-12 0.159 8.37E-05 0.572 4.49E-04 1.61E-12 8.51E-03 0.819 0.0112 0.0139
direction increase increase same increase increase same increase same decrease same decrease increase decrease same increase same
perm_pval <0.001 8.00E-03 <0.001 0.1 0.004 0.885 0.126 0.592 0.049 0.18 0.099 7.00E-03 0.521 0.282 <0.001 0.667
MW.pval 7.75E-24 6.69E-04 1.39E-10 4.15E-04 4.22E-06 0.753 1.76E-03 0.385 2.54E-03 0.0322 6.87E-03 1.70E-04 0.389 0.183 9.68E-15 0.583
direction increase increase decrease same decrease same same same decrease same same decrease same same increase same
perm_pval <0.001 0.015 <0.001 0.108 0.005 0.765 0.111 0.575 0.09 0.098 0.108 7.00E-03 0.545 0.186 <0.001 0.67
MW.pval 7.44E-24 4.54E-04 1.50E-10 5.28E-04 4.43E-06 0.584 1.28E-03 0.365 7.65E-03 0.0113 8.29E-03 2.54E-04 0.43 0.117 9.68E-15 0.557
direction increase increase decrease same decrease same same same same same same decrease same same increase same
perm_pval <0.001 0.049 <0.001 0.015 0.699 0.361 0.736 0.224 0.014 0.361 0.01 <0.001 0.773 0.491 <0.001 0.737
MW.pval 2.10E-24 9.65E-03 2.79E-09 1.04E-05 0.635 0.158 0.577 0.0969 4.22E-04 0.2 1.14E-04 2.68E-08 0.697 0.385 3.48E-15 0.645
direction decrease decrease increase increase same same same same increase same increase decrease same same increase same
perm_pval <0.001 0.248 0.564 8.00E-03 <0.001 0.495 < 0.001 0.622 <0.001 0.118 0.41 0.023 <0.001 0.117 0.104 0.741
MW.pval 7.34E-27 0.139 0.428 1.44E-07 1.90E-07 0.275 1.59E-22 0.437 3.52E-14 0.0207 0.203 2.95E-04 6.76E-06 0.0351 0.0188 0.659
direction increase same same increase increase same increase same decrease same same increase decrease same same same
perm_pval <0.001 0.099 <0.001 0.019 0.229 0.346 0.668 0.259 0.28 0.284 0.05 1.00E-03 0.735 0.601 <0.001 0.975
MW.pval 2.10E-24 0.0483 8.95E-12 4.37E-06 0.103 0.144 0.411 0.0731 0.0953 0.145 2.51E-03 3.68E-06 0.642 0.498 9.68E-15 0.977
direction decrease same increase increase same same same same same same increase decrease same same increase same
perm_pval <0.001 0.106 <0.001 <0.001 <0.001 0.906 < 0.001 0.665 0.003 0.764 0.031 <0.001 0.012 0.585 <0.001 0.094
MW.pval 2.31E-23 0.038 6.54E-20 1.43E-11 4.29E-10 0.825 1.12E-38 0.498 1.46E-04 0.644 2.45E-03 2.03E-09 2.78E-03 0.505 3.48E-14 7.42E-03
direction increase same increase increase increase same increase same decrease same decrease increase decrease same increase same
perm_pval <0.001 0.013 <0.001 0.102 2.00E-03 0.855 0.112 0.579 0.055 0.192 0.12 4.00E-03 0.489 0.296 <0.001 0.682
MW.pval 7.75E-24 6.69E-04 1.39E-10 4.15E-04 4.22E-06 0.753 1.76E-03 0.385 2.54E-03 0.0322 6.87E-03 1.70E-04 0.389 0.183 9.68E-15 0.583
direction increase increase decrease increase decrease same same same same same same decrease same same increase same
perm_pval <0.001 0.016 <0.001 0.102 3.00E-03 0.743 0.104 0.587 0.087 0.104 0.097 6.00E-03 0.539 0.203 <0.001 0.666
MW.pval 7.44E-24 4.54E-04 1.50E-10 5.28E-04 4.43E-06 0.584 1.28E-03 0.365 7.65E-03 0.0113 8.29E-03 2.54E-04 0.43 0.117 9.68E-15 0.557
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Experiment 2 (DIV25-29) Experiment 3 (DIV21-25)











































WT 24 24 12 60 24 20 24 68
Het 24 24 12 60 24 28 24 76
perm_pval <0.001 0.665 n/a 0.64 <0.001 0.075 <0.001 0.118
MW.pval 0.322 0.715 n/a 0.74 0.324 6.91E-03 0.0825 7.82E-03
direction increase same n/a same decrease same increase same
perm_pval 0.985 0.42 0.149 0.838 0.028 <0.001 <0.001 < 0.001
MW.pval 0.984 0.148 7.01E-03 0.678 0.0109 1.93E-21 2.40E-06 8.97E-25
direction same same same same increase increase increase increase
perm_pval 0.974 0.419 0.155 0.797 0.036 <0.001 <0.001 < 0.001
MW.pval 0.953 0.159 7.33E-03 0.629 0.0199 1.42E-21 3.34E-06 8.70E-22
direction same same same same decrease decrease decrease decrease
perm_pval 0.802 0.21 0.245 0.875 0.02 0.616 0.023 0.029
MW.pval 0.667 0.0406 0.036 0.795 5.39E-03 0.45 8.51E-03 5.78E-03
direction same same same same increase same increase increase
perm_pval 0.29 0.004 0.577 0.229 0.136 <0.001 0.021 < 0.001
MW.pval 0.105 5.12E-06 0.379 0.0459 0.0658 1.08E-14 6.87E-03 8.26E-13
direction same decrease same same same increase increase increase
perm_pval 0.02 0.141 0.998 0.871 0.362 <0.001 0.044 < 0.001
MW.pval 6.65E-05 5.88E-03 1 0.752 0.167 2.48E-19 7.12E-03 4.91E-12
direction decrease same same same same decrease decrease decrease
perm_pval 0.098 0.557 0.1 0.989 0.307 <0.001 0.033 < 0.001
MW.pval 7.49E-03 0.373 8.20E-03 0.982 0.239 4.86E-17 0.0126 3.50E-14
direction same same same same same increase increase increase
perm_pval 0.053 0.043 0.165 0.539 0.637 0.976 0.007 0.016
MW.pval 2.06E-03 3.13E-03 0.0311 0.306 0.588 0.969 8.43E-04 6.29E-03
direction same decrease same same same same decrease decrease
perm_pval 0.662 0.96 0.473 0.935 <0.001 0.018 0.63 0.633
MW.pval 0.52 0.937 0.226 0.909 1.32E-05 2.20E-03 0.514 0.567
direction same same same same increase decrease same same
perm_pval 0.313 0.002 0.016 0.601 0.04 <0.001 0.12 < 0.001
MW.pval 0.11 1.60E-07 2.50E-04 0.358 0.011 8.68E-24 0.046 3.86E-08
direction same increase decrease same decrease decrease same decrease
perm_pval 0.152 0.465 0.112 0.95 0.516 <0.001 0.047 < 0.001
MW.pval 0.0134 0.297 7.32E-03 0.921 0.43 2.79E-17 0.0213 1.09E-10
direction same same same same same decrease decrease decrease
perm_pval 0.059 0.1 0.892 0.647 <0.001 0.066 0.002 0.048
MW.pval 1.91E-03 6.44E-03 0.843 0.443 9.19E-08 1.28E-02 1.93E-05 3.97E-03
direction same same same same increase decrease increase increase
perm_pval 0.972 0.588 0.183 0.834 0.018 <0.001 <0.001 < 0.001
MW.pval 0.949 0.388 0.0111 0.667 0.00765 6.18E-18 4.54E-06 1.50E-21
direction same same same same increase increase increase increase
perm_pval 0.932 0.505 0.346 0.894 0.181 <0.001 <0.001 < 0.001
MW.pval 0.859 0.215 0.142 0.812 0.0851 3.37E-16 8.60E-08 1.24E-15
direction same same same same same decrease decrease decrease
perm_pval 0.069 0.282 0.957 0.059 0.256 0.179 <0.001 0.073
MW.pval 0.00174 0.0568 0.939 6.70E-04 0.163 0.0487 1.32E-11 8.89E-03
direction same same same same same same increase same
perm_pval 0.014 0.702 0.333 0.076 0.004 <0.001 0.019 < 0.001 
MW.pval 2.36E-04 0.529 0.0858 2.62E-03 3.09E-03 4.97E-19 6.16E-03 5.03E-09
direction decrease same same same decrease decrease increase decrease
perm_pval 0.021 0.48 0.55 0.03 0.088 <0.001 0.001 < 0.001
MW.pval 2.29E-04 0.249 0.284 2.55E-04 0.0575 1.03E-18 1.70E-05 1.29E-06
direction decrease same same decrease same decrease increase decrease
perm_pval 0.159 0.795 0.459 0.573 0.383 <0.001 0.599 < 0.001
MW.pval 0.0231 0.696 0.21 0.405 0.287 2.70E-17 0.537 2.09E-12
direction same same same same same decrease same decrease
perm_pval 0.617 0.537 0.69 0.74 <0.001 <0.001 <0.001 < 0.001
MW.pval 0.46 0.295 0.49 0.566 8.89E-08 4.95E-12 2.20E-08 3.77E-29
direction same same same same decrease decrease decrease decrease
perm_pval 0.919 0.269 0.013 0.833 0.474 <0.001 0.039 < 0.001
MW.pval 0.914 0.0692 1.26E-04 0.755 0.439 3.03E-18 0.0129 7.53E-20
direction same same decrease same same increase increase increase
perm_pval 0.735 0.003 0.13 0.155 <0.001 <0.001 0.119 < 0.001
MW.pval 0.601 1.25E-08 6.85E-03 0.0119 1.24E-06 3.94E-23 0.0267 4.26E-24
direction same increase same same increase increase same increase
perm_pval 0.739 <0.001 0.155 0.142 <0.001 <0.001 0.14 < 0.001
MW.pval 0.599 1.04E-08 6.85E-03 0.0118 1.02E-06 3.94E-23 0.0347 5.52E-24
direction same increase same same increase increase same increase
perm_pval 0.54 0.477 0.943 0.56 <0.001 <0.001 0.032 0.609
MW.pval 0.31 0.231 0.91 0.289 6.34E-09 2.46E-14 1.94E-03 0.453
direction same same same same increase decrease increase same
perm_pval 0.182 0.033 0.09 0.994 0.41 <0.001 0.017 0.001
MW.pval 0.105 1.09E-03 4.84E-03 0.991 0.288 8.11E-24 6.26E-04 3.97E-06
direction same increase same same same increase decrease increase
perm_pval 0.434 0.643 0.826 0.46 <0.001 <0.001 0.07 0.568
MW.pval 0.246 0.41 0.648 0.174 8.43E-09 2.61E-14 5.73E-03 0.375
direction same same same same increase decrease same same
perm_pval 0.7 0.17 0.036 0.772 0.027 <0.001 <0.001 < 0.001
MW.pval 0.517 0.0153 2.82E-04 0.62 9.03E-03 2.42E-23 3.37E-06 4.45E-26
direction same same decrease same increase increase increase increase
perm_pval 0.714 0.002 0.152 0.158 <0.001 <0.001 0.11 < 0.001
MW.pval 0.601 1.25E-08 6.85E-03 0.0119 1.24E-06 3.94E-23 0.0267 4.26E-24
direction same increase same same increase increase same increase
perm_pval 0.716 0.001 0.168 0.157 <0.001 <0.001 0.123 < 0.001
MW.pval 0.599 1.04E-08 6.85E-03 0.0118 1.02E-06 3.94E-23 0.0347 5.52E-24
direction same increase same same increase increase same increase
Experiment 2 (DIV17-21)Experiment 1 (DIV23-29)
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Figure 4.4 Combined analyses highlight variability in firing across MEA experimental 
replicates. Average (+/- SEM) MFR (normalized to WT firing) analyzed across select days in 
vitro for hippocampal experimental groups 1 (A), 2 (B) and 3 (C), along with neocortical 
experimental groups 1 (D) and 2 (E). Mutant network MFR showed a high degree of variability, 




















































































































Figure 4.5 Consistent MEA features across hippocampal and neocortical experimental 
replicates. Average (+/- SEM) network spike duration (“duration of NS”) of combined 
hippocampal plates, normalized to WT values, analyzed across select DIVs for experimental 
groups 1 (A), 2 (B) and 3 (C). For all 3 experimental groups, mean network spike duration was 
significantly increased. The average (+/- SEM) number of electrodes contributing to a network 
spike (“peak NS”) from combined neocortical plates, normalized to WT values, and analyzed 
across select days in vitro for experimental groups 1 (D) and 2 (E). Both experimental groups 

















































































































Figure 4.6 C-Fos expression in seizure-induced and control sham mice. Representative images 
of c-Fos (EGFP) immunostaining of WT and Hnrnpu HET non-stimulated (Sham) and minimal 









Figure 4.7 Regional differences in c-Fos expression. Density (cells/mm2) of c-Fos positive cells 
among WT and HET sham and seizure-induced mice summarized with a combined and an 
individual animal analysis for the ventral subiculum (A) & (B), dorsal subiculum (C) & (D), 
dentate gyrus (E) & (F), CA1 (G) & (H) and neocortex (I) and (J). Mann Whitney U p-values: 








4.3 Discussion  
In effort to investigate whether transcriptional dysregulation of the subiculum in the 
hippocampus is linked to hyperactivity phenotypes, neuronal activity of the hippocampus and 
neocortex was monitored using both electrophysiological and molecular approaches.  
 
Neocortical and hippocampal MEA studies reveal a high degree of variability and remain 
inconclusive 
Evaluation of basic developmental and mature network properties using MEAs has 
previously proven useful in identifying hyperactive phenotypes in mouse models of epilepsy. 
Furthermore, MEAs can serve as a medium-throughput platform for screening candidate drugs for 
their effects on such phenotypes. Primary neuronal cultures coupled to MEA, such as described 
here, also offer the ability to screen multiple drugs with replicate wells on the same plate over 
time, and thus can provide information on how drugs effect not only mature firing, but also network 
development. This is in contrast to other electrophysiological tools, such as patch-clamp or MEAs 
coupled to brain slices, which are both acute experiments.  
Nevertheless, these data highlight important considerations and limitations of the MEA. 
First of all, for the hippocampal studies, a high degree of plate-to-plate variability was observed 
across all features evaluated, resulting in inconsistency amongst results of each experimental 
group. While the first experiment showed an increased mean firing rate that was nearly 1.5 to 2-
fold higher than WT networks, the second and third experimental groups did not corroborate this 
finding. Furthermore, the firing rates of WT networks alone showed variability amongst plates and 
experimental groups (Figures 4.2G). One leading explanation for this is the diversity of cell types 
within the cultures. Specifically, subtle differences in the cell types obtained from dissection and 
included in the dissociation and seeding could vary for each plate and thus lead to changes in 
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network function. Considering biologically-relevant networks are abolished upon dissociation, 
minor differences in cell-type composition may also impact how networks are re-established in 
culture. The subiculum, for example, is the major output source and the most inferior component 
of the hippocampus, situated immediately adjacent to the neocortex, and may therefore be difficult 
to fully dissect as part of the hippocampus in a newborn pup. If subiculum-derived pyramidal 
neurons—which show transcriptional vulnerability to Hnrnpu loss—have altered activity in 
mutants, then an incomplete dissection of this brain region, or inclusion of these cells in the 
neocortical cultures, may theoretically cause variation in activity between replicates.   
For neocortical networks, the initial experiment failed to reveal any significant differences 
in neuronal activity with the exception of a reduction in the peak number of electrodes contributing 
to network spikes. However, a second experiment demonstrated numerous significant features 
including a consistently-elevated MFR and also a decrease in the peak number of electrodes 
contributing to network spikes. This drastic difference between experimental groups may be 
explained, at least in part, to the modified experimental conditions. Specifically, cells were plated 
at double the density for the second experiment, and were maintained in a different media meant 
to increase neuron viability, activity and maturation. While the overall firing rate appeared similar 
between experimental batches (Figure 4.3E), the timeline of network maturation was strikingly 
different, showing nearly a 10-day difference in the level of synchrony of WT networks between 
the two experimental groups (Figure 4.3B compared to 4.3D). Perhaps the accelerated network 
development of the second experimental group was sufficient to expose a hyperactive phenotype 
in mutants. Additional replicate experiments utilizing these conditions are warranted to validate 
any neocortical phenotypes.    
Despite the surplus of MEA data collected on both hippocampal and neocortical primary 
cultures, no clear conclusions regarding region-specific activity phenotypes in mutants can be 
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drawn. Future studies focused on preserving microcircuits, such as MEA or patch-clamp 
electrophysiology performed on brain slices, could help elucidate whether any region-specific 
activity differences exist. These assays can provide single-cell (patch-clamp) and network-level 
(MEA) activity information derived from intact, physiologically-relevant circuits, thereby 
avoiding the problem of varied cell-type composition of cultured networks. Furthermore, these 
studies permit the assessment of activity directly within the subiculum, which was also not possible 
with the heterogeneous dissociated hippocampal cultures.   
 
C-Fos immunostaining revealed genotype-specific differences in neuronal activity across the 
neocortex and hippocampus 
C-Fos immunostaining was next used to assess region-specific activity differences while 
preserving brain architecture and neuronal circuits. C-Fos expression was evaluated in WT and 
Hnrnpu+/113DEL mutant mice following induction of a minimal clonic forebrain seizure, along with 
non-stimulated mice. In both WT and mutant mice, a modest, yet highly significant, increase in c-
Fos staining was observed within the neocortex, yet not the hippocampus, following minimal 
clonic seizure induction. This is consistent with a prior study, which failed to identify substantial 
c-Fos labeling of the hippocampus following minimal electroshock-induced clonic seizures, yet 
reported significant labeling following maximal electroshock-induced tonic seizures (Eells et al. 
2004).  
With regard to genotype-specific differences, contrary to our prediction, this study 
identified an apparent decrease in c-Fos positive cells in the ventral subiculum of non-stimulated 
Hnrnpu mutant animals. This difference was not observed in mutants upon seizure induction as 
one mutant demonstrated an increase in c-Fos labeling compared to WT. No changes were 
observed in the dorsal subiculum, with the exception of a slight decrease in WT c-Fos staining 
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upon seizure induction. The ventral and dorsal subiculum are predominantly thought to perform 
different functions within the hippocampus: the dorsal subiculum plays a major role in spatial 
learning and memory, whereas the ventral subiculum is important for inhibiting the hypothalamic-
pituitary-adrenal (HPA) axis (S. O’Mara 2005). Interestingly, in a rat model of temporal lobe 
epilepsy, the earliest seizure activity was most frequently found in the ventral region of the 
hippocampus, including the ventral subiculum (Toyoda et al. 2013). This region of the brain is 
homologous to the human anterior hippocampus, which is considered more epileptogenic (D. W. 
King and Marsan 1977; Masukawa et al. 1995), and is associated with a spectrum of cognitive 
functions including anxiety and stress, fear response, novelty detection, memory and spatial 
representation and processing of contextual information (Maren 1999; Mueller, Dolgas, and 
Herman 2004; Herman and Mueller 2006; Oswald and Good 2000; Deadwyler and Hampson 2004; 
Lisman and Grace 2005; Fanselow 2000). The ventral subiculum in particular has also been shown 
to support seizure initiation in temporal lobe epilepsy (Huberfeld et al. 2011) and reportedly plays 
a role in the spread of seizure-like activity to the amygdala, hypothalamus, pre-optic region and 
basal forebrain (Kliot and Poletti 1979).      
The link between reduced c-Fos expression in the ventral subiculum and downregulation 
of the EE gene Mef2c within the subiculum (discussed thoroughly in Chapter 3) is unclear. Given 
that haploinsufficiency of Mef2c has been associated with epilepsy and increased excitatory 
neurotransmission within the hippocampus, we initially hypothesized that reduced Mef2c 
expression would result in overactive pyramidal neurons of the subiculum. In response to increased 
neuronal activity, Mef2c is activated and functions to restrict excitatory synapse development. 
Heterozygous loss of Mef2c and CNS-specific Mef2c complete knockout reportedly resulted in an 
increase in the number of excitatory synapses and enhanced synaptic transmission in the 
hippocampus (Barbosa et al. 2008; Tu et al. 2017). Interestingly, however, a conditional Mef2c 
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knockout in cortical and hippocampal excitatory neurons was associated with a decrease in cortical 
network activity in vivo, due to excessive inhibitory and reduced excitatory neurotransmission 
(Harrington et al. 2016). These mice also demonstrated various cognitive impairments, including 
social deficits, repetitive behaviors and learning and memory impairments. Mef2c was proposed 
to cell-autonomously regulate the density of synapses that formed on dendrites of cortical 
pyramidal neurons through the repression of genes important for excitatory synapse elimination 
and GABAergic synapse production. Thus, perhaps the reduction of Mef2c observed in the 
subiculum of Hnrnpu mutants results in excessive inhibitory synapse formation, enhanced 
excitatory synapse elimination and a consequential reduction in neuronal activity.  
It remains unclear whether this reduced neuronal activity in the ventral subiculum (1) 
directly influences seizure predisposition, (2) represents a secondary, compensatory effect from 
another mechanism that promotes seizure susceptibility, or (3) is completely unrelated to this 
phenotype. While seizures result from a hyperexcitable and hypersynchronous state, hypoexcitable 
networks—such as caused by hyperinhibition—are also unstable and may contribute to further 
network dysregulation (Navidhamidi, Ghasemi, and Mehranfard 2017). Hypoexcitable neurons 
have been previously reported as a pathological factor in other neurological disease models such 
as autism, intellectual disability and even epilepsy (Brumback et al. 2018; Brew et al. 2007; Alari 
et al. 2018). As stated previously, the ventral subiculum functions in various cognitive processes 
including stress, anxiety, fear, novelty-detection and processing of contextual information. 
Reduced neuronal activity within the ventral subiculum could therefore play a role in the various 
comorbidities associated with heterozygous loss of Hnrnpu. As discussed in Chapter 2, the adult 
mouse behavioral studies revealed a mild, transient novelty-induced hyperactivity in mutant mice. 
Moreover, contextual learning and memory, as assessed by fear conditioning utilizing a foot-
shock, revealed a clear decrease in response (freezing) upon being placed in the same context as 
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the initial foot-shock. These results, however, were precluded by the fact that this reduced freezing 
was also observed during the initial training session, suggesting that mutants are inherently less 
responsive to this form of stress.  
   Overall, findings from this c-Fos study support regional-specific differences of neuronal 
activity as hinted by the single-cell RNA-sequencing study. As predicted, the subiculum shows 
altered firing in mutants, yet this activity was reduced instead of elevated. While this study is 
limited by small sample size, the results support the need for further functional characterization of 
excitatory neurons within the ventral subiculum. Whole cell patch-clamping of pyramidal neurons 
within this hippocampal sub-region can provide both qualitative and quantitative information on 
excitatory and inhibitory synapses via measurement of miniature excitatory and inhibitory post-
synaptic potentials (mEPSC and mIPSC). MEA studies on slices can also provide network-level 
information on ventral subiculum activity and communication to other brain regions. Furthermore, 
in vivo studies including fiber photometry offer the ability to monitor activity in the subiculum in 
freely moving animals. Future studies focused on evaluating the role of Mef2c in Hnrnpu mutant 
subiculum activity, such as through genetic epistasis experiments, could also prove useful in 
elucidating potential disease mechanisms. Importantly, unveiling a link between the subiculum 
and seizure predisposition or other comorbidities could lay the foundation for improved targeted 
therapeutics of hnRNP U-related phenotypes, such as through targeting important molecular 










Within a week prior to dissection, 48-well MEA plates (Axion Biosystems #M768-KAP-
48) were coated overnight at room temp with 50ug/mL poly-D-lysine (Sigma-Aldrich #P0899-
50MG) diluted in borate buffer. Plates were subsequently washed 3 times with molecular grade 
water and stored in phosphate buffered saline (PBS) at 4C until use. On the day of dissociation, 
PBS was aspirated and the plates were allowed to dry in a sterile hood.  
Cortical and hippocampal neurons were dissected and dissociated as reviewed in Chapter 
1 Methods: Primary Neuronal Culture with the following modifications: pelleted cells were 
resuspended at a density of 1250 cells/uL in pre-warmed Neurobasal complete media: Neurobasal-
A (Gibco #10888022), 1X GlutaMax (Gibco #10888022), 1% HEPES (Gibco #15630080), 1% 
Penicillin/Streptomycin (Gibco #15140122(, 1% fetal bovine serum (FBS)(Gibco #26140079), 
5ug/mL Laminin (Sigma-Aldrich #L2020). Of note, 1X B27 supplement (Gibco #17504044) was 
added for the first two sets of experiments, whereas 1X B27 Plus supplement (Gibco A3582801) 
was used for the third experimental replicate. A total of 50,000 cells were plated on a pre-coated 
48-well MEA plate in a 40uL drop, and were allowed to adhere to the plate for at least 1 hr prior 
to adding 200uL of additional Neurobasal complete media. The day after plating (DIV1), 100% of 
the media was replaced with the same media but lacking the FBS (NBA/B27 media). Cultures 
were maintained at 37C in 5% CO2. 50% media changes using NBA/B27 media were performed 
every-other day following each recording session starting on DIV3. 
 
Analysis of spontaneous MEA recordings 
Recordings were performed prior to media changes starting on DIV5. Plates were allowed 
to equilibrate for 5 min then were recorded for 15 min using Axion Biosystems Maestro 768 
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channel amplifier at 37C in a carbogen filled gas-controlled chamber and Axion Integrated Studios 
(AxIS) software v2.4. A Butterworth band-pass filter (200-3000Hz) and adaptive threshold spike 
detector set at 7x the standard deviation of noise was used for all recordings. Spike list and raw 
data were captured and stored. Using a custom MEA analysis software package (meaRtools) 
(Gelfman et al. 2018), spike list files were used to extract over 70 activity-related spike, burst and 
network features, including spiking and bursting rates, density of spikes within bursts, burst 
duration, and various measures of network synchrony. All data was first evaluated to filter out 
inactive electrodes and wells. For an electrode to be considered active, at least 1 spike per minute 
was required, and wells in which fewer than 4 electrodes were active for >50% of the recorded 
days were considered inactive and filtered out from downstream analyses. The Poisson surprise 
method was used for burst detection (Legéndy and Salcman 1985; Gelfman et al. 2018). For 
network-spike events, we used a bin length of 10ms to capture these events, and we required a 
minimum of 3 active electrodes to fire simultaneously to be considered a network spike.  
A total of 3 experiments batches, each containing 4-5 biological replicate plates, were 
reported. For each set of experiments, Hnrnpu+/113DEL wells of each plate were first normalized to 
WT wells, and then combined across all plates. Data normalization was performed by computing 
the average value amongst WT wells for each DIV, then dividing the resulting values of each well 
(both WT and mutant) per DIV by this mean. Normalized data were then subjected to permutation 
Mann-Whitney U testing.  Specifically, for each parameter, calculated values for each well across 
all chosen DIVs were combined and subjected to an MWU test. The genotype labels for each active 
well were then shuffled and permuted 1,000 times to create 1,000 data sets that were each 
subsequently tested using MWU. The permuted p-values were reported as the rank of the true, un-




Immediate Early Gene Expression Studies 
Prior to the experiment, adult (11-12 weeks of age) male F1 Hybrid mice (C57BL/6NJ x 
FVB/NJ) were placed in a habituation cage at least one hour prior to electroshock. Two males of 
each genotype were administered a high-frequency (299Hz, 16ms pulse-width, 0.2s shock 
duration) minimal electroshock of 7 mA through a transcorneal electrode in effort to evoke a clonic 
forebrain seizure. To serve as controls and to evaluate spontaneous activity differences, two males 
of each genotype were handled the same, but not administered the electroshock. All mice were 
sacrificed 1-hour post-stimulus or 1-hour post-handling, and immediately perfused with PBS 
followed by 4% PFA. Whole brains were dissected and left in 4% PFA overnight, then placed in 
PBS. Brains were subsequently sliced in 100uM sections using a vibratome, then transferred to 
PBS in a 24-well culture dish and washed 2X in PBS for 10 min each. Slices were incubated 
overnight in c-Fos primary antibody (Santa Cruz sc-52, 1:1000 in blocking solution) at 4C and 
washed 3X in PBS. Slices were next incubated overnight in secondary antibody (Jackson 
Immunology, 488 antirabbit, 1:500) at 4C, then washed 3X in PBS and mounted. Slices were 
imaged using a Zeiss 510META confocal microscope, and quantified using Imaris Software 
Package (Oxford Instruments) relying on automatic thresholding for each image. Slices containing 
both the ventral and dorsal subiculum (ranging from bregma -3.18 to -3.58) were used for 
quantification. Five brain regions of interest (ROI), including the dentate gyrus, CA1, dorsal and 
ventral subiculum and neocortex, were manually demarcated using the corresponding nuclear 
counterstaining image and Allen Brain Atlas as a reference. The area (mm2) of each ROI was 




Chapter 5: Conclusions 
Recent advances in genetic studies have offered a gateway into understanding the 
pathogenesis of previously elusive diseases. Starting with the genetic etiology, we can introduce 
the equivalent mutation(s) in animal models and then functionally characterize the effects of these 
mutations at a molecular, cellular and whole-organism level using disease phenotype-relevant in 
vitro and in vivo assays. Findings from these studies can then be used to inform additional 
investigations into disease mechanisms, and ultimately lead to improved therapeutics. The primary 
objective of this thesis work has been to illustrate a precision medicine approach in epilepsy, 
whereby we model a rare genetic form of epileptic encephalopathy in mice and perform a thorough 
battery of tests to assess the resulting neurophysiological changes and transcriptomic 
consequences. Information gained from these studies was then used to inform on potential disease-
relevant targets and cell types so as to lay the groundwork for improved, precision-based therapies.  
While a clear link exists between hnRNP U and neurodevelopmental disease, how such a 
ubiquitously-expressed, multifunctional protein causes a severe neurological disorder has 
remained elusive. I hypothesized that hnRNP U’s pervasive role in gene expression could be a 
major contributing factor. First of all, altered splicing of target mRNAs linked to cardiomyopathy 
were observed following conditional loss of Hnrnpu from the heart in mice (Ye et al. 2015). These 
mice died postnatally from cardiomyopathy, and had splicing changes involving known 
cardiomyopathy genes. Furthermore, altered RNA homeostasis has been a well-described 
mechanism underlying various neurological diseases, such as neurodegenerative (i.e. ALS, 
spinocerebellar ataxia, spinal muscular atrophy) and other neurodevelopmental diseases (autism, 
epilepsy, intellectual disability etc.), as neurons rely on tight regulation of gene expression for 
proper function (Nussbacher et al. 2019). This strict level of regulation is conferred by proteins 
that function in RNA metabolism (i.e. those involved in transcription, mRNA processing, stability, 
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decay, transport and translation), such as RNA and DNA-binding proteins, and thus it is 
unsurprising that disruptions within the corresponding genes are often associated with neurological 
disease. For example, altered dosage of gene expression regulators FMRP, RBFOX1 or MECP2 in 
association with autism and intellectual disability, cause dysregulation of a wide-array of gene and 
mRNA targets important in neural development and function (Nussbacher et al. 2019; L. Chen et 
al. 2015).   
To our knowledge, this body of work represents the first in-depth characterization of an 
hnRNP U disease model. From these studies, Hnrnpu+/113DEL mice were observed to have impaired 
growth and reduced postnatal viability, abnormal brain morphology, increased seizure 
susceptibility, delayed pup development and abnormal adult behaviors. Furthermore, transcription 
profiling revealed altered RNA homeostasis involving long, disease-relevant neuronal genes—
especially among subiculum-derived pyramidal neurons. These transcriptional changes were 
consistent with a widespread, yet low-magnitude level of gene dysregulation with the exception of 
a single, more robustly dysregulated epilepsy gene, Mef2c, found to be downregulated greater than 
50% in the subiculum. Follow-up investigation into differences in neuronal activity within the 
hippocampus and subiculum in particular, revealed a reduction in the level of active neurons in the 
ventral subiculum of freely-moving animals—a finding that could contribute to an overall 
undesirable network state and subsequent network dysfunction.  
This constitutive Hnrnpu knockout mouse model contains a single loss-of-function 
mutation in exon 1 of mouse Hnrnpu, and thus serves as a model of the various loss-of-function 
alleles identified in human patients. As reviewed thoroughly in the Introduction, patients 
demonstrate seizure onset around 1 year of age, delayed development (primarily impacting motor 
and verbal skills), various abnormal brain MRI findings, short stature and autistic-like behaviors. 
Whereas in mice, a persistent growth impairment, slight delay in pup developmental milestones, a 
158 
 
striking deficit in pup isolation calls, mild novelty-induced hyperactivity, abnormal gait, subtle 
differences in brain morphology and greater seizure susceptibility were observed. No spontaneous 
seizures were observed, and learning and memory did not appear to be strongly affected.  
While this mouse model did not completely recapitulate the epileptic condition in humans, 
Hnrnpu mutant mice did exhibit abnormal neurodevelopment. Incomplete face validity (i.e. 
similarity in phenotype) is not uncommon, especially among genetic mouse models of epilepsy 
and other neurological disorders (McGraw, Ward, and Samaco 2017). Many such epilepsy models 
fail to demonstrate spontaneous seizures, yet show greater seizure susceptibility (Teoh et al. 2019; 
Amador et al. 2019), such as observed with Hnrnpu mutant mice. This is perhaps unsurprising 
considering the mouse brain is developmentally, structurally and functionally different than the 
human brain. Gene by environment interactions are also vastly different for mice compared to 
humans, which may impact penetrance and variable expressivity of disease genes. Furthermore, it 
is often unclear what represents a true phenotypic “correlate” among different species. For 
example, it is controversial whether pup USVs, which are compromised in the Hnrnpu mutant 
mice and other models of ASD, represent a true analog of human speech and communication, as 
recent findings suggest that the brain region responsible for USVs is different than that involved 
in human speech (Ey et al. 2013; Ferhat et al. 2016; Zimmer et al. 2019). Thus, poor face validity 
does not necessarily abrogate the utility of a model as it may still display construct validity 
(similarity in underlying mechanisms), and thus could still provide relevant and valuable 
information on human disease pathology.  
While the work described here does not provide direct evidence of the underlying cause(s) 
of mutant phenotypes, clear correlations between phenotype and transcriptional changes were 
observed. First, bulk RNA-sequencing of neocortex along with certain cell types of the neocortex 
(SST+ interneurons) and hippocampus (subiculum) revealed enrichment of known epilepsy genes 
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among significantly downregulated genes. Many of these downregulated genes cause epilepsy 
upon heterozygous loss of gene function including Grin2b, Stxbp1, Pchd19 and Syn1 (Platzer et 
al. 2017; Yamamoto et al. 2016; Niazi et al. 2019; Fassio et al. 2011). Thus, perhaps a modest 
reduction in expression among multiple epilepsy genes is capable of conferring a higher baseline 
state of neuronal excitability. Furthermore, developmental delay and autism genes were also 
enriched among downregulated genes within the neocortex, particularly within SST+ interneurons, 
inhibitory progenitors, radial glia and layer 5/6 pyramidal neurons along with subiculum-derived 
excitatory neurons of the hippocampus. These disease genes are responsible for important neuronal 
processes, such as neuron migration, neurite outgrowth and synaptic transmission—a finding 
further supported by Gene Ontology pathway enrichment analyses of significantly downregulated 
genes.  
It is thus conceivable that the combined dysregulation of these disease genes, in concert 
with other important neuronal genes, could present multiple “hits” to the same process leading to 
neuron dysfunction. Possible examples of this include defective axon guidance and neuronal 
migration—Hnrnpu mutants had an overabundance of dysregulated genes that normally play a 
role in both pathways, and subsequent neuroimaging studies revealed evidence of axon pathfinding 
defects through the internal capsule, along with a double layer of cells within the hippocampus, 
suggestive of migration deficits (reviewed in Chapter 2). Furthermore, pathway enrichment also 
highlighted GABA secretion and the synaptic vesicle cycle as potentially impacted neuronal 
processes, which may impart greater seizure susceptibility due to an imbalance in neuronal 
inhibition and excitation. Additional studies to validate the role of these genes in relevant Hnrnpu-
related phenotypes is warranted. For example, investigation of the electrophysiological properties 
of mutant and WT neurons and neuronal networks, such as through whole-cell patch-clamp or 
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multielectrode arrays, following administration of GABA-receptor modulators (i.e. agonists and 
antagonists) may reveal different responses in GABA processing. 
The transcriptomic study also revealed a clear length-dependent effect on nascent 
transcripts, where the longest genes were the most downregulated in expression relative to shorter 
genes. This finding fits with the observed significant dysregulation of numerous disease-relevant, 
neuronally-expressed genes, as these genes are comparatively longer than those expressed in other 
tissue types (Zylka, Simon, and Philpot 2015). As discussed in detail in Chapter 3 Discussion, 
length-dependent effects on gene expression have been linked to abnormal neural development 
and function in cases of defective transcription elongation—a process in which hnRNP U is known 
to play a role. These long gene effects have also been reported in other gene expression regulator-
mediated neurological diseases. For instance, the Rett syndrome gene MECP2 was shown to 
repress expression of long genes by binding preferentially to methylated CA sites within long 
genes  (Gabel et al. 2015). Reducing expression of long genes improved cellular phenotypes 
associated with Rett syndrome. Moreover, FMR1, the gene causative of Fragile X syndrome, 
normally functions to boost the translation of particularly large proteins associated with 
neurodevelopmental dysfunction (Greenblatt and Spradling 2018). Additionally, ALS-associated 
genes TARDBP and FUS reportedly mediate the processing of large genes with extremely long 
introns that play important roles in neuronal function (Lagier-Tourenne et al. 2012). Length-
dependent effects on gene expression across other brain-expressed DRBP’s were also identified, 
including those associated with known neurological diseases.  While hnRNP U’s exact role in the 
transcription of these long genes remains unknown, this global length-dependent effect on gene 
expression could explain how the brain—and neurons in particular—are vulnerable to the 
reduction of hnRNP U. Further investigation of hnRNP U’s role in transcription initiation and 
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elongation is certainly warranted and may provide a direct link to an underlying disease 
mechanism.  
While the majority of transcriptional changes observed in Hnrnpu mutants have minor 
effect sizes, one gene in particular, Mef2c, was a clear outlier. Mef2c was found to be 
downregulated over two-fold specifically within the subiculum of the hippocampus—a region of 
the brain highly implicated in temporal lobe epilepsies. Mef2c itself is a long gene (>100kb), a 
known hnRNP U RNA target in cardiac tissue, and a known disease gene. Loss-of-function 
mutations and deletions encompassing human MEF2C cause a neurodevelopmental syndrome 
with strong phenotypic overlap to that of patients with HNRNPU mutations. However, why Mef2c 
is more drastically dysregulated compared to other genes remains unclear. One potential 
explanation is that hnRNP U may regulate Mef2c at multiple levels. Small changes in dosage of 
gene expression regulators, such as hnRNP U, can be exacerbated from effects on multiple levels 
of gene expression of its targets (Nussbacher et al. 2019). However, if this is the case, one might 
expect this multi-level regulation to exist for other Hnrnpu targets, resulting in more substantial 
gene dysregulation for a greater number of target genes. A second possibility is that another 
regulator of Mef2c is dysregulated in Hnrnpu mutants and thus leads to secondary effects on Mef2c 
gene expression.  
Mef2c is part of the MEF2 group of transcription factors that function to suppress the 
development of excitatory synapses. This occurs in an activity-dependent manner, such that upon 
increased neuronal activity, MEF2 transcription factors become activated and subsequently 
promote the expression of genes that limit excitatory synapse number (Flavell et al. 2006). This 
process is imperative for proper learning and memory, which rely on the activity-dependent 
plasticity of synapses (Barbosa et al. 2008). Hence, loss of Mef2c results in excessive synapse 
formation and impaired learning and memory (Barbosa et al. 2008).  Furthermore, a 
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haploinsufficient Mef2c mouse model demonstrated a functional excitatory/inhibitory imbalance, 
favoring increased neuroexcitability within the hippocampus (Tu et al. 2017). These mice also 
demonstrated autistic-like behaviors, decreased neurogenesis and increased neuronal apoptosis. 
These phenotypes were ameliorated upon chronic in vivo treatment with the NMDA-receptor 
antagonist Nitrosynapsin.   
Considering the magnitude of Mef2c dysregulation observed in the subiculum is essentially 
equivalent to haploinsufficiency, this gene alone could substantially contribute to one or more 
hnRNP U-related phenotypes. If so, Mef2c could serve as an obvious therapeutic target, and 
Nitrosynapsin could then be tested for its efficacy in treating hnRNP U-related in vitro and in vivo 
phenotypes. Genetic epistasis experiments, such as heterozygous Mef2c and Hnrnpu double 
knockout mice or a cross between heterozygous Hnrnpu mutant and a constitutively active form 
of Mef2c (Barbosa et al. 2008), could formally assess the relationship between Mef2c and Hnrnpu.  
Beyond Mef2c, pyramidal neurons of the subiculum demonstrated an overall greater 
burden of gene expression dysregulation compared to other cell populations. Furthermore, known 
disease genes, including epilepsy, developmental delay and autism, tended to be over-represented 
(using relaxed significance thresholds) in the dysregulated genes of this cell population. This brain 
region is particularly important from a seizure standpoint, as it serves as the major output of 
information from the hippocampus to cortical and subcortical regions and has been shown to play 
a role in the ictogenesis of temporal lobe epilepsy (Yi Wang et al. 2017). And although the site of 
seizure origin has not been reported for most HNRNPU patients, two patients were described as 
having temporal lobe epilepsy (Bramswig et al. 2017; Leduc et al. 2017). As a whole, these 
findings support an apparent vulnerability of these subiculum-derived pyramidal neurons to 
heterozygous loss of Hnrnpu.  
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Excessive gene dysregulation of this hippocampal subfield could culminate in a higher 
baseline level of neuronal excitability stemming from the hippocampus. Should altered activity 
exist within the hippocampus or the subiculum in particular, this discovery combined with the 
single cell RNA-sequencing data, could both be used to inform additional mechanistic studies 
interrogating the role of hnRNP U within this brain region, and could even lay the groundwork for 
improved drug development. In effort to test this hypothesis, two different experimental 
approaches to assess region-specific network activity were performed: multielectrode arrays and 
c-Fos immunostaining. MEAs serve a non-invasive tool that permit the long-term investigation of 
the activity patterns of heterogeneous cultured neural networks. Given the inherent variability of 
this assay, numerous MEA studies were performed on both neocortical and hippocampal primary 
cultures, and failed to reveal any reproducible phenotypes with the exception of longer network 
spikes in hippocampal networks and decreased number of electrodes contributing to network 
spikes in neocortical networks (see Chapter 4). While the significance of these findings are unclear 
(specifically whether they are present in vivo, represent an abnormal or hyper-excitable state and 
what cell types are responsible), both quantitative and qualitative differences in network events 
could theoretically have deleterious effects on the proper transmission of information (Laughlin 
and Sejnowski 2003; Staley et al. 2014).  
Given the overall variability and unclear nature of these MEA results, region-specific 
activity differences were assessed using an approach that preserves brain architecture and circuits. 
Expression of the immediate early gene and neuronal activity marker, c-Fos, was monitored 
through protein immunostaining of mutant and WT electroshock-stimulated and non-stimulated 
mice. Unexpectedly, a reduction in the density of c-Fos positive cells was observed within the 
ventral subiculum of freely-moving, non-stimulated Hnrnpu mutants. While hypoexcitability has 
been previously reported as a feature in neurological disorders including autism, epilepsy and 
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intellectual disability (Brumback et al. 2018; Alari et al. 2018; Brew et al. 2007), the significance 
of this finding in relation to Hnrnpu-associated epilepsy and other comorbidities requires further 
investigation. Nevertheless, the c-Fos results emphasize the potential utility of this brain region 
and cell-type specific transcriptomic approach in pinpointing targetable disease phenotypes caused 
from a complex transcriptional-regulator, like hnRNP U. Additional electrophysiological studies, 
such as fiber photometry, juvenile EEGs or whole-cell patch clamp and MEA studies on whole 
brain slices, can help further validate differences in spontaneous network activity among the 
subiculum of Hnrnpu mutants. Importantly, clear region-specific differences in activity may be 
further exploited for therapeutic purposes.   
Overall, the thesis work presented here highlights a comprehensive precision medicine-
based approach to modeling Hnrnpu-related epilepsy. The extensive mouse phenotyping efforts 
not only confirm abnormal neurodevelopment upon heterozygous loss of Hnrnpu, but can also be 
used in the future for screening candidate therapeutic compounds or drugs aimed at elucidating 
disease mechanisms. Furthermore, the single-cell RNA-sequencing data underscore the utility of 
this approach for disease modeling, as it has provided the ability to compare transcriptional 
dysregulation across cell populations, not only offering insight on important dysregulated genes, 
but also the brain regions and cell-types most susceptible to heterozygous loss of Hnrnpu. 
Functional evaluation of these brain regions using electrophysiological and molecular methods 
were performed with the end goal of pinpointing disease-relevant therapeutic targets and 
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Since the beginning of the human genome project, there 
has been exceptional enthusiasm for how genetics and 
eventually genomics would transform drug discovery. 
With the benefit of hindsight, it is now clear that much of 
this enthusiasm was, at best, premature. With the recent 
rapid evolution in genomic technologies, we are entering 
a new phase in genomics, one in which it is now possible 
to comprehensively characterize the genomes of both 
patients and healthy individuals. Importantly, the devel‑
opment of sequencing technologies has been paired with 
a transition towards integrating genomic data with elec‑
tronic medical records, ultimately facilitating the genera‑
tion of a data commons useful for identifying relationships 
between genomic variation and clinical presentation1.
This new phase of genomics, which is increasingly 
referred to as precision medicine, has sparked a new 
chapter in the relationship between genomics and drug 
development — one we argue will be laborious and 
lengthy but eventually substantially more productive 
than any of the earlier phases. Here, we first review the 
key recent phases of the relationship between genomics 
and drug development. Next, we describe the core ele‑
ments of precision medicine and how advances in the 
field are expected to influence both drug development 
and drug use. We end with additional considerations and 
challenges we expect precision medicine to confront. 
Our key message is that above all, precision medicine 
is a new window into the biology of disease, and this 
new understanding of the physiological and molecular 
basis of disease will transform drug development and 
clinical use.
Early efforts, ESTs and drug discovery
The mid‑20th century began what has since been termed 
the ‘golden age’ of drug discovery2–4, the start of which 
was largely characterized by observation‑based discov‑
eries from the phenotypic screening of animals, whole 
organs or tissues using synthetic small molecules5,6. 
This ‘molecular roulette’ approach gave rise to many of 
the medicines in current use, including anti biotics and 
immunosuppressants4,5. However, the overall productiv‑
ity of this approach began to decline, and by the 1970s, 
a general push towards understanding the biological 
functions and structural properties of putative drugs and 
their targets (that is, rational drug development) arose4,7. 
For a few decades thereafter, drug discovery was domi‑
nated by a ‘function‑to‑gene’ approach8, which focused 
on investigating a specific protein as a potential drug 
target, such as one associated with or causative of a par‑
ticular disease. This type of approach gave rise to drugs 
that treat a variety of chronic diseases, such as captopril 
(an angiotensin‑ converting enzyme (ACE) inhibitor) 
and other cardio vascular medicines4. Nevertheless, by 
the early 1990s, an appreciable decline in pharmaceutical 
productivity began, partly owing to a lack of appropri‑
ately validated new drug targets. This period, however, 
coincided with major advances in both computation 
and biotechnology, which together cultivated the field 
of genomics as an innovator for the pharmaceutical 
industry.
In the early 1990s, the discovery and use of expressed 
sequencing tags (ESTs) as a tool to transcriptionally pro‑
file populations of cells were the first major technological 
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advances that led to the widespread and systematic inte‑
gration of genomics into drug discovery pipelines and 
spearheaded a transition to a ‘gene‑to‑screen’ approach 
by industry8–10. The main assumption underlying this 
approach is that the complex combination of genes 
expressed in a given cell is a primary contributor to the 
overall cellular phenotype. Thus, in the context of dis‑
ease, differentially expressed genes in dysfunctional cell 
populations or tissues could be causally involved in the 
disease process and could therefore serve as possible 
drug targets11,12. EST profiling not only provided the abil‑
ity to detect these differences in gene expression but also 
led to the identification of new genes and dysregulated 
pathways, all of which delivered a plethora of new targets 
with potential therapeutic implications. The more ideal 
candidates, such as those with predicted druggability 
and/or those with gene expression limited to the cell or 
tissue types of interest, were then chosen for cloning and 
additional functional analyses, and if still promising, these 
analyses were followed up with high‑throughput com‑
pound screening or rational drug design8. Of course, the 
challenge in such work was to discriminate causal from 
incidental differences. In fact, this highlights a general 
challenge in ‘omic’ studies, in which a signal is easy to find, 
but very low P values can often make it too easy to confuse 
causation and correlation, and discriminating between 
these two is crucial in the context of drug development.
By shedding light on disease‑associated genes and 
pathways, EST profiling began to shift the focus in drug 
discovery and development from alleviating symptoms 
to attacking the underlying mechanisms of disease. 
Furthermore, this approach substantially expanded 
the array of potential targets, in turn providing wide‑
spread optimism that genomics could help resolve the 
burgeoning pharmaceutical productivity crisis of the 
early 1990s6. Accordingly, the late 1990s and early 2000s 
saw a surge of partnerships between genomics firms 
that developed proprietary databases of expression 
data and pharmaceutical companies that had exper‑
tise and resources in drug development4,6,13. By 2001, 
pharmaceutical companies allocated nearly 60–70% of 
their discovery portfolios to drugs with novel targets14. 
Nevertheless, from 1991 to 2000, drugs based on novel 
targets had nearly a 40% lower portfolio retention rate 
compared with those with clinically validated targets14. 
Although numerous factors have been demonstrated 
to be at fault, one potential contributor was that early 
genomics transformed the bottleneck of the productivity 
crisis from target discovery to effective prioritization of 
numerous candidate targets. Given that the genomics 
leads were both plentiful and often of little direct value 
in terms of elucidating the biological functions of the 
targets6, there was no immediately available basis for pri‑
oritization. Consequently, from 1978 to 2002, there was 
a tenfold increase in research and development spend‑
ing, and this increase, paired with an inflated number 
of false positives and growing drug attrition rates, led 
to an overall continued decline in both pharmaceutical 
productivity and optimism in this approach15. Target 
validation, through either a robust genetic link between 
the target and the disease or a greater understanding 
of the role played by the target in the disease aetiology, 
improved the value of genetic information. For example, 
in the AstraZeneca portfolio from 2005 to 2010, targets 
with stronger validation of the biological role of the tar‑
get in human disease were less likely to fail in clinical 
development owing to a lack of efficacy16. Furthermore, 
a broad analysis identified an increased proportion of 
targets with direct genetic evidence as the development 
pipeline progresses through to approval17.
GWAS and drug discovery
The rising challenge of clinical trial failures led drug 
developers to seek information that better identified 
targets worth pursuing. This coincided with the publica‑
tion of the human genome sequence in 2003, followed 
by the characterization and arrangement of nearly three 
million single nucleotide polymorphisms (SNPs) into 
genome‑wide haplotype maps as part of the International 
HapMap project18, both of which provided the tools nec‑
essary to begin to understand the relationship between 
common human genomic variation and complex diseases. 
This was primarily accomplished through genome‑wide 
association studies (GWAS) — an unbiased and cost‑ 
effective approach to genotyping and comparing much of 
the common genomic variation of cohorts with particular 
diseases or traits to that of control populations. GWAS are 
grounded on the principle of linkage disequilibrium at 
a population level between common SNPs or ‘markers’ 
and disease‑causing variants. Markers that associate 
with the disease more often than expected indicate the 
presence of causal variants in the genomic vicinity of the 
associated variants, which, in theory, could be identified 
through additional genetic analyses, such as fine mapping 
or re‑sequencing.
From a drug discovery standpoint, identifying genetic 
determinants of common disease through GWAS pro‑
vided valuable knowledge about the genetic architecture 
of disease and potential pointers to underlying causative 
mechanisms and engendered the promise of discovering 
better candidate targets for common, complex diseases 
such as diabetes, cancer and autoimmune conditions19,20. 
From 2007 to 2012, nearly 2,000 significantly associated 
loci of complex diseases and traits were discovered, 
which translated to nearly 2,000 new potential pharma‑
cological leads21. Some of these loci were found to be 
associated with multiple diseases, such as SNPs discov‑
ered at the IL23R locus that were associated with several 
autoimmune conditions including psoriasis, inflam‑
matory bowel disease and ankylosing spondylitis22–25. 
These pleiotropic genes were of particular interest given 
their potential as targets for blockbuster drugs treat‑
ing several diseases19. Monoclonal antibodies targeting 
interleukin‑23 (IL‑23) and/or IL‑12 (along with the 
downstream cytokine IL‑17) for the treatment of vari‑
ous immune‑mediated conditions are already used clin‑
ically or are in clinical trials with promising results26–31 
(NCT02407223, NCT02204397 and NCT02698475).
Despite these efforts, the vast majority of well‑ 
accepted disease‑associated loci have yet to be biolog‑
ically explained, which has hindered the widespread 
implementation of GWAS findings in drug discovery 
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pipelines. GWAS data often fail to uncover causal var‑
iants and, in many cases, even fail to implicate specific 
genes. GWAS findings often implicate numerous can‑
didate genomic regions, which can include nearly all 
the genes close to the identified signal: as such, concrete 
guidance for drug development is limited. A hallmark 
example involves the FTO locus, in which multiple 
intronic SNPs within the gene encoding FTO (α‑keto‑
glutarate‑dependent dioxygenase) were shown to be 
strongly enriched in individuals with increased body 
mass. This finding was highly significant and replicated 
across different ethnic populations and age groups 
with an overall estimated 1.2‑fold increase in the risk 
of obesity32–36. Although FTO has been the subject of 
intense investigation to determine its contribution to 
obesity, a solid causal link has yet to be established, and 
the roles of other genes under regulatory control of the 
FTO locus, such as IRX3 and IRX5, have recently been 
implicated37,38.
The challenge in making effective use of most GWAS 
findings in the context of drug development has been 
formally explained recently by Pritchard39 and colleagues 
in the form of their omnigenic model. They note that for 
many human traits and diseases, there are as many as 
100,000 contributing SNPs that are distributed through‑
out the genome. In the early days of GWAS, a similar 
explanation was proposed for the genetics of human 
height using a strictly orthogonal approach. Relying on 
the effect size distribution of height‑associated SNPs as 
a basis for estimating the full distribution of effect size 
for all height variants, including those that remained 
undiscovered, it was inferred that as many as 93,000 
independent variants would be required to account for 
the heritability of height40. To explain this observation, 
Pritchard and colleagues argue in their omnigenic model 
that these small‑effect ‘peripheral’ genes (theoretically 
any gene expressed in the disease‑relevant cell type) are 
part of such highly interconnected cellular networks 
that any single weak‑effect perturbation on peripheral 
genes could affect the regulation of strong‑effect ‘core’ 
disease genes (consistent with the ‘small‑world’ property 
of networks). The model suggests that the sum of these 
numerous small effects on core genes could substantially 
alter disease expression. In addition, although informa‑
tion on peripheral gene involvement from GWAS could 
be useful in determining individualized disease risks, 
drug discovery and development would instead clearly 
benefit far more from the firm identification and target‑
ing of the strong‑effect core genes. To the extent that this 
model is accurate, it provides a compelling explanation 
of why the vast majority of GWAS findings have had 
little relevance to drug discovery.
PCSK9: ‘nature’s gift’ to drug discovery
We can identify one final phase before the transition 
to precision medicine, which relies upon the use of 
genomics to identify gene variants that point directly to 
new targets for treating common conditions. The over‑
arching idea was that more successful preclinical models 
could be developed using these ‘experiments of nature’ 
for the initial target validation41. Recent technological 
advances have increased the efficacy and speed and 
reduced the cost of high‑throughput sequencing, which 
has improved our ability to characterize and interpret 
human genomic variation — particularly rare variation. 
By understanding the phenotypic effects of a spectrum 
of rare mutations ranging from loss‑of‑function to 
gain‑of‑function mutations within a single gene, genet‑
ics provides information on the putative efficacy and/or 
toxic effects resulting from the modulation of that par‑
ticular gene product in humans. This knowledge thereby 
builds confidence in the rationale for targeting that gene 
product for the treatment of a more common human 
disease, rather than relying on information gained from 
less predictive animal or cellular models. Although this 
approach still relies on genomics to directly inform drug 
development, it is distinct from precision medicine in 
that the choice of treatment does not take into account 
the patient’s underlying mechanism of disease.
The poster child for this approach is proprotein con‑
vertase subtilisin/kexin type 9 (PCSK9), a target for the 
treatment of high cholesterol. In 2003, gain‑of‑function 
mutations in PCSK9 were identified in French fami‑
lies with autosomal dominant hypercholesterolaemia, 
a condition associated with an increase in the risk of 
early‑ onset cardiovascular disease42. Loss‑of‑function 
mutations were also subsequently identified in associa‑
tion with both low plasma levels of low‑density lipopro‑
tein cholesterol (LDL‑C) in African American and white 
cohorts and an overall decreased risk of coronary events 
with no notable health problems43–46. Functional analyses 
demonstrated that PCSK9 is a hepatic secretory protein 
that can enter the circulation and bind to LDL receptors 
(the primary source for clearance of circulating choles‑
terol), ultimately mediating LDL receptor endo cytosis 
and subsequent degradation47,48. The combination of 
these genetic, phenotypic and molecular findings served 
as the basis for pursuing PCSK9 as a drug target with the 
rationale that PCSK9 inhibition would result in a sur‑
plus of available LDL receptors, thereby reducing plasma 
LDL‑C levels and lowering the risk of adverse cardiac 
events49. A series of clinical trials were conducted using 
humanized monoclonal antibodies against PCSK9 in 
treating populations of patients stratified based on cho‑
lesterol levels, cardiovascular disease risks, use of other 
lipid‑ modifying enzymes and duration of treatment, and 
the US Food and Drug Administration (FDA) has since 
approved two monoclonal antibodies (alirocumab and 
evolocumab) for the treatment of high cholesterol not 
adequately controlled by statins or diet49 (see Further 
information). These approvals were based largely on evi‑
dence demonstrating a significant reduction (36–60%) in 
LDL‑C following treatment. Additional trials evaluating 
the efficacy in preventing adverse cardiovascular events 
(such as cardiovascular death, myocardial infarction and 
stroke) are ongoing (NCT01624142, NCT01764633 and 
NCT01663402). Thus far, results from the FOURIER 
trial support a lower incidence of adverse cardiovascular 
events in patients with atherosclerotic cardiovascular dis‑
ease treated with evolocumab while on a statin therapy, 
with no apparent increase in other adverse outcomes such 
as new‑onset diabetes or neurocognitive side effects50.
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The promise of this approach in identifying and vali‑
dating drug targets with overall higher chances for success‑
ful clinical trial outcomes and lower drug attrition rates 
has seemingly revived the excitement for genetics in drug 
discovery41,51,52. In the past few years, new partnerships 
and initiatives among the pharmaceutical industry have 
been established, at least partly in an effort to carry out 
larger, systematic hunts for these ‘experiments of nature’ 
through genome sequencing and extreme phenotyping 
of large patient populations. In 2012, Amgen acquired 
the Iceland‑based genomics company deCODE and have 
since published a set of nearly 7,000 rare loss‑of‑ function 
mutations in a large Icelandic population for use in their 
drug discovery pipeline53. Regeneron Pharmaceuticals 
has partnered with Geisinger Health System, together 
forming the DiscovEHR collaboration, with the aim of 
performing genomic analyses on 250,000 patients and 
correlating these data with patients’ clinical records. 
This initiative has already revealed a role for ANGPTL4 
in coronary artery disease, as loss‑of‑ function mutations 
are associated with good lipid profiles and a lower risk 
of coronary artery disease54. These findings mirror the 
effects of monoclonal antibodies in animal models54, 
further supporting ANGPTL4 as a candidate drug tar‑
get. Although this overall approach to drug discovery is 
certainly compelling and has led to enthusiastic reviews, 
it remains unclear how many of these pointers human 
genomic variation will ultimately provide. With the nota‑
ble exceptions of drugs targeting sclerostin (encoded by 
SOST) and the α‑subunit of the voltage‑gated sodium 
channel protein type 9 Nav1.7 (encoded by SCN9A) 
(BOX 1), early attempts to utilize this approach have rarely 
resulted in new drugs being discovered and developed. 
Hence, it seems likely that such pointers to generally use‑
ful medicines, regardless of underlying causes of disease 
in individual patients, may be fairly rare.
Precision medicine and drug development
At its core, precision medicine embodies an effort to 
understand the underlying cause of disease in individ‑
ual patients. By definition, this opportunity in drug 
development is distinct from any of the earlier described 
phases. Once the underlying cause of a patient’s disease 
is identified, this information can then be used to gain 
new insights into the underlying basic biology and dis‑
ease pathogenesis, which will ultimately foster the discov‑
ery of treatments targeting the precise cause of disease. 
Development of the medicine will then be done for those 
patient populations most likely to benefit. Inevitably, this 
will result in a transition away from the production of 
‘one‑size‑fits‑all’ treatments towards targeted treatments 
that are more efficacious in small groups of patients. 
Driving the transition from a stochastic clinical practice 
model, precision medicine therapies will also require the 
co‑development of diagnostic tools to identify the optimal 
treatment for individual patients. In the rest of this section, 
we discuss developments in precision medicine along with 
the opportunities they present for drug development. We 
draw examples in particular from those therapeutic areas 
that are expected to advance most quickly towards a pre‑
cision medicine framework, including genetic disorders 
with a strong genetic component (particularly neurolog‑
ical diseases such as epilepsy) and cancer.
Cancer
The field of oncology has been a clear pioneer of pre‑
cision medicine. The move towards personalized ther‑
apies was likely in part due to the general cytotoxicity 
and severe side effects of existing ‘one‑size‑fits‑all’ cancer 
drugs along with the identification of associated tumour‑ 
specific vulnerabilities as potential drug targets. Classic 
chemotherapy agents comprise a broad spectrum of drugs 
with variable efficacies for different tumour types that 
often affect both cancerous and vulnerable healthy cells. 
Therapies can now be designed to more precisely target 
cancer cells through two primary methods: selectively 
disrupting pathways necessary for cancer cell survival 
or growth (pathway‑based targeted therapy), and artifi‑
cially modulating patients’ immune systems to generate 
a response against cancer cells (immunotherapy) (FIG. 1).
Targeted therapies. Pathway‑based targeted therapies 
rely on pre‑existing knowledge of the underlying biol‑
ogy of the specific tumour, with the overall objective of 
modulating an aberrant protein or pathway essential for 
cancer subsistence. Not only does this approach help 
Box 1 | Gene to drug: SOST and SCN9A
In the late 1990s, before the advent of next-generation sequencing, Brunkow and 
colleagues149 examined 22 families from an Afrikaner population in South Africa who 
had sclerosteosis, a rare, severe sclerosing skeletal dysplasia that results in massive 
bone overgrowth. Through genetic mapping and positional cloning, they identified 
mutations in a novel gene, SOST149. The product of SOST, sclerostin, is an inhibitor of 
the activity of osteoblasts, key bone-resorbing cells, and is produced in the bone by 
osteocytes150. Sclerostin was identified as a drug target for a potential anabolic 
treatment to restore lost bone. The monoclonal antibody romosozumab, which binds 
to sclerostin, was developed with the therapeutic intention of increasing bone 
formation151. Romosozumab increases bone formation and decreases bone 
resorption152, and phase III data in postmenopausal women demonstrated a 73% 
lower risk of spine fracture over 12 months compared with placebo153. If approved, 
romosozumab would be the first in a new class of anabolic therapies for osteoporosis 
and would build confidence in the use of genomics to identify new drug targets and 
thus the promise of precision medicine beyond oncology. Following a complete 
response letter for the biologics licence application in July 2017, two further phase III 
romosozumab studies have been included in a resubmission to the FDA (see Further 
information).
Another promising example of a human-validated target is the discovery of the role 
of SCN9A in pain. In 2004, a group of investigators published results from a linkage 
analysis performed on a Chinese family with a rare autosomal dominant form of 
erythromelalgia154. This analysis led to the identification of a missense mutation in 
SCN9A, which encodes the α-subunit of the voltage-gated sodium channel Nav1.7. 
This study also identified a second missense mutation in SCN9A in a sporadic case of 
erythromelalgia. Subsequently, linkage analysis of a cohort of 11 families and 2 sporadic 
cases of paroxysmal extreme pain disorder reported 8 missense mutations in SCN9A155. 
Functional analyses of three of these mutations demonstrated a persistent sodium 
current, suggestive of gain-of-function effects. Interestingly, a separate study found 
three different homozygous null mutations in SCN9A in three consanguineous families 
with congenital indifference to pain, a condition characterized by the absence of 
nociception156. Single nucleotide polymorphisms in SCN9A have also been suggested to 
alter pain perception in the general population157,158. Following these discoveries, there 
has been a push to develop inhibitors and modulators of Nav1.7 for the treatment of 
pain. Drugs including raxatrigine and funapide are currently in phase II/III clinical trials 
(NCT02935608 and NCT02365636).
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spare healthy cells, it also promotes the substratifica‑
tion of tumour types, allowing treatments to be tailored 
correspondingly. The small‑molecule kinase inhibitor 
imatinib (Gleevec; Novartis), which is used to target the 
constitutively active protein product of the BCR–ABL 
fusion gene in chronic myelogenous leukaemia (CML) 
and gain‑of‑function mutations in the genes encoding 
mast/stem cell growth factor receptor KIT (also known 
as SCFR) or platelet‑derived growth factor receptor‑α 
(PDGFRα) in gastrointestinal stromal tumours (GISTs), 
served as one of the first clinical success stories for tar‑
geted cancer treatment. Whereas previous CML treat‑
ments, such as interferon‑α and allogeneic bone marrow 
transplantation, had low efficacy with substantial risks 
of morbidity and mortality55, Gleevec demonstrated 
complete responses in >90% of patients with interferon‑ 
resistant, chronic‑phase CML and in 75–90% of those 
with advanced GISTs56–58.
Drugs targeting other oncogenic kinases, including 
receptor tyrosine‑protein kinase erbB‑2 (HER2), BRAF 
or epidermal growth factor receptor (EGFR), have also 
demonstrated clinical responses in specific groups of 
patients56. Overexpression of HER2 is associated with 
a particularly aggressive form of breast cancer with 
overall poor prognosis. Treatment with trastuzumab 
(Herceptin; Genentech/Roche), a monoclonal anti‑
body that targets HER2, has shown a significant sur‑
vival benefit, with a 20% reduction in the risk of death 
at 30 months59. Activating mutations in BRAF, which 
are present in nearly half of all melanomas, are now 
Figure 1 | Precision therapy approaches in oncology. Precision therapies in 
cancer generally use two primary approaches: pathway-based targeted 
therapies and immunotherapies. For both approaches, access to tumour cells 
(through resection or biopsy of solid tumours, or blood sample for 
haematological cancers or circulating tumour cells) enables an investigation 
into tumour biomarkers using various tools, including companion diagnostics, 
next-generation sequencing, gene expression profiling and proteomics. 
For pathway-based targeted treatments, these biomarker studies are used 
for the discovery of key drivers and master regulators of networks and 
pathways that promote tumour proliferation and survival. US Food and Drug 
Administration (FDA)-approved drugs that target these particular pathways 
can then be identified, or opportunities for drug repurposing or development 
may be explored for new targets. Alternatively, precision immunotherapy 
approaches include cell-based therapies, vaccines and biologics. Autologous 
(patient-derived) tumour cell and dendritic cell vaccines are generated from 
extracted tumours and dendritic cells, respectively. Extracted tumours may 
also be used to isolate tumour- infiltrating lymphocytes (TILs). This, in 
combination with tumour antigen data obtained from biomarker studies, has 
given rise to TIL-based adoptive cell therapies and chimeric antigen receptor 
(CAR) T cell therapies. The identification of tumour antigens, such as 
tumour-specific neoantigens or tumour-associated antigens, is also important 
for other personalized therapies, including antigen vaccines, programmed 
cell death 1 ligand 1 (PDL1)–PD1 checkpoint inhibitors and other monoclonal 
antibodies aimed at targeting tumour-promoting antigens.
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targeted by the mutation‑selective inhibitors vemu‑
rafenib and dabrafenib. Both inhibitors have shown sub‑
stantially increased objective response rates compared 
with standard chemotherapy60,61. Small‑molecule and 
monoclonal antibody inhibitors that target EGFR have 
since become first‑line therapy for EGFR‑mutant non‑
small‑cell lung cancer (NSCLC) with overall improved 
objective response rates, better quality of life and longer 
progression‑free survival62–67. Importantly, this move to 
a precision medicine era in oncology has necessitated 
growth in the development of companion diagnostics to 
enable the right patient to be matched with these targeted 
medicines, as illustrated by the increase in FDA approvals 
of such diagnostics (TABLE 1).
Table 1 | Companion diagnostics currently approved by the FDA
Drug (brand name) Indication Biomarker Technology (year PMA 
first approved)
Afatinib (Gilotrif) NSCLC EGFR exon 19 deletions or 
exon 21 (L858R) substitution 
mutations
RT-PCR (2013)
Cetuximab (Erbitux) and 
panitumumab (Vectibix)
Colorectal cancer KRAS mutation negative or 
KRAS and NRAS* mutation 
negative
IHC (2004); RT-PCR 
(2012); NGS* (2017)
Crizotinib (Xalkori) NSCLC ALK overexpression or gene 
fusion
FISH (2011); IHC (2015)
Crizotinib (Xalkori) NSCLC ROS1 fusions NGS (2017)
Dabrafenib (Tafinlar) and 
trametinib (Mekinist)
Melanoma BRAFV600E or BRAFV600K mutations RT-PCR (2013); NGS 
(2017)
Dabrafenib (Tafinlar) and 
trametinib (Mekinist)




Liver iron concentration MRI (2013)
Enasidenib (Idhifa) AML IDH2 mutation positive PCR (2017)
Erlotinib (Tarceva) NSCLC EGFR exon 19 deletions or 
exon 21 (L858R) substitution 
mutations
RT-PCR (2013)
Gefitinib (Iressa) NSCLC EGFR exon 19 deletions or 
exon 21 (L858R) substitution 
mutations
RT-PCR (2015); NGS 
(2017)
Imatinib (Gleevec) Gastrointestinal stromal 
tumours
KIT expression IHC (2005)
Midostaurin (Rydapt) AML FLT3 mutation-positive PCR (2017)
Olaparib (Lynparza) Ovarian cancer BRCA1 or BRCA2 mutation PCR and Sanger 
sequencing (2014)
Osimertinib (Tagrisso) NSCLC EGFRT790M mutations RT-PCR (2016)
Pembrolizumab (Keytruda) NSCLC PDL1 expression IHC (2016)
Rucaparib (Rubraca) Ovarian cancer BRCA1 or BRCA2 mutation NGS (2016)
Trastuzumab (Herceptin) Breast cancer HER2 expression and/or ERBB2 
amplification
ISH (2011); CISH (2011); 
IHC (2012)
Trastuzumab (Herceptin); 
pertuzumab (Perjeta) and 
ado-trastuzumab emtansine 
(Kadcyla)
Breast cancer, gastric 
cancer
ERBB2 amplification FISH (2005); ICC (1998)
Vemurafenib (Zelboraf) Melanoma BRAFV600E mutations RT-PCR (2011)
Venetoclax (Venclexta) B cell chronic 
lymphocytic leukaemia
Deletion of 17p (which contains 
TP53)
FISH (2016)
All FDA-cleared or FDA-approved companion diagnostic devices on 14 August 2017, not including humanitarian device 
exemptions. The FDA describes a companion diagnostic as an “in vitro diagnostic device that provides information that is 
essential for the safe and efficacious use of the corresponding therapeutic product” (see the FDA website). Thus, the number of 
approvals of companion diagnostics is a measure of progress in the approval of new precision medicines. Notably, all but two 
companion diagnostics were approved after 2005, and all but one were developed for oncology indications. AML, acute 
myelogenous leukaemia; CISH, chromogenic in situ hybridization; EGFR, epidermal growth factor receptor; FISH, fluorescence 
in situ hybridization; HER2, receptor tyrosine-protein kinase erbB-2; IHC, immunohistochemistry; ISH, in situ hybridization; KIT, 
mast/stem cell growth factor receptor KIT; MRI, magnetic resonance imaging; NSCLC, non-small-cell lung cancer; NGS, 
next-generation sequencing; PDL1, programmed cell death 1 ligand 1; PMA, premarket approval application; RT-PCR, real-time 
PCR. *Panitumumab only.
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Precision medicine extends beyond kinase inhibitors: 
treatment with poly(ADP‑ribose) polymerase (PARP) 
inhibitors results in the synthetic lethality of tumour 
cells containing mutations in BRCA1 or BRCA2, which 
has provided a new therapy option for ovarian cancer68. 
Specifically, the defect in homologous recombination 
repair (HRR) caused by loss‑of‑function mutations in 
BRCA1 or BRCA2 renders the tumour cells sensitive to 
PARP inhibition, ultimately resulting in tumour cell 
death69. Interestingly, PARP inhibitors are efficacious for 
BRCA‑mutated ovarian tumours70–72, but they may also 
prove beneficial for other subgroups of patients without 
identifiable germline BRCA mutations but with similar 
defects in HRR (also known as ‘BRCAness’). Clinical 
trials evaluating the efficacy of PARP inhibitors for 
the treatment of other tumour types containing HRR 
mutations are now under way (NCT01682772 and 
NCT01585805), and the PARP inhibitor olaparib has 
been granted breakthrough therapy designation by the 
FDA for the treatment of metastatic castration‑resistant 
prostate cancer with mutations in BRCA1, BRCA2 or 
ATM (see Further information).
Although a pathway‑based approach was broadly 
thought to become the primary approach to treating 
cancer, this concept has been challenged by the emer‑
gence of acquired drug resistance in patients — a phe‑
nomenon primarily resulting from ancillary mutations 
in the targeted protein or compensatory modifications 
to other components of the same or parallel pathways. 
Advances in understanding tumour resistance and the 
key mutations responsible have led to the development 
of the next generation of kinase inhibitors and a com‑
binatorial approach to targeted therapies. The power 
of precision medicine to drive drug development is 
demonstrated by osimertinib, a third‑generation EGFR 
tyrosine kinase inhibitor designed to target the T790M 
mutation that provides resistance to other EGFR inhib‑
itors, which was approved by the FDA less than 2 years 
and 9 months after the first dose was given to a patient 
in a clinical study73.
Immunotherapies. Decades of progress in our under‑
standing of tumour immunology have recently propelled 
immunotherapy to the forefront of cancer treatments. 
Despite the capacity of the immune system to detect 
and eliminate cancer cells, intrinsic tumour cell and 
tumour microenvironmental changes can augment 
immune evasion, which enables tumour progression. 
Immunotherapies aim to harness and reinforce the 
inherent power of the cancer–immunity cycle (BOX 2) 
through a multitude of innovative methods, including 
the stimulation of immune cells to boost and strengthen 
the host response — through treatments such as can‑
cer vaccines and adoptive T cell therapy (ACT) — or 
by counteracting immunosuppression, for example, 
through immune checkpoint blockades74,75 (FIG. 1).
Cancer vaccines deliver cancer cell antigens for sub‑
sequent uptake by antigen‑presenting cells and pres‑
entation to future cytotoxic T cells. Work in this field 
initially focused on developing vaccines to prime the 
immune system to recognize cancer germline antigens 
or antigens differentially overexpressed in tumour cells. 
Although discouraging clinical data have historically 
plagued this approach76, growing evidence supporting 
the targeting of tumour‑specific neoantigens by T cells 
has revitalized interest in therapeutic vaccines76–80. These 
neoantigens, which are the product of mutations that 
accumulate throughout oncogenesis, can serve to refine 
the capability of the immune system to distinguish self 
from non‑self 81, thereby fostering the induction of a 
potent anticancer immune response while sparing nor‑
mal, healthy cells. Various clinical trials are now under 
way to evaluate personalized vaccines for the treatment 
of cancers including melanoma, pancreatic cancer 
and glioblastoma (NCT01970358, NCT03122106 and 
NCT02510950). Currently, the selection of neoanti‑
gens that are the most immunogenic and hence best to 
include in the vaccine remains a key challenge.
ACT is yet another new and encouraging immuno‑
therapeutic approach that takes advantage of the 
tumour‑targeting nature of T  cells. For ACT of 
tumour‑infiltrating lymphocytes (TILs), activated T cells 
are extracted from tumour samples, expanded ex vivo 
and subsequently infused back into the patient. This 
approach, coupled with prior lymphodepletion, led to a 
breakthrough in the treatment of melanoma, with a clin‑
ical response rate of approximately 50–70% in patients 
with advanced melanoma82–84. Clinical trials are cur‑
rently in progress for TIL‑based treatment of melanoma 
and other metastatic solid tumours, including ovarian, 
renal cell, nasopharyngeal and hepatocellular carcino‑
mas (NCT02360579, NCT02482090, NCT02926053 and 
NCT01174121). Notably, ACT of TILs predominantly 
targeting tumour‑specific neoantigens has also been 
associated with long‑lasting tumour regression in cases 
of melanoma and has been described in a case of meta‑
static cholangiocarcinoma85,86.
Another burgeoning ACT approach is the genetic 
modification of patients’ own T cells to express receptors 
that not only recognize tumour‑associated antigens but 
also foster T cell activation, expansion and persistence. 
This form of treatment, also referred to as chimeric 
antigen receptor (CAR) T cell therapy, has shown the 
most benefit thus far in patients with B cell malignan‑
cies through the targeting of the tumour‑associated B 
lymphocyte antigen CD19 (REF. 87). Additional phase I 
Box 2 | The cancer–immunity cycle
As reviewed by Chen and Mellman89, a spontaneous anticancer immune response — 
coined the cancer–immunity cycle — is initially generated from the uptake of cancer 
cell antigens (such as debris from cancer cell death) by antigen-presenting cells (APCs, 
predominantly dendritic cells). These antigens may subsequently bind to the major 
histocompatibility complex, which presents antigens on the surface of APCs and 
activates T cells by binding to cognate T cell receptors. These activated killer T cells 
are then capable of infiltrating tumour beds (thus becoming tumour-infiltrating 
lymphocytes), where they target and destroy tumour cells. Tumour cell death results 
in more antigenic debris available for uptake by APCs, thus further propagating  
the immune response. Despite the potential potency of this anticancer cycle, the 
adaptability and evolution of tumour cells, along with natural host immune checkpoint 
mechanisms, can lead to an impaired and dampened immune response, causing tumour 
progression and metastasis.
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and II clinical trials are currently evaluating CAR T cells 
that target various tumour‑associated antigens (such 
as epithelial cell adhesion molecule (EPCAM), HER2, 
glypican 3 (GPC3), GD2 and mucin 1 (MUC1)) for the 
treatment of numerous other tumour types, such as 
breast, ovarian, gastric, brain, colorectal, nasopharyn‑
geal, oesophageal, pancreatic, prostate, lung and hepatic 
cancers (NCT02723942, NCT03013712, NCT02713984 
and NCT02617134).
Immunosuppression within the tumour micro‑
environment, resulting from the activation of immune 
checkpoints, is another obstacle in cancer treatment. 
Under normal circumstances, these checkpoint mech‑
anisms function to prevent an excessive immune 
response; however, for tumour cells, exploitation 
of checkpoints promotes immune evasion, such as 
through the T cell negative regulators programmed 
cell death protein 1 (PD1)–programmed cell death 1 
ligand 1 (PDL1) and cytotoxic T lymphocyte antigen 4 
(CTLA4)88,89. Inhibition of the PD1–PDL1 interaction 
or the CTLA4 pathway using monoclonal antibodies has 
shown significant and long‑lasting clinical responses in 
addition to an acceptable safety profile and improved 
tolerability versus chemotherapy, and these antibodies 
are now a dominant class of therapeutic90–95. Recent 
impressive long‑term aggregate data for advanced 
NSCLC demonstrated 2‑year survival and 5‑year sur‑
vival of up to 37% and 16%, respectively, compared with 
14.5% and 4.9% based on standard treatment96 (see 
Further information). Across many indications, includ‑
ing NSCLC, head and neck squamous cell carcinoma 
and urothelial bladder cancer, tumour expression of 
PDL1 identifies those patients more likely to respond to 
monotherapy94,96–100; however, the complexity of tumour 
biology will ultimately determine the future utility of 
immune therapy in combination strategies with other 
therapeutic modalities.
As discussed by Vanneman and Dranoff 101, the 
benefits and limitations of pathway‑based targeted 
treatments and immunotherapy imply potential syn‑
ergistic roles in cancer therapy. Although targeted 
therapies have been associated with the development 
of acquired tumour resistance, they are effective at 
inducing rapid tumour regression in defined subsets 
of patients. Immunotherapy has also demonstrated 
successful clinical responses with the added benefit of 
long‑term immune memory of tumour cells, yet these 
responses typically occur in a fraction of patients — for 
example, approximately 40–60% of individuals receiv‑
ing both therapies targeting CTLA4 and those target‑
ing PD1 or PDL1 for metastatic melanoma and renal 
cell carcinoma respond102,103 — likely owing in part 
to untargeted tumour‑mediated immunosuppressive 
mechanisms. Evidence suggests, however, that targeted 
therapies can help to alleviate these immunosuppressive 
effects104, and numerous clinical studies are now under 
way evaluating the efficacy of combined targeted ther‑
apies and immunotherapies. For example, clinical trials 
of immune checkpoint inhibitors in combination with 
mitogen‑activated protein kinase (MAPK) and vascular 
endothelial growth factor (VEGF) pathway inhibitors 
for treatment of metastatic melanoma, NSCLC and 
renal cell carcinoma are planned or in progress, with the 
prospect that MAPK and VEGF pathway inhibition will 
not only directly affect tumour cell growth and angio‑
genesis but also affect tumour antigenicity and lym‑
phocyte infiltration, thereby complementing immune 
checkpoint therapy105 (NCT02027961, NCT02130466 
and NCT02724878).
Clinical trial design. The transition to precision med‑
icine approaches in cancer has also sparked a much‑
needed shift in the design and implementation of 
clinical trials. In order for targeted cancer therapies to 
be adequately assessed for their efficacy, they need to be 
tested in the appropriate group of patients: those who are 
predicted to respond. Basket trials, for instance, evalu‑
ate the effectiveness of a drug based on its underlying 
mode of action rather than strictly on the specific form 
of cancer it was intended to treat106. For example, the 
ongoing CREATE trial evaluates the use of crizotinib 
in treating patients with a variety of tumour types, all 
with targetable variants in the hepatocyte growth factor 
(HGF) receptor (also known as MET) and/or AKT path‑
ways (NCT01524926). Alternatively, in umbrella trials, 
genomically guided targeted treatments are provided to 
groups of patients with the same cancer type, and out‑
comes are compared to controls receiving only standard 
therapy. The ALCHEMIST trial, for instance, tests the 
effectiveness of a variety of therapies that target either 
EGFR‑driven or ALK tyrosine kinase receptor‑driven 
early‑stage NSCLC following completion of standard 
therapy (NCT02194738).
An even more personalized approach to clinical trials 
are the n‑of‑1 trials, which aim to treat patients individ‑
ually, yet in a controlled and consistent manner, in an 
effort to determine whether the patient is a responder 
or non‑responder to targeted therapy, with the long‑
term goal of aggregating these results in ways that 
could inform how to treat other subsets of patients107. 
An n‑of‑1 clinical trial that is currently in process at 
Columbia University Medical Center aims to recruit 260 
patients with various tumour types to assess the effec‑
tiveness of targeting the master regulators that drive 
cancer formation and progression in single patients108. 
These master regulators are at ‘bottlenecks’: points at 
which tumour‑driving cellular networks converge on 
one or a few proteins that could serve as an Achilles heel 
for tumour cells109. Data from whole‑genome sequenc‑
ing and RNA transcriptome analysis will be evaluated to 
find master regulators that are known targets of drugs 
that are either FDA‑approved or at advanced stages 
of clinical testing. Candidate compounds will then be 
functionally tested using the patient’s tumour sample 
to determine the effects on tumour growth and survival.
Highly genetic conditions
Large‑scale exome and genome sequencing efforts and 
improvements in variant interpretation are resulting 
in the fast‑paced discovery of disease‑associated genes 
and pathogenic mutations. Thus, precision medicine 
may soon become a reality for many highly genetic 
R E V I E W S














































conditions. A clear illustration of this paradigm is the 
targeted treatment of genetically identified causes of dis‑
ease. Disease‑causing and disease‑contributing genetic 
variants provide a window into underlying pathological 
mechanisms and can thus serve as a starting point for 
identifying treatments that act upon these mechanisms. 
In fact, precision medicine‑based therapies, such as 
those that replace deficient proteins, directly target 
underlying molecular defects and disease‑associated 
pathways or interfere with the expression of disease‑ 
relevant genes, have already received FDA approval and 
are currently in clinical use — we highlight a few of these 
therapies below. We also draw upon recent examples 
of precision medicine efforts in genetically explained 
epilepsies as an illustration of our expectations for the 
direction of the field.
Molecular replacement and pathway modification. 
Unsurprisingly, initial precision medicine efforts have 
focused largely on common Mendelian diseases, likely 
owing in part to the increasing knowledge of impli‑
cated genes, variant classification and the functional 
effects of pathogenic mutations. Classic early examples 
include diet modifications for certain inborn errors of 
metabolism, such as phenylketonuria (PKU), a dis order 
caused by the toxic build‑up of phenylalanine in the 
brain due to a deficiency in the enzyme phenylalanine 
hydroxylase. Low phenylalanine diets instituted from 
birth, which have been the standard of care for PKU for 
50 years, are imperative for normal brain development 
and function. Another success story has been enzyme 
replacement therapy for various lysosomal storage dis‑
orders, a group of nearly 50 disorders caused primarily 
by a deficiency in lysosomal enzymes. The discovery 
that lysosomal enzymes are targeted to lysosomes by 
the mannose‑6‑phosphate receptor pathway110 set the 
stage for the use of exogenously supplied, functional 
lysosomal enzymes as a form of treatment111. Enzyme 
replacement therapy is now used clinically for the treat‑
ment of several lysosomal storage disorders, such as 
Gaucher disease, Fabry disease, Hunter syndrome and 
Pompe disease.
More recently, drugs targeting mutant proteins 
directly have engendered interest in conditions with his‑
torically limited treatment options. For example, in 2006, 
Vertex Pharmaceuticals entered a collaboration with 
Cystic Fibrosis Foundation Therapeutics for the accel‑
erated development of ivacaftor, a drug that has since 
been approved by the FDA for the treatment of cystic 
fibrosis in patients with mutations in CFTR that result 
in a glycine to aspartate substitution at residue 551 in 
the protein product, cystic fibrosis transmembrane con‑
ductance regulator (CFTR) (see Further information). 
Ivacaftor is a CFTR channel potentiator that functions by 
stabilizing the open state of the channel, thus targeting 
the underlying CFTR gating defect associated with the 
G551D mutation112.
Molecular chaperones have been used to directly 
target the underlying molecular defect in Fabry dis‑
ease, a multisystemic X‑linked lysosomal storage 
disorder caused by a functional deficiency in the 
lysosomal enzyme α‑galactosidase A (αGALA, encoded 
by GLA). Two recent phase III studies (the FACETS and 
ATTRACT studies, NCT00925301 and NCT01218659, 
respectively) evaluating the safety and efficacy of the 
chaperone drug migalastat, which targets certain GLA 
mutations that affect enzyme conformation, have 
demonstrated favourable clinical outcomes for patients 
carrying these mutations compared with placebo or 
enzyme replacement therapy113,114. Migalastat has since 
been approved for the treatment of Fabry disease by the 
European Medicines Agency, and a new drug application 
will be submitted to the FDA by the end of this year (see 
Further information).
Targeting disease‑associated pathways has also 
proved successful, such as targeting the mechanistic 
target of rapamycin (mTOR) pathway for the treatment 
of tuberous sclerosis complex (TSC). Everolimus, an 
mTOR complex 1 (mTORC1) inhibitor, received FDA 
approval in 2012 for the treatment of patients with 
TSC‑related subependymal giant cell astrocytomas and 
renal angiomyolipomas. Results of a recent phase III 
trial (the EXIST‑3 trial) evaluating the use of everoli‑
mus as adjunctive treatment for TSC‑related intractable 
epilepsy also revealed a significant decrease in seizure 
frequency compared with the placebo group115. As such, 
everolimus may be considered for the treatment of other 
genetic epilepsies that have mTORC1 activation, such as 
DEPDC5‑related epilepsy.
Most targeted drugs affect either the mutant pro‑
tein product or associated pathway, but some drugs 
have been designed to interfere at the level of gene 
expression. For example, the antisense oligonucleotide 
(ASO) drug nusinersen (Spinraza; Biogen) was granted 
accelerated approval by the FDA in December 2016 for 
the treatment of spinal muscular atrophy (SMA) (see 
Further information). Nusinersen aims to rescue the 
disease‑causing impaired function of SMN1 by promot‑
ing the production of a stable form of survival motor 
neuron protein (SMN) from the nearly identical SMN2. 
A specific C to T change in SMN2 relative to SMN1 
causes exon 7 to be spliced out in SMN2, which leads to 
an unstable protein product. This process is targeted and 
blocked by nusinersen, leading to production of a full‑
length, functional SMN protein from SMN2116. Interim 
analysis of a phase III clinical trial of infantile‑onset 
SMA demonstrated improved motor milestones in 40% 
of patients receiving treatment, whereas no improve‑
ment was observed in sham‑treated patients (see Further 
information). This capacity of ASOs to modulate gene 
expression, even in the central nervous system, has gen‑
erated enthusiasm for this approach in the treatment of 
other diseases of the central nervous system117. Phase I 
and II clinical trials evaluating the safety and tolerability 
of ASOs for treatment of adults with early‑manifest 
Huntington disease are also ongoing (NCT02519036).
Epilepsy. With rapid gene discovery and good in vitro 
and animal models, epilepsy is arguably uniquely posi‑
tioned to serve as a model for precision medicine for 
genetic conditions (FIG. 2). Epilepsy is a common neuro‑
logical disorder characterized by recurrent, spontaneous 
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seizures, ranging in frequency and severity, stemming 
from neuronal hyperexcitability and neuronal network 
hypersynchrony. Epilepsy is extremely heterogeneous in 
both clinical presentation and aetiology, thereby com‑
plicating seizure prevention and treatment. Even with 
more than 24 anti‑epileptic drugs available on the mar‑
ket, seizures cannot be controlled in nearly one‑third of 
patients118,119. Recent, large‑scale sequencing studies of 
the rare and more severe group of epilepsy disorders, the 
epileptic encephalopathies, have made major progress in 
uncovering new causative genes120,121. These include, but 
are not limited to, genes involved in ion channel activ‑
ity, synaptic transmission, cell signalling and growth. In 
addition, various model systems and electrophysiology 
assays are available that can assess the functional con‑
sequences of these disease‑associated mutations and, 
importantly, can also serve as platforms for drug screen‑
ing122,123. Armed with these tools, we can now take the 
causative epilepsy mutations of individual patients, rap‑
idly assess their functional effects using the plethora of 
model systems and assays available and screen for drugs 
that alleviate these effects (FIG. 2).
Recent research evaluating gain‑of‑function muta‑
tions in KCNT1, which encodes potassium channel 
subfamily T member 1, in association with epilepsy of 
infancy with migrating focal seizures and autosomal 
dominant nocturnal frontal lobe epilepsy has revealed 
that quinidine, a drug approved for the treatment of 
cardiac arrhythmias, could reversibly block KCNT1 
channels in in vitro systems124. Subsequent functional 
analyses of these epilepsy‑associated KCNT1 muta‑
tions using patch clamp analysis of a heterologous 
expression system (Xenopus laevis oocytes) confirmed 
a gain‑of‑function effect on current amplitude that was 
mitigated by quinidine125. Three patients with KCNT1 
mutations have since been clinically treated with quini‑
dine and reported in the literature, two of whom showed 
partial responses with a reduction in seizure frequency, 
and one who showed no response126,127. Although this 
particular targeted therapy does not seem to work well 
and is limited by its therapeutic index, this example still 
serves to illustrate the paradigm. This experience with 
KCNT1 also highlights the clear necessity for careful 
and objective clinical evaluation of candidate targeted 
treatments.
Another epilepsy example has been the use of 
memantine for treatment of GRIN2A‑related epileptic 
encephalopathy. Analysis of a single child’s GRIN2A 
mutation via patch clamp in a heterologous expression 
system (X. laevis oocytes) identified a gain‑of‑function 
effect with increased N‑methyl‑d‑aspartic acid recep‑
tor (NMDAR) activity128. Subsequent screening of an 
NMDAR antagonist library using this system revealed 
substantial inhibition of NMDAR by memantine, a drug 
previously demonstrated to have anticonvulsive effects 
in animal models of epilepsy but traditionally used in 
the treatment of Alzheimer disease. The use of meman‑
tine as an adjuvant therapy for this patient was reported 
to result in a reduction in seizure burden and a subse‑
quent decrease in the number of seizure medications 
needed. Memantine has also recently demonstrated 
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Figure 2 | Precision medicine for highly genetic diseases — epileptic 
encephalopathy as a model. A patient with epileptic encephalopathy can undergo 
genetic testing, including screening of an epilepsy gene panel or whole-exome 
sequencing for detection of single nucleotide variants, or microarray analysis for 
identification of copy number variants (CNVs) (right panel). Novel variants are 
interpreted using existing variant annotation tools and gene-level intolerance scores 
to determine likely pathogenicity. Patient registries have been established to house 
the data on disease-causing mutations and their associated phenotypes for future 
diagnostic efforts. Advances in gene-editing technologies have revolutionized the 
ability to generate functional models of pathogenic variants (bottom panel). In vivo 
modelling of whole organisms and in vitro modelling of neural networks along with 
individual neurons (derived from mouse or human induced pluripotent stem cells) and 
heterologous cell models can be thoroughly evaluated for pro-epileptic states using a 
variety of electrophysiological platforms, including electroencephalography, 
electroconvulsive threshold studies, multielectrode arrays and patch–clamp studies. 
Additional molecular and cellular studies, such as those assessing protein–protein 
interactions, protein localization or gene expression, can also be performed to further 
dissect disease pathogenesis and identify potential drug targets. These drug targets can 
be used as the basis for drug repositioning or drug development efforts (left panel). The 
efficacy of candidate compounds can then be tested using the previously established 
electrophysiological screening platforms. Compounds that are already US Food and 
Drug Administration (FDA)-approved and demonstrate amelioration of the disease 
phenotype in functional models may be considered for use in the patient under the care 
and surveillance of their physician. Efforts in epilepsy precision medicine have been 
thoroughly reviewed by the EpiPM Consortium122. NME, new molecular entity; SUDEP, 
Sudden Unexplained Death in Epilepsy.
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therapeutic effects in two children with gain‑of‑func‑
tion GRIN2D mutations, with an overall mild to mod‑
erate improvement in seizures noted129.
Thus far, it has proven easier to target gain‑of‑ function 
mutations through the use of inhibitors, but there is some 
promise for targeting loss‑of‑ function or dominant‑ 
negative mutations. For instance, KCNQ2‑related epi‑
leptic encephalopathy has recently been targeted with 
retigabine (also known as ezogabine), a potassium 
channel activator. KCNQ2, which encodes a subunit of 
the voltage‑gated potassium channel KV7.2, functions to 
modulate neuronal excitability130. Investigation of epilep‑
tic encephalopathy‑ associated mutations via patch clamp 
analysis of the X. laevis oocyte heterologous expression 
system revealed loss‑of‑ function and dominant‑negative 
effects on KV7.2 channel activity131. Additional in vitro 
and mouse in vivo studies found that treatment with reti‑
gabine ameliorates the effects of these dominant‑negative 
mutations and can attenuate seizure activity in mouse 
models132,133. A small retrospective study of 11 children 
with KCNQ2‑related epileptic encephalopathy treated 
with retigabine found that 3 of 4 patients treated before 
6 months of age had seizure improvement, whereas clin‑
ical response was less impressive for patients treated after 
6 months, with only 2 out of 7 showing improvement134.
Although a diagnosis of epilepsy conveys no infor‑
mation about the underlying mechanism of disease, 
identifying and uncovering the functional effects of a 
causal mutation suggests potential therapies. Precision 
medicine for epilepsy remains in its infancy, but these 
examples serve to illustrate how the paradigm is evolv‑
ing. As this work progresses, we envision that the 
targeted treatments will become increasingly more 
effective. For instance, it is clear that the effectiveness of 
quinidine for the treatment of KCNT1‑related epilepsy 
is restricted by dose‑ limiting cardiotoxicity. Yet, it is also 
clear that, using this same paradigm, it could be possible 
to identify more potent inhibitors as targeted treatments 
for this disease.
Outlook
It remains unclear how generalizable this precision 
medicine approach will be for other diseases — espe‑
cially those in which a single responsible and strongly 
contributing genetic mutation is found in only a small 
number of individuals. Three factors, however, suggest 
that precision medicine will eventually reach multiple 
areas of medicine. First, for relatively common diseases 
and traits that are traditionally considered to be com‑
plex, there are now many examples of cases influenced 
by rare, strongly acting mutations. For instance, genes 
initially identified to be associated with the more severe 
and devastating epilepsies are also clearly implicated in 
more common epilepsies, such as genetic generalized 
epilepsy or the non‑lesional focal epilepsies135. This has 
also been demonstrated for other complex diseases, 
including autism, congenital heart disease, idiopathic 
pulmonary fibrosis and immunodeficiencies, as well 
as quantitative traits, including height, lipid levels and 
blood pressure136–146. Second, there may be scope for 
precision medicine approaches in other conditions 
in which there is genetic heterogeneity, but pathway 
homogeneity. For example, there are multiple genes 
altered in patients with amyotrophic lateral sclerosis, 
including TBK1, OPTN and SQSTM1, that seem to act 
at similar stages in the autophagy pathway147. We there‑
fore find it plausible that targeted treatments developed 
for specific genetically defined conditions, such as for 
patients with TBK1 mutations, may be useful in cases 
with different causes that act through the same pathway, 
such as patients with OPTN mutations. Third, we postu‑
late that genetically complex causes of disease may often 
affect similar pathways and patients may share com‑
monalities in optimal treatment with individuals with 
strongly acting mutations. We thus imagine that some 
fraction of treatments used for defined genetic condi‑
tions may yet work for individuals without those genetic 
causes but who share similar disease mechanisms.
The role of precision medicine in drug development 
for cancer is already clear, as outlined above. Outside 
of cancer, the precision medicine paradigm is contrib‑
uting to the drug development process by focusing on 
targets responsible for disease in individual patients 
and the stratification of clinical trials based on the 
underlying mechanistic causes of disease. There will 
be a growing number of trials that are targeted to the 
precise genetic and mechanistic cause of disease, as the 
examples of GRIN2A and KCNT1 illustrate. Although 
this may seem a slow and cumbersome approach to 
identify a medicine for wide use, it is worth empha‑
sizing that some of the treatments targeted to specific 
underlying causes of disease may have wider applica‑
tion beyond individuals carrying those precise genetic 
causes. Beyond such examples of explicitly targeted 
treatments, current clinical trials routinely include 
patients who have diseases with a broad range of under‑
lying causes. It is reasonable to assume that treatments, 
even when not explicitly targeted, will work better for 
diseases driven by particular underlying mechanisms. 
Currently, this is a source of variation in treatment 
response that is often ignored in most clinical trials. As 
two simple examples, we now know that clinical trials 
in refractory epilepsy and in chronic kidney disease 
include patients who have disease caused by very dif‑
ferent underlying mechanisms, which can be revealed 
through genetic evaluation. Even if drugs are studied in 
such all‑comer populations, dividing patients into sub‑
groups that are mechanistically distinct may identify 
populations in whom these drugs are more effective, 
as demonstrated by the clinical benefit of olaparib in 
patients with recurrent platinum‑ sensitive serous ovar‑
ian cancer and BRCA mutations148. Evaluation of a can‑
didate medicine without recognition of this underlying 
diversity in the patient population is likely to be a key 
contributor to drug development failures due to insuf‑
ficient overall efficacy14. Utilizing genetic and genomic 
approaches to stratify clinical populations into mech‑
anistic subgroups is very likely to permit a molecular 
classification of disease that results in a higher success 
rate within those molecularly defined subpopulations, 
thereby benefiting patients, physicians, drug developers, 
regulators and payers.
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